Person · CIK 1055951

Orbimed Advisors

Director at Aspen Neuroscience, ADARx Pharmaceuticals, Electra Therapeutics, BlossomHill Therapeutics, Braveheart Bio, Scribe Therapeutics, Yarrow Bioscience, Sionna Therapeutics, Shattuck Labs, Q32 Bio, Prelude Therapeutics, ImageneBio, Turnstone Biologics, Corvus Pharmaceuticals, Compass Therapeutics, Edgewise Therapeutics, MBX Biosciences and Lomond Therapeutics Holdings; 10% owner at Enliven Therapeutics, Traws Pharma, Adicet Bio, PMV Pharmaceuticals, NeuroPace and Xtant Medical Holdings; Shareholder; Director at Keros Therapeutics; Shareholder at Disc Medicine; Stockholder at Passage BIO

Earlier: Upstream Bio, ARS Pharmaceuticals, scPharmaceuticals, Terns Pharmaceuticals, TELA Bio, Alpine Immune Sciences, Kinnate Biopharma, Verona Pharma, Theseus Pharmaceuticals, ArriVent Biopharma, Galecto, Gracell Biotechnologies, Tricida, Third Harmonic Bio, SpringWorks Therapeutics, Sierra Oncology, Arcutis Biotherapeutics, 89bio, Janux Therapeutics, Repare Therapeutics, Acutus Medical, Synlogic, Oric Pharmaceuticals, Decibel Therapeutics, Prevail Therapeutics, Cti Biopharma, Aerpio Pharmaceuticals, LogicBio Therapeutics, Graybug Vision, Inspire Medical Systems, Pandion Therapeutics, Fusion Pharmaceuticals, Alector, Principia Biopharma, NextCure, Turning Point Therapeutics, Avedro, Synthorx, SI-BONE, Guardant Health, Arvinas Holding Company, SteadyMed, ViewRay, Constellation Pharmaceuticals, Crinetics Pharmaceuticals, ARMO BioSciences, Adaptimmune Therapeutics, Rhythm Pharmaceuticals, Pieris Pharmaceuticals, Audentes Therapeutics, GLAUKOS, Kala Pharmaceuticals, Loxo Oncology, Arsanis, Roka BioScience, Aeglea BioTherapeutics, Nabriva Therapeutics, Response Biomedical, Relypsa, Selecta Biosciences, Intellia Therapeutics, Otonomy, Dimension Therapeutics, Sientra, Intercept Pharmaceuticals, Mirati Therapeutics, Acceleron Pharma, Ambit Biosciences, Supernus Pharmaceuticals, Anthera Pharmaceuticals, Amarin, Complete Genomics, Pacira Pharmaceuticals, ChemoCentryx, Athersys, NxStage Medical, Kun Run Biotechnology, Biodel, ARYx Therapeutics, Cryocor, Insulet, Volcano, Avanir Pharmaceuticals, Given Imaging, Dov Pharmaceutical, Orphan Medical, Aerogen, Memory Pharmaceuticals, Orthovita and Lifecell

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$2B

Noticed on Form 144$671.1M

Bought on Form 4$1B

Companies117

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Aspen Neuroscience ASPE	Common Stock	See footnotes	3,589,132	Nov 2, 2026 · Filing · EDGAR
ADARx Pharmaceuticals ADRX	Common Stock	See footnotes	588,235	Sep 28, 2026 · Filing · EDGAR
Electra Therapeutics ETRA	Common Stock	See footnotes	1,758,279	Sep 21, 2026 · Filing · EDGAR
BlossomHill Therapeutics BLSM	Common Stock	See footnotes	2,714,279	Aug 10, 2026 · Filing · EDGAR
Braveheart Bio BRVE	Common Stock	See footnotes	273,333	Aug 7, 2026 · Filing · EDGAR
Yarrow Bioscience YARW	Common Stock	See footnote	33,287	Jul 27, 2026 · Filing · EDGAR
Yarrow Bioscience YARW	Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock	See footnote	583,545	Jul 27, 2026 · Filing · EDGAR
Scribe Therapeutics SCTX	Common Stock	See footnotes	1,348,825	Jul 27, 2026 · Filing · EDGAR
Sionna Therapeutics SION	Common Stock	See footnotes(	2,671,822	May 11, 2026 · Filing · EDGAR
Sionna Therapeutics SION	Common Stock	See footnotes	2,469,959	Jul 7, 2026 · Filing · EDGAR
Enliven Therapeutics IMRA	Common Stock	See Footnotes	6,555,102	Jun 22, 2026 · Filing · EDGAR
Enliven Therapeutics IMRA	Common Stock	By OrbiMed Private Investments VII, LP	2,532,402	Mar 16, 2020 · Filing · EDGAR
Shattuck Labs STTK	Common Stock	See Footnote	1,051,021	Jun 11, 2026 · Filing · EDGAR
Shattuck Labs STTK	Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock	See Footnote	5,303,908	Jun 11, 2026 · Filing · EDGAR
Q32 Bio QTTB	Common Stock	By OrbiMed Private Investments VII, LP	2,252,987	Mar 25, 2024 · Filing · EDGAR
Q32 Bio QTTB	Common Stock	See footnotes	625,000	May 28, 2026 · Filing · EDGAR
Traws Pharma TRAW	Common Stock	See Footnote	1,203,250	Apr 16, 2026 · Filing · EDGAR
Traws Pharma TRAW	Common Stock	By OrbiMed Private Investments VIII, LP	1,045,261	Apr 1, 2024 · Filing · EDGAR
Traws Pharma TRAW	Common Stock	See footnotes	602,000	Sep 16, 2024 · Filing · EDGAR
Traws Pharma TRAW	Series C Warrants (right to buy) exercise $1.67, into Common Stock	See Footnote	1,793,187	Apr 16, 2026 · Filing · EDGAR
Traws Pharma TRAW	Series A Warrants (right to buy) exercise $1.67, into Common Stock	See Footnote	597,729	Apr 16, 2026 · Filing · EDGAR
Traws Pharma TRAW	Series B Warrants (right to buy) exercise $1.67, into Common Stock	See Footnote	597,729	Apr 16, 2026 · Filing · EDGAR
Prelude Therapeutics PRLD	Common Stock	See footnote	9,250,191	Sep 29, 2020 · Filing · EDGAR
Prelude Therapeutics PRLD	Common Stock	See footnotes	526,300	Apr 21, 2026 · Filing · EDGAR
Prelude Therapeutics PRLD	Non-Voting Common Stock into Common Stock	See Footnotes	5,596,886	Jan 11, 2021 · Filing · EDGAR
ImageneBio IKNA	Common Stock	See Footnotes	2,098,097	Jun 24, 2022 · Filing · EDGAR
ImageneBio IKNA	Non-Voting Common Stock	See Footnotes	157,288	Jun 22, 2022 · Filing · EDGAR
ImageneBio IKNA	Common Stock	See Footnote	20,691	Apr 14, 2026 · Filing · EDGAR
ImageneBio IKNA	Non-Voting Common Stock	See Footnote	13,107	Jul 25, 2025 · Filing · EDGAR
ImageneBio IKNA	Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock	See Footnote	384,689	Apr 14, 2026 · Filing · EDGAR
Adicet Bio TORC	Stock Option (Right to Buy) exercise $16.11, expires Sep 17, 2030, into Common Stock	See Footnote	30,000	Sep 17, 2020 · Filing · EDGAR
Adicet Bio TORC	Stock Option (Right to Buy) exercise $16.11, expires Sep 17, 2030, into Common Stock	See Footnote	30,000	Sep 17, 2020 · Filing · EDGAR
Keros Therapeutics KROS	Common Stock	See footnote	1,119,812	Apr 13, 2020 · Filing · EDGAR
Keros Therapeutics KROS	Common Stock	See footnotes	45,057	Nov 21, 2025 · Filing · EDGAR
PMV Pharmaceuticals PMVP	Common Stock	See Footnotes	4,975,291	Oct 23, 2025 · Filing · EDGAR
PMV Pharmaceuticals PMVP	Common Stock	See footnote	114,039	Sep 29, 2020 · Filing · EDGAR
Corvus Pharmaceuticals CRVS	Common Stock	See Footnotes	7,165,006	Jun 27, 2025 · Filing · EDGAR
Passage BIO PASG	Common Stock	See footnotes	6,066,343	Jun 26, 2025 · Filing · EDGAR
Passage BIO PASG	Common Stock	See Footnote	5,947,323	Mar 3, 2020 · Filing · EDGAR
NeuroPace NPCE	Common Stock	See Footnotes	3,238,199	May 14, 2025 · Filing · EDGAR
NeuroPace NPCE	Common Stock	See Footnote	235,000	Apr 21, 2021 · Filing · EDGAR
Xtant Medical Holdings XTNT	Common Stock, $0.000001 par value	See footnote	91,256	Feb 5, 2020 · Filing · EDGAR
Compass Therapeutics CMPX	Common Stock	Directly	12,714,404	Jun 19, 2020 · Filing · EDGAR
Compass Therapeutics CMPX	Common Stock	See footnotes	15,219,994	Apr 9, 2025 · Filing · EDGAR
Edgewise Therapeutics EWTX	Common Stock	See footnotes	443,792	Apr 3, 2025 · Filing · EDGAR
Disc Medicine GMTX	Common Stock	See footnote	1,139,507	Dec 29, 2022 · Filing · EDGAR
Disc Medicine GMTX	Common Stock	See Footnotes	186,541	Mar 24, 2025 · Filing · EDGAR
MBX Biosciences MBX	Common Stock	By OrbiMed Private Investments VII, LP	3,158,428	Sep 16, 2024 · Filing · EDGAR
MBX Biosciences MBX	Common Stock	See footnotes	747,887	Feb 18, 2025 · Filing · EDGAR
MBX Biosciences MBX	Common Stock	By OrbiMed Genesis Master Fund, L.P.	653,787	Sep 16, 2024 · Filing · EDGAR
Lomond Therapeutics Holdings	Common Stock	See Footnote	2,677,256	Nov 1, 2024 · Filing · EDGAR
Upstream Bio	Common Stock	See Footnote	4,554,873	Oct 15, 2024 · Filing · EDGAR
Upstream Bio	Common Stock	By OrbiMed Private Investments VIII, LP	1,007,040	Oct 10, 2024 · Filing · EDGAR
Upstream Bio	Common Stock	By OrbiMed Israel Partners II, L.P.	251,760	Oct 10, 2024 · Filing · EDGAR
ARS Pharmaceuticals	Common Stock	See Footnote	8,019,187	Aug 26, 2024 · Filing · EDGAR
ARS Pharmaceuticals	Common Stock	By OrbiMed Private Investments VI, LP	7,519,188	Dec 8, 2020 · Filing · EDGAR
ARS Pharmaceuticals	Common Stock	By OrbiMed Partners Master Fund Limited	952,377	Dec 8, 2020 · Filing · EDGAR
ARS Pharmaceuticals	Common Stock	By OPI VI ? IP HoldCo LLC	269,323	Dec 3, 2020 · Filing · EDGAR
ARS Pharmaceuticals	Common Stock	By OPI VI -IP HoldCo LLC	269,323	Dec 8, 2020 · Filing · EDGAR
scPharmaceuticals	Common Stock	See footnotes	252,858	Aug 13, 2024 · Filing · EDGAR
Terns Pharmaceuticals	Common Stock	See footnotes	755,635	Jul 16, 2024 · Filing · EDGAR
Terns Pharmaceuticals	Pre-Funded Warrant into Common Stock	See footnotes	64,050	Aug 16, 2022 · Filing · EDGAR
TELA Bio	Common Stock	Directly	3,027,542	Nov 13, 2019 · Filing · EDGAR
TELA Bio	Common Stock	See footnotes	2,407,242	Jul 2, 2024 · Filing · EDGAR
TELA Bio	Warrant (right to buy) exercise $28.65, expires Jan 18, 2027, into Common Stock	Directly	758,623	Nov 13, 2019 · Filing · EDGAR
Theseus Pharmaceuticals	Common Stock	By OrbiMed Private Investments VII, LP	16,339,518	Oct 12, 2021 · Filing · EDGAR
Theseus Pharmaceuticals	Common Stock	By OrbiMed Genesis Master Fund, L.P.	499,150	Oct 12, 2021 · Filing · EDGAR
ArriVent Biopharma	Common Stock	See footnotes	1,513,664	Jan 30, 2024 · Filing · EDGAR
Galecto	Common Stock	See footnotes	1,510,375	Aug 15, 2023 · Filing · EDGAR
Galecto	Common Shares	See footnote	1,031,811	Nov 2, 2020 · Filing · EDGAR
Verona Pharma	Ordinary Shares	See footnotes	3,777,778	May 15, 2023 · Filing · EDGAR
Tricida	Common Stock	By OrbiMed Private Investments V, LP	9,614,280	Dec 11, 2019 · Filing · EDGAR
Tricida	Common Stock	By David P. Bonita	5,511	Dec 11, 2019 · Filing · EDGAR
Tricida	Comm on Warrants to Purchase Common Stock exercise $11.00, into Common Stock	See footnotes	666,667	Nov 15, 2021 · Filing · EDGAR
Third Harmonic Bio	Common Stock	See Footnote	5,779,071	Sep 19, 2022 · Filing · EDGAR
SpringWorks Therapeutics	Common Stock	See footnote	7,406,307	Sep 17, 2019 · Filing · EDGAR
SpringWorks Therapeutics	Common Stock	See Footnotes	5,599,842	Sep 12, 2022 · Filing · EDGAR
Sierra Oncology	Common Stock	See footnote (4),	226,704	Jan 26, 2022 · Filing · EDGAR
Sierra Oncology	Common Stock	See footnote	226,704	Jan 26, 2022 · Filing · EDGAR
Arcutis Biotherapeutics	Common Stock	See Footnotes	415,142	Jun 24, 2022 · Filing · EDGAR
89bio	Common Stock	See footnote	2,002,221	Nov 13, 2019 · Filing · EDGAR
89bio	Common Stock	See Footnotes	1,829,436	Jan 26, 2022 · Filing · EDGAR
Janux Therapeutics	Common Stock	See Footnotes	231,098	Dec 29, 2021 · Filing · EDGAR
Repare Therapeutics	Common Stock	See Footnote	99,200	Jun 23, 2020 · Filing · EDGAR
Repare Therapeutics	Common Stock	See Footnotes	96,190	Sep 7, 2021 · Filing · EDGAR
Acutus Medical	Common Stock	See Footnotes	4,022	Jul 19, 2021 · Filing · EDGAR
Synlogic	Common Stock, $0.001 par value	See Footnotes	3,696,662	Apr 20, 2021 · Filing · EDGAR
Oric Pharmaceuticals	Common Stock	See Footnotes	2,212,571	Mar 30, 2021 · Filing · EDGAR
Decibel Therapeutics	Common Stock	See footnotes	883,418	Feb 17, 2021 · Filing · EDGAR
Cti Biopharma	Common Stock	See Footnotes	7,520,600	Jan 7, 2021 · Filing · EDGAR
Cti Biopharma	Series X Preferred Stock into Common Stock	See footnotes	2,980,000	Mar 6, 2020 · Filing · EDGAR
Aerpio Pharmaceuticals	Common Stock	See Footnotes	5,193,946	Dec 8, 2020 · Filing · EDGAR
LogicBio Therapeutics	Common Stock	See Footnotes	296,296	Oct 1, 2020 · Filing · EDGAR
Graybug Vision	Common Stock	See footnote	4,163,347	Sep 29, 2020 · Filing · EDGAR
Inspire Medical Systems	Common Stock	Directly	2,444,221	May 7, 2018 · Filing · EDGAR
Pandion Therapeutics	Series B Preferred Stock into Common Stock	See footnote	469,637	Jul 16, 2020 · Filing · EDGAR
Fusion Pharmaceuticals	Common Shares	By OrbiMed Private Investments VII, L.P.	2,930,670	Jun 30, 2020 · Filing · EDGAR
Fusion Pharmaceuticals	Common Shares	By OrbiMed Partners Master Fund Limited	192,100	Jun 30, 2020 · Filing · EDGAR
Alector	Common Stock	See Footnotes	1,906,718	Apr 16, 2020 · Filing · EDGAR
Principia Biopharma	Common Stock	See footnote	2,605,713	Sep 18, 2018 · Filing · EDGAR
Principia Biopharma	Common Stock	See Footnotes	1,605,713	May 21, 2019 · Filing · EDGAR
NextCure	Common Stock	By OrbiMed Private Investments VI, LP	2,711,013	May 13, 2019 · Filing · EDGAR
Turning Point Therapeutics	Common Stock	See footnote	2,027,550	Apr 22, 2019 · Filing · EDGAR
Avedro	Common Stock	See Footnote	4,240,128	Feb 19, 2019 · Filing · EDGAR
Avedro	Series AA Warrant (right to buy) exercise $0.04, expires Mar 20, 2027, into Common Stock	See Footnote	106,617	Feb 19, 2019 · Filing · EDGAR
Synthorx	Common Stock	See Footnote	5,316,355	Dec 11, 2018 · Filing · EDGAR
SI-BONE	Common Stock	By OrbiMed Private Investments V, LP	985,368	Oct 19, 2018 · Filing · EDGAR
Guardant Health	Common Stock	By OrbiMed Royalties Opportunities II, LP	8,972	Oct 9, 2018 · Filing · EDGAR
Arvinas Holding Company	Series B Preferred Stock into Common Stock	See Footnote	1,385,252	Sep 26, 2018 · Filing · EDGAR
Arvinas Holding Company	Series C Preferred Stock into Common Stock	See Footnote	218,558	Sep 26, 2018 · Filing · EDGAR
SteadyMed	Ordinary Shares	See Footnote	1,536,098	Aug 4, 2016 · Filing · EDGAR
ViewRay	Common Stock	See footnote	75,371	Mar 30, 2016 · Filing · EDGAR
ViewRay	Common Stock	See Footnotes	68,898	Aug 20, 2018 · Filing · EDGAR
Constellation Pharmaceuticals	Common Stock	See footnote	417,921	Jul 23, 2018 · Filing · EDGAR
Crinetics Pharmaceuticals	Series B Preferred Stock into Common Stock	See Footnotes	1,739,282	Jul 17, 2018 · Filing · EDGAR
ARMO BioSciences	Common Stock	By OrbiMed Private Investments IV, LP	3,709,356	Jun 22, 2018 · Filing · EDGAR
ARMO BioSciences	Common Stock	By OrbiMed Private Investments V, LP	409,547	Jun 22, 2018 · Filing · EDGAR
Adaptimmune Therapeutics	Ordinary Shares with a nominal value of GBP0.001 per share	See Footnotes	29,753,404	May 24, 2016 · Filing · EDGAR
Adaptimmune Therapeutics	American Depositary Shares representing Ordinary Shares	See Footnotes	4,901,310	Jun 6, 2018 · Filing · EDGAR
Rhythm Pharmaceuticals	Common Stock	See Footnotes	2,750,079	May 22, 2018 · Filing · EDGAR
Pieris Pharmaceuticals	Common Stock	See Footnotes	38,870	Apr 30, 2018 · Filing · EDGAR
Audentes Therapeutics	Common Stock	See Footnotes	3,539,997	Mar 12, 2018 · Filing · EDGAR
Kala Pharmaceuticals	Common Stock	See Footnotes	3,447,840	Feb 8, 2018 · Filing · EDGAR
Loxo Oncology	Common Stock	See Footnotes	941,000	Dec 8, 2017 · Filing · EDGAR
Arsanis	Common Stock	See Footnotes	1,868,966	Nov 20, 2017 · Filing · EDGAR
Roka BioScience	Common Stock, par value $0.001 per share	See footnote	44	Jul 16, 2014 · Filing · EDGAR
Roka BioScience	Warrants into Common Stock	See Footnotes	53,909	Sep 21, 2016 · Filing · EDGAR
Roka BioScience	Series A Convertible Preferred Stock into Common Stock	See Footnotes	37.74	Sep 21, 2016 · Filing · EDGAR
Aeglea BioTherapeutics	Common Stock	See Footnotes	1,469,524	Feb 21, 2017 · Filing · EDGAR
Aeglea BioTherapeutics	Common Stock	See footnote	1,360,224	Apr 12, 2016 · Filing · EDGAR
Nabriva Therapeutics	Common Shares	See footnotes	224,166	Dec 30, 2016 · Filing · EDGAR
Relypsa	Common Stock	See Footnotes	3,356,400	Jul 25, 2016 · Filing · EDGAR
Selecta Biosciences	Common Stock	See Footnote	1,825,415	Jun 27, 2016 · Filing · EDGAR
Intellia Therapeutics	Common Stock	See Footnote	2,662,180	May 11, 2016 · Filing · EDGAR
Otonomy	Common Stock	See Footnotes	1,850,094	Nov 30, 2015 · Filing · EDGAR
Dimension Therapeutics	Common Stock	See Footnotes	5,397,698	Oct 27, 2015 · Filing · EDGAR
Sientra	Common Stock, par value $0.01 per share	See Footnotes	17,100	Oct 12, 2015 · Filing · EDGAR
Intercept Pharmaceuticals	Common Stock, par value $0.001 per share	See Footnote	2,150,634	Oct 16, 2012 · Filing · EDGAR
Intercept Pharmaceuticals	Common Stock, par value $0.001 per share	See Footnotes	1,120,609	Jul 17, 2015 · Filing · EDGAR
Mirati Therapeutics	Common Stock, par value $0.001 per share	See Footnotes	1,267,000	Feb 3, 2015 · Filing · EDGAR
Acceleron Pharma	Common Stock	See footnote	576,889	Sep 24, 2013 · Filing · EDGAR
Ambit Biosciences	Common Stock, $0.001 par value per share	See Footnotes	14,067	May 23, 2013 · Filing · EDGAR
Supernus Pharmaceuticals	Common Stock	See Footnotes	817,000	Feb 13, 2013 · Filing · EDGAR
Anthera Pharmaceuticals	Common Stock	See Footnotes	7,462,000	Jan 30, 2013 · Filing · EDGAR
Amarin	Ordinary Shares	See Footnote	7,944	Jul 27, 2012 · Filing · EDGAR
Amarin	Ordinary Shares	See Footnotes	5,700	Sep 4, 2012 · Filing · EDGAR
Complete Genomics	Common Stock	See Footnotes	27,859	Jul 13, 2012 · Filing · EDGAR
Pacira Pharmaceuticals	Common Stock	See footnote	2,828,941	Feb 8, 2011 · Filing · EDGAR
Pacira Pharmaceuticals	Common Stock	See footnotes	2,446,000	Mar 12, 2012 · Filing · EDGAR
ChemoCentryx	Common Stock	See Footnotes	908,509	Feb 13, 2012 · Filing · EDGAR
Athersys	Common Stock	See Foonotes	1,693,100	Apr 14, 2011 · Filing · EDGAR
Athersys	Common Stock	See Footnotes	1,600,450	Apr 26, 2011 · Filing · EDGAR
Athersys	Common Stock	See Foonote	16,100	Apr 14, 2011 · Filing · EDGAR
Athersys	Common Stock	See Footnote	15,250	Apr 26, 2011 · Filing · EDGAR
NxStage Medical	Common Stock	See Footnotes	2,690,476	Dec 9, 2010 · Filing · EDGAR
Kun Run Biotechnology	Series A Preferred Stock	By Caduceus Asia Partners, L.P.	5,228,758	Apr 30, 2010 · Filing · EDGAR
Kun Run Biotechnology	Warrant to Purchase Series A Preferred Stock into Common Stock	By Caduceus Asia Partners, L.P.	1,568,627	Apr 30, 2010 · Filing · EDGAR
Biodel	Common Stock	See footnote	1,812,892	Feb 12, 2008 · Filing · EDGAR
Biodel	Common Stock	See footnotes	1,485,904	Jun 10, 2009 · Filing · EDGAR
ARYx Therapeutics	Common Stock	See footnote	3,340,139	Nov 14, 2008 · Filing · EDGAR
ARYx Therapeutics	Common Stock	FN	2,125,493	Nov 13, 2007 · Filing · EDGAR
ARYx Therapeutics	Common Stock	See Footnotes	1,340,139	May 22, 2009 · Filing · EDGAR
Cryocor	Common Stock	Directly	1,096,936	Jul 13, 2005 · Filing · EDGAR
Cryocor	Common Stock	FN, 1, 2, 3	1,231,936	Jul 13, 2005 · Filing · EDGAR
Cryocor	Common Stock	FN	1,231,936	Jul 13, 2005 · Filing · EDGAR
Cryocor	Common Stock	See Footnote	389,432	Jun 14, 2007 · Filing · EDGAR
Insulet	Common Stock	See Footnote	1,568,841	May 18, 2007 · Filing · EDGAR
Volcano	Common Stock	By Caduceus Private Investments II, LP	1,578,832	Jun 20, 2006 · Filing · EDGAR
Volcano	Common Stock	By Caduceus Private Investments II (QP), LP	591,146	Jun 20, 2006 · Filing · EDGAR
Volcano	Common Stock	By UBS Juniper Crossover Fund, L.L.C.	195,705	Jun 20, 2006 · Filing · EDGAR
Avanir Pharmaceuticals	Class A Common Stock	See FN	2,335,258	Feb 13, 2006 · Filing · EDGAR
Avanir Pharmaceuticals	Common Stock	FN	1,706,137	May 31, 2006 · Filing · EDGAR
Given Imaging	Common Stock	see footnotes below	3,637,255	Sep 21, 2004 · Filing · EDGAR
Given Imaging	Common Stock	FN 3 and 4	3,610,402	May 24, 2006 · Filing · EDGAR
Dov Pharmaceutical	Common Stock	FN	258,000	May 16, 2006 · Filing · EDGAR
Aerogen	Series A-1 Convertible Preferred Stock exercise $3.00, into Common Stock	See	917,510	Mar 11, 2004 · Filing · EDGAR
Memory Pharmaceuticals	Common Stock	See	1,006,280	Apr 8, 2004 · Filing · EDGAR
Orthovita	Common Stock	see footnote 2 and 6	8,395,244	Jul 22, 2003 · Filing · EDGAR
Orthovita	Common Stock	See footnote 1 and 2	6,365,144	Sep 25, 2003 · Filing · EDGAR
Orthovita	Common Stock	See	5,350,000	Jan 14, 2004 · Filing · EDGAR
Orthovita	Common Stock	See footnote	5,350,000	Jan 14, 2004 · Filing · EDGAR
Lifecell	Common Stock	see footnote 2	1,643,000	Dec 23, 2003 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	—	—	$15M
Q3 2026	$3.9M	—	$96.1M
Q2 2026	$96.4M	$107.3M	$28.5M
Q1 2026	$1.4M	$497K	—
Q4 2025	$7.9M	$175.3M	$5M
Q3 2025	$900K	$4.9M	$5.5M
Q2 2025	$44.3M	$6.4M	$10M
Q1 2025	$20.4M	$32.5M	$11.9M
Q4 2024	$268K	$2.7M	$14M
Q3 2024	$24.6M	$23.7M	$14M
Q2 2024	$33.3M	$25.1M	$3M
Q1 2024	—	$18.2M	$20.5M
Q4 2023	$61.5M	$203.7M	—
Q3 2023	$1.8M	$6.5M	$9.6M
Q2 2023	$12.2M	$64.5M	$15.6M
Q1 2023	—	—	$2.5M
Q4 2022	$138.2M	Not machine-readable	$7.3M
Q3 2022	$15.4M	Not machine-readable	$19M
Q2 2022	$25.9M	Not machine-readable	$2.6M
Q1 2022	$10.9M	Not machine-readable	$6M
Q4 2021	$10.6M	Not machine-readable	$28.8M
Q3 2021	$11.6M	Not machine-readable	$34.5M
Q2 2021	$12.1M	Not machine-readable	$16M
Q1 2021	$123.7M	Not machine-readable	$55.1M
Q4 2020	$8.6M	Not machine-readable	$72.3M
Q3 2020	$45M	Not machine-readable	$57.1M
Q2 2020	$11M	Not machine-readable	$60.5M
Q1 2020	$149.6M	Not machine-readable	$31.2M
Q4 2019	$96.6M	Not machine-readable	$18.4M
Q3 2019	$11.6M	Not machine-readable	$5.7M
Q2 2019	$30.3M	Not machine-readable	$37M
Q1 2019	$20.5M	Not machine-readable	$9.8M
Q4 2018	$23.1M	Not machine-readable	$29.9M
Q3 2018	$43.1M	Not machine-readable	$14.2M
Q2 2018	$13.7M	Not machine-readable	$8M
Q1 2018	$72.2M	Not machine-readable	$34.2M
Q4 2017	$61.7M	Not machine-readable	$17.7M
Q3 2017	$54.5M	Not machine-readable	$4.8M
Q2 2017	—	—	$6.9M
Q1 2017	$20M	Not machine-readable	$10.4M
Q3 2016	$164.3M	Not machine-readable	$3.9M
Q2 2016	—	—	$39.8M
Q1 2016	—	—	$8.3M
Q4 2015	$33.9M	Not machine-readable	$8.9M
Q3 2015	$2.1M	Not machine-readable	$4.4M
Q2 2015	$49.7M	Not machine-readable	—
Q1 2015	$102.1M	Not machine-readable	$2M
Q3 2014	$79.7M	Not machine-readable	$10.9M
Q2 2014	$28.2M	Not machine-readable	—
Q4 2013	$26M	Not machine-readable	$12M
Q2 2013	—	—	$5.7M
Q1 2013	$2.3M	Not machine-readable	$1.1M
Q4 2012	$2.1M	Not machine-readable	$5M
Q3 2012	$12M	Not machine-readable	—
Q2 2012	$8.9M	Not machine-readable	$5.5M
Q1 2012	$7M	Not machine-readable	—
Q4 2011	$2.2M	Not machine-readable	—
Q2 2011	$76.9M	Not machine-readable	—
Q1 2011	$5.9M	Not machine-readable	$3.7M
Q4 2010	$53K	Not machine-readable	$5.4M
Q3 2010	$33.8M	Not machine-readable	$81K
Q2 2009	$8.1M	Not machine-readable	—
Q1 2009	—	—	$126K
Q3 2008	—	—	$549K
Q2 2008	—	—	$26.1M
Q1 2008	$2.2M	Not machine-readable	—
Q4 2007	—	—	$3M
Q2 2007	—	—	$15M
Q2 2006	$9.2M	Not machine-readable	—
Q3 2005	$4.1M	Not machine-readable	—
Q2 2004	$5.1M	Not machine-readable	—
Q1 2004	$790K	Not machine-readable	—
Q4 2003	$4M	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Enliven Therapeutics IMRA · Jefferies · No 10b5-1 plan stated · 2 notices
Jun 22, 2026	26,323 · ~$1.2M	Jun 22, 2026	Not sold within 90 days	Filing · EDGAR
Jun 22, 2026	833,800 · ~$38.3M	Jun 22, 2026	Partly sold Sold 811,870 in 2 sales, Jun 22 to Jun 22 · $36.8M likely match Form 4	Filing · EDGAR
Enliven Therapeutics IMRA · Themis Trading · No 10b5-1 plan stated · 2 notices
Jun 15, 2026	272,322 · ~$11.5M	Jun 15, 2026	Sold as noticed Sold 273,799 in 2 sales, Jun 15 to Jun 22 · $12.3M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Jun 15, 2026	9,086 · ~$385K	Jun 15, 2026	Sold as noticed Sold 9,086 at $45.02 on Jun 15 · $409K Form 4	Filing · EDGAR
Sionna Therapeutics SION · TD Cowen · 10b5-1 plan adopted Feb 10, 2025 · 3 notices
Jun 1, 2026	210,876 · ~$9M	May 29, 2026	Not sold within 90 days	Filing · EDGAR
May 29, 2026	1,082,480 · ~$46.3M	May 29, 2026	Partly sold Sold 201,863 in 3 sales, May 27 to Jul 7 · $9.1M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Nov 24, 2025	1,047,770 · ~$46.5M	Nov 24, 2025	Partly sold Sold 174,257 in 9 sales, Nov 24 to Feb 3 · $7.8M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Adicet Bio TORC · Themis Trading · No 10b5-1 plan stated · 1 notice
Apr 9, 2026	78,499 · ~$514K	Apr 9, 2026	Partly sold Sold 64,242 in 3 sales, Apr 7 to Apr 8 · $411K likely match Form 4	Filing · EDGAR
Keros Therapeutics KROS · Themis Trading · No 10b5-1 plan stated · 1 notice
Mar 31, 2026	45,057 · ~$497K	Mar 31, 2026	Not sold within 90 days	Filing · EDGAR
PMV Pharmaceuticals PMVP · Morgan Stanley · No 10b5-1 plan stated · 1 notice
Oct 23, 2025	1,000,000 · ~$1.5M	Oct 23, 2025	Not sold within 90 days	Filing · EDGAR
Disc Medicine GMTX · Themis Trading · No 10b5-1 plan stated · 12 notices
Oct 20, 2025	482,308 · ~$43.4M	Oct 20, 2025	Not sold within 90 days	Filing · EDGAR
Oct 20, 2025	186,541 · ~$16.8M	Oct 20, 2025	Not sold within 90 days	Filing · EDGAR
Oct 20, 2025	746,171 · ~$67.1M	Oct 20, 2025	Not sold within 90 days	Filing · EDGAR
Mar 10, 2025	74,800 · ~$4.2M	Mar 10, 2025	Not sold within 90 days	Filing · EDGAR
Mar 10, 2025	193,400 · ~$10.8M	Mar 10, 2025	Partly sold Sold 68,536 in 12 sales, Mar 12 to Mar 24 · $3.7M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Mar 10, 2025	299,200 · ~$16.7M	Mar 10, 2025	Sold as noticed Sold 302,015 in 15 sales, Mar 10 to Mar 20 · $16.4M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Dec 15, 2023	243,680 · ~$14.9M	Dec 12, 2023	Not sold within 90 days	Filing · EDGAR
Dec 15, 2023	630,000 · ~$38.5M	Dec 12, 2023	Not sold within 90 days	Filing · EDGAR
Dec 15, 2023	974,720 · ~$59.5M	Dec 12, 2023	Not sold within 90 days	Filing · EDGAR
Dec 12, 2023	121,840 · ~$7.4M	Dec 12, 2023	Not sold within 90 days	Filing · EDGAR
Dec 12, 2023	315,000 · ~$19.2M	Dec 12, 2023	Partly sold Sold 147,600 at $56.75 on Dec 14 · $8.4M likely match Form 4	Filing · EDGAR
Dec 12, 2023	487,360 · ~$29.7M	Dec 12, 2023	Partly sold Sold 421,524 in 11 sales, Dec 12 to Dec 18 · $24.2M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
PMV Pharmaceuticals PMVP · Themis Trading · No 10b5-1 plan stated · 2 notices
Sep 10, 2025	2,283,654 · ~$3.7M	Sep 10, 2025	Partly sold Sold 1,500,000 in 2 sales, Sep 10 to Oct 23 · $2.4M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Nov 22, 2023	87,786 · ~$198K	Nov 22, 2023	Sold as noticed Sold 87,786 at $2.23 on Nov 22 · $196K Form 4	Filing · EDGAR
Passage BIO PASG · Themis Trading · No 10b5-1 plan stated · 7 notices
Jul 21, 2025	132,645 · ~$738K	Jul 21, 2025	Not sold within 90 days	Filing · EDGAR
Jul 15, 2025	53,293 · ~$362K	Jul 15, 2025	Not sold within 90 days	Filing · EDGAR
Jul 7, 2025	259,000 · ~$112K	Jul 7, 2025	Not sold within 90 days	Filing · EDGAR
Jun 24, 2025	1,076,120 · ~$378K	Jun 24, 2025	Partly sold Sold 213,257 at $0.33 on Jun 26 · $70K likely match Form 4	Filing · EDGAR
Jan 6, 2025	1,140,740 · ~$946K	Jan 6, 2025	Not sold within 90 days	Filing · EDGAR
Dec 4, 2024	2,985,518 · ~$2.7M	Dec 4, 2024	Partly sold Sold 600,564 in 7 sales, Dec 20 to Jan 14 · $384K likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Sep 16, 2024	927,572 · ~$749K	Sep 16, 2024	Partly sold Sold 398,810 in 9 sales, Sep 16 to Dec 11 · $304K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Passage BIO PASG · International Strategy & Investment Group · No 10b5-1 plan stated · 1 notice
Apr 15, 2025	787,179 · ~$301K	Apr 15, 2025	Partly sold Sold 755,026 in 8 sales, Apr 15 to Jun 25 · $255K likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Compass Therapeutics CMPX · Jefferies · No 10b5-1 plan stated · 1 notice
Apr 9, 2025	3,571,428 · ~$5.7M	Apr 9, 2025	Sold as noticed Sold 3,571,428 at $1.59 on Apr 9 · $5.7M Form 4	Filing · EDGAR
Keros Therapeutics KROS · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 2 notices
Aug 13, 2024	29,400 · ~$1.3M	Aug 13, 2024	Sold as noticed Sold 29,400 at $44.01 on Aug 13 · $1.3M Form 4	Filing · EDGAR
Aug 13, 2024	220,600 · ~$9.9M	Aug 13, 2024	Sold as noticed Sold 220,600 at $44.01 on Aug 13 · $9.7M Form 4	Filing · EDGAR
Terns Pharmaceuticals · TD Cowen · No 10b5-1 plan stated · 3 notices
Jul 15, 2024	131,700 · ~$1.2M	Jul 15, 2024	Not sold within 90 days	Filing · EDGAR
Jul 15, 2024	976,800 · ~$9.1M	Jul 15, 2024	Not sold within 90 days	Filing · EDGAR
Jul 15, 2024	152,400 · ~$1.4M	Jul 15, 2024	Partly sold Sold 56,164 in 6 sales, Jul 15 to Jul 16 · $562K likely match Form 4	Filing · EDGAR
TELA Bio · Themis Trading · No 10b5-1 plan stated · 2 notices
Jun 28, 2024	428,386 · ~$2.2M	Jun 28, 2024	Sold as noticed Sold 428,300 in 3 sales, Jun 28 to Jul 2 · $2M Form 4	Filing · EDGAR
Apr 19, 2023	192,000 · ~$2M	Apr 19, 2023	Sold as noticed Sold 192,000 in 3 sales, Apr 19 to Apr 21 · $1.8M Form 4	Filing · EDGAR
Enliven Therapeutics IMRA · Morgan Stanley · No 10b5-1 plan stated · 2 notices
May 17, 2024	1,000,000 · ~$22.1M	May 16, 2024	Sold as noticed Sold 1,000,000 at $22.14 on May 16 · $22.1M Form 4	Filing · EDGAR
May 17, 2024	33,300 · ~$737K	May 16, 2024	Sold as noticed Sold 33,300 at $22.14 on May 16 · $737K Form 4	Filing · EDGAR
Verona Pharma · Themis Trading · No 10b5-1 plan stated · 2 notices
Mar 4, 2024	1,000,000 · ~$18.2M	Mar 4, 2024	Not sold within 90 days	Filing · EDGAR
May 11, 2023	2,575,811 · ~$60.4M	May 11, 2023	Partly sold Sold 482,913 in 4 sales, May 11 to May 15 · $9.9M likely match Form 4	Filing · EDGAR
Alpine Immune Sciences · Themis Trading · No 10b5-1 plan stated · 2 notices
Dec 27, 2023	1,385,131 · ~$28M	Dec 27, 2023	Sold as noticed Sold 1,383,771 in 5 sales, Dec 27 to Dec 28 · $25.4M Form 4	Filing · EDGAR
Dec 27, 2023	161,216 · ~$3.3M	Dec 27, 2023	Sold as noticed Sold 162,576 at $19.96 on Dec 27 · $3.2M Form 4	Filing · EDGAR
Galecto · Merrill Lynch, Pierce, Fenner & Smith · No 10b5-1 plan stated · 2 notices
Oct 2, 2023	37,675 · ~$27K	Oct 2, 2023	Not sold within 90 days	Filing · EDGAR
Oct 2, 2023	585,274 · ~$421K	Oct 2, 2023	Not sold within 90 days	Filing · EDGAR
NeuroPace NPCE · JP Morgan Chase · No 10b5-1 plan stated · 1 notice
Oct 2, 2023	288,100 · ~$2.6M	Oct 2, 2023	Partly sold Sold 8,314 in 2 sales, Oct 2 to Oct 3 · $75K likely match Form 4	Filing · EDGAR
Galecto · Bank of America · No 10b5-1 plan stated · 13 notices
Aug 30, 2023	78,659 · ~$46K	Aug 30, 2023	Not sold within 90 days	Filing · EDGAR
Aug 30, 2023	1,222,125 · ~$709K	Aug 30, 2023	Not sold within 90 days	Filing · EDGAR
Aug 21, 2023	97,204 · ~$60K	Aug 21, 2023	Not sold within 90 days	Filing · EDGAR
Aug 21, 2023	1,510,375 · ~$932K	Aug 21, 2023	Not sold within 90 days	Filing · EDGAR
Aug 21, 2023	75,473 · ~$57K	Aug 15, 2023	Not sold within 90 days	Filing · EDGAR
Aug 15, 2023	1,172,714 · ~$880K	Aug 15, 2023	Not sold within 90 days	Filing · EDGAR
Aug 15, 2023	75,473 · ~$57K	Aug 15, 2023	Not sold within 90 days	Filing · EDGAR
Jul 31, 2023	930,717 · ~$2.8M	Jul 31, 2023	Sold as noticed Sold 937,431 in 3 sales, Jul 31 to Aug 15 · $1M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Jul 31, 2023	162,153 · ~$490K	Jul 31, 2023	Partly sold Sold 68,027 in 2 sales, Jul 31 to Aug 15 · $118K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Jul 25, 2023	26,700 · ~$63K	Jul 25, 2023	Not sold within 90 days	Filing · EDGAR
Jul 25, 2023	7,800 · ~$18K	Jul 25, 2023	Not sold within 90 days	Filing · EDGAR
Jul 13, 2023	132,100 · ~$337K	Jul 13, 2023	Partly sold Sold 118,622 in 5 sales, Jul 13 to Jul 31 · $321K likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jul 13, 2023	9,800 · ~$25K	Jul 13, 2023	Sold as noticed Sold 9,800 at $2.40 on Jul 13 · $24K Form 4	Filing · EDGAR
Gracell Biotechnologies · Themis Trading · No 10b5-1 plan stated · 1 notice
Jun 15, 2023	305,748 · ~$1.8M	Jun 15, 2023	Not sold within 90 days	Filing · EDGAR
Galecto · Themis Trading · No 10b5-1 plan stated · 4 notices
Apr 10, 2023	1,686 · ~$3K	Apr 10, 2023	Not sold within 90 days	Filing · EDGAR
Apr 10, 2023	22,638 · ~$43K	Apr 10, 2023	Partly sold Sold 19,541 in 3 sales, Apr 10 to Apr 17 · $36K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Apr 5, 2023	109,532 · ~$245K	Apr 5, 2023	Sold as noticed Sold 109,298 in 11 sales, Apr 5 to Apr 17 · $232K Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Apr 5, 2023	8,143 · ~$18K	Apr 5, 2023	Partly sold Sold 7,913 in 4 sales, Apr 5 to Apr 12 · $17K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Sales without a matching Form 144 · 595 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Enliven Therapeutics (IMRA): Sold 46,776 at $45.00 on Jun 22, 2026 · $2.1M	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 184,639 at $46.22 on May 11, 2026 · $8.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 59,767 at $44.58 on May 8, 2026 · $2.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 48,546 at $44.61 on May 7, 2026 · $2.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 2,948 at $44.52 on Apr 18, 2026 · $131K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 52,397 at $44.68 on Apr 17, 2026 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 226,906 at $45.34 on Apr 16, 2026 · $10.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 235,863 at $44.64 on Apr 15, 2026 · $10.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Sionna Therapeutics (SION): Sold 47,814 at $44.51 on Apr 14, 2026 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Adicet Bio (TORC): Sold 40,416 at $6.52 on Apr 8, 2026 · $264K	Filing · EDGAR
—	—	—	Sold without notice Corvus Pharmaceuticals (CRVS): Sold 1,176,332 at $4.16 on Jun 27, 2025 · $4.9M	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 34,000 at $15.94 on May 14, 2025 · $542K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 134,136 at $15.83 on May 14, 2025 · $2.1M	Filing · EDGAR
—	—	—	Sold without notice Xtant Medical Holdings (XTNT): Sold 17,109,618 at $0.42 on Apr 10, 2025 · $7.2M	Filing · EDGAR
—	—	—	Sold without notice Xtant Medical Holdings (XTNT): Sold 56,004,974 at $0.42 on Apr 10, 2025 · $23.5M	Filing · EDGAR
—	—	—	Sold without notice ARS Pharmaceuticals: Sold 83,695 at $13.00 on Aug 26, 2024 · $1.1M	Filing · EDGAR
—	—	—	Sold without notice ARS Pharmaceuticals: Sold 69,500 at $13.03 on Aug 23, 2024 · $906K	Filing · EDGAR
—	—	—	Sold without notice ARS Pharmaceuticals: Sold 391,482 at $12.94 on Aug 22, 2024 · $5.1M	Filing · EDGAR
—	—	—	Sold without notice ARS Pharmaceuticals: Sold 13,300 at $14.61 on Aug 21, 2024 · $194K	Filing · EDGAR
—	—	—	Sold without notice ARS Pharmaceuticals: Sold 394,400 at $13.52 on Aug 21, 2024 · $5.3M	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 4,674 at $14.03 on May 3, 2024 · $66K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 8,842 at $14.01 on May 2, 2024 · $124K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 15,690 at $14.02 on May 1, 2024 · $220K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 1,781 at $14.06 on Apr 24, 2024 · $25K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 21,791 at $14.29 on Apr 23, 2024 · $311K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 24,609 at $14.05 on Apr 22, 2024 · $346K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 18,253 at $14.02 on Apr 19, 2024 · $256K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 2,623 at $14.06 on Apr 18, 2024 · $37K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 300 at $14.15 on Apr 17, 2024 · $4K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 14,069 at $14.01 on Apr 16, 2024 · $197K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 23,101 at $14.42 on Apr 12, 2024 · $333K	Filing · EDGAR
—	—	—	Sold without notice NeuroPace (NPCE): Sold 461,899 at $14.49 on Apr 11, 2024 · $6.7M	Filing · EDGAR
—	—	—	Sold without notice Galecto: Sold 132,100 at $2.40 on Jul 13, 2023 · $317K	Filing · EDGAR
—	—	—	Sold without notice Galecto: Sold 8,878 at $1.97 on Apr 17, 2023 · $17K	Filing · EDGAR
—	—	—	Sold without notice Galecto: Sold 28,110 at $1.86 on Apr 14, 2023 · $52K	Filing · EDGAR
—	—	—	Sold without notice Galecto: Sold 11,245 at $1.86 on Apr 14, 2023 · $21K	Filing · EDGAR
—	—	—	Sold without notice Galecto: Sold 9,459 at $1.82 on Apr 13, 2023 · $17K	Filing · EDGAR
—	—	—	Notice not machine-readable Galecto: Sold 9,459 at $1.82 on Apr 11, 2023 · $17K	Filing · EDGAR
—	—	—	Notice not machine-readable Galecto: Sold 34,745 at $1.79 on Apr 10, 2023 · $62K	Filing · EDGAR
—	—	—	Notice not machine-readable Verona Pharma: Sold 92,992 at $24.11 on Dec 23, 2022 · $2.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Verona Pharma: Sold 1,116,048 at $23.23 on Dec 23, 2022 · $25.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Verona Pharma: Sold 961,328 at $22.27 on Dec 23, 2022 · $21.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Verona Pharma: Sold 684,696 at $22.07 on Dec 22, 2022 · $15.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Verona Pharma: Sold 3,284,800 at $21.71 on Dec 22, 2022 · $71.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 3,629,226 at $0.22 on Nov 25, 2022 · $798K	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 5,617,300 at $0.21 on Nov 23, 2022 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 1,034,421 at $0.22 on Nov 22, 2022 · $228K	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 30,000 at $31.98 on Sep 12, 2022 · $959K	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 123,897 at $31.96 on Sep 12, 2022 · $4M	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 69,568 at $37.47 on Aug 9, 2022 · $2.6M	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 205,000 at $38.33 on Aug 8, 2022 · $7.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 35,944 at $21.31 on Jun 24, 2022 · $766K	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 306,027 at $21.31 on Jun 24, 2022 · $6.5M	Filing · EDGAR
—	—	—	Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 26,253 at $15.93 on May 26, 2022 · $418K	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 102,800 at $20.71 on Apr 8, 2022 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 97,200 at $20.71 on Apr 8, 2022 · $2M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 177,196 at $20.66 on Apr 7, 2022 · $3.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 167,800 at $20.66 on Apr 7, 2022 · $3.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 171,204 at $20.69 on Apr 6, 2022 · $3.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics: Sold 162,000 at $20.69 on Apr 6, 2022 · $3.4M	Filing · EDGAR
—	—	—	Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 34,500 at $21.17 on Mar 31, 2022 · $730K	Filing · EDGAR
—	—	—	Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 75,000 at $22.39 on Mar 30, 2022 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 365,000 at $21.52 on Mar 29, 2022 · $7.9M	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 10,740 at $8.38 on Jan 26, 2022 · $90K	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 10,742 at $8.38 on Jan 26, 2022 · $90K	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 24,545 at $8.40 on Jan 25, 2022 · $206K	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 24,546 at $8.40 on Jan 25, 2022 · $206K	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 3,700 at $20.30 on Dec 29, 2021 · $75K	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 36,700 at $20.30 on Dec 29, 2021 · $745K	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 11,100 at $19.00 on Dec 21, 2021 · $211K	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 108,300 at $19.00 on Dec 21, 2021 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 36,500 at $19.07 on Dec 16, 2021 · $696K	Filing · EDGAR
—	—	—	Notice not machine-readable Janux Therapeutics: Sold 356,800 at $19.07 on Dec 16, 2021 · $6.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Corvus Pharmaceuticals (CRVS): Sold 1,109,644 at $6.09 on Sep 20, 2021 · $6.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 26 at $33.93 on Sep 7, 2021 · $882 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 861 at $33.93 on Sep 7, 2021 · $29K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 212 at $34.00 on Sep 3, 2021 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 6,985 at $34.00 on Sep 3, 2021 · $237K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 483 at $34.24 on Sep 2, 2021 · $17K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 15,941 at $34.24 on Sep 2, 2021 · $546K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 382 at $33.98 on Sep 1, 2021 · $13K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 12,586 at $33.98 on Sep 1, 2021 · $428K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 249 at $33.94 on Aug 31, 2021 · $8K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 8,223 at $33.94 on Aug 31, 2021 · $279K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 197 at $33.92 on Aug 30, 2021 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 6,500 at $33.92 on Aug 30, 2021 · $220K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 209 at $33.94 on Aug 27, 2021 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 6,884 at $33.94 on Aug 27, 2021 · $234K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 126 at $34.52 on Aug 26, 2021 · $4K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 4,157 at $34.52 on Aug 26, 2021 · $143K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 208 at $34.34 on Aug 25, 2021 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 6,874 at $34.34 on Aug 25, 2021 · $236K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 119 at $34.07 on Aug 24, 2021 · $4K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 3,920 at $34.07 on Aug 24, 2021 · $134K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 209 at $34.06 on Aug 23, 2021 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 6,885 at $34.06 on Aug 23, 2021 · $235K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 78 at $33.99 on Aug 18, 2021 · $3K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 2,852 at $33.99 on Aug 18, 2021 · $97K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 512 at $34.12 on Aug 17, 2021 · $17K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Repare Therapeutics: Sold 16,886 at $34.12 on Aug 17, 2021 · $576K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 15,959 at $85.01 on Jul 1, 2021 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 6,502 at $85.17 on Jun 28, 2021 · $554K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 22,334 at $85.14 on Jun 25, 2021 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 34,200 at $85.22 on Jun 24, 2021 · $2.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 100 at $85.00 on Jun 23, 2021 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 30,852 at $85.09 on Jun 10, 2021 · $2.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 5,049 at $85.33 on Jun 9, 2021 · $431K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 42,633 at $85.37 on Jun 8, 2021 · $3.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 371 at $84.90 on Jun 7, 2021 · $31K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 27,869 at $23.93 on Mar 30, 2021 · $667K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 75,555 at $23.31 on Mar 29, 2021 · $1.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 27,816 at $23.88 on Mar 26, 2021 · $664K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 51,523 at $24.70 on Mar 25, 2021 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 32,959 at $24.80 on Mar 24, 2021 · $817K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 3,992 at $24.32 on Mar 23, 2021 · $97K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 7,673 at $26.47 on Mar 22, 2021 · $203K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 21,275 at $26.47 on Mar 19, 2021 · $563K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 6,059 at $28.03 on Mar 18, 2021 · $170K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 18,790 at $28.43 on Mar 17, 2021 · $534K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 41,353 at $27.72 on Mar 16, 2021 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 89,210 at $29.14 on Mar 15, 2021 · $2.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 90,521 at $30.29 on Mar 12, 2021 · $2.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Oric Pharmaceuticals: Sold 58,551 at $33.04 on Mar 11, 2021 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable SpringWorks Therapeutics: Sold 1,220,000 at $83.19 on Mar 1, 2021 · $101.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Cti Biopharma: Sold 2,000,000 at $3.50 on Jan 7, 2021 · $7M	Filing · EDGAR
—	—	—	Notice not machine-readable Alpine Immune Sciences: Sold 600,000 at $14.25 on Dec 28, 2020 · $8.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Aerpio Pharmaceuticals: Sold 21,400 at $1.96 on Dec 8, 2020 · $42K	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 137,500 at $28.00 on Sep 21, 2020 · $3.9M	Filing · EDGAR
—	—	—	Notice not machine-readable 89bio: Sold 137,500 at $28.00 on Sep 21, 2020 · $3.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 43,543 at $108.54 on Aug 18, 2020 · $4.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 94,900 at $107.49 on Aug 17, 2020 · $10.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 20,257 at $109.03 on Aug 14, 2020 · $2.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 29,251 at $109.93 on Aug 13, 2020 · $3.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 42,679 at $107.45 on Aug 12, 2020 · $4.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 39,877 at $105.78 on Aug 11, 2020 · $4.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 47,700 at $105.23 on Aug 10, 2020 · $5M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 28,993 at $106.18 on Aug 7, 2020 · $3.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 15,086 at $23.53 on Apr 16, 2020 · $355K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 47,097 at $23.53 on Apr 16, 2020 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 5,636 at $23.52 on Apr 14, 2020 · $133K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 17,595 at $23.52 on Apr 14, 2020 · $414K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 69,893 at $23.79 on Apr 9, 2020 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 218,208 at $23.79 on Apr 9, 2020 · $5.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 20,041 at $23.65 on Apr 8, 2020 · $474K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 62,573 at $23.65 on Apr 8, 2020 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 2,224 at $23.10 on Apr 7, 2020 · $51K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 6,946 at $23.10 on Apr 7, 2020 · $160K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 60,645 at $24.50 on Mar 31, 2020 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 189,355 at $24.50 on Mar 31, 2020 · $4.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 13,684 at $24.66 on Mar 25, 2020 · $337K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 42,727 at $24.66 on Mar 25, 2020 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 16,409 at $24.45 on Mar 24, 2020 · $401K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 51,235 at $24.45 on Mar 24, 2020 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 3,541 at $26.05 on Mar 23, 2020 · $92K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 11,057 at $26.05 on Mar 23, 2020 · $288K	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 500,000 at $83.52 on Mar 6, 2020 · $41.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 400,000 at $84.42 on Mar 3, 2020 · $33.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 25,000 at $84.55 on Mar 3, 2020 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 75,000 at $83.21 on Mar 3, 2020 · $6.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 38,808 at $26.00 on Mar 2, 2020 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 445,086 at $26.00 on Mar 2, 2020 · $11.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 1,390,309 at $26.00 on Mar 2, 2020 · $36.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 1,392 at $19.50 on Jan 9, 2020 · $27K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 91,818 at $19.50 on Jan 9, 2020 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 286,787 at $19.50 on Jan 9, 2020 · $5.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 1,200 at $18.60 on Dec 26, 2019 · $22K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 2,325 at $18.60 on Dec 26, 2019 · $43K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 7,275 at $18.60 on Dec 26, 2019 · $135K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 8,000 at $19.59 on Dec 24, 2019 · $157K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 15,476 at $19.59 on Dec 24, 2019 · $303K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 48,324 at $19.59 on Dec 24, 2019 · $947K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 10,400 at $19.82 on Dec 23, 2019 · $206K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 20,350 at $19.82 on Dec 23, 2019 · $403K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 63,535 at $19.82 on Dec 23, 2019 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 37,900 at $19.66 on Dec 20, 2019 · $745K	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 73,879 at $19.66 on Dec 20, 2019 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 230,721 at $19.66 on Dec 20, 2019 · $4.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 105,500 at $18.52 on Dec 17, 2019 · $2M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 205,793 at $18.52 on Dec 17, 2019 · $3.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 642,807 at $18.52 on Dec 17, 2019 · $11.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 1,500,000 at $40.00 on Dec 11, 2019 · $60M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 2,306 at $72.13 on Nov 27, 2019 · $166K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 47,981 at $71.67 on Nov 27, 2019 · $3.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 3,100 at $70.60 on Nov 27, 2019 · $219K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 50,478 at $70.16 on Nov 26, 2019 · $3.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 20,135 at $69.55 on Nov 26, 2019 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 157,636 at $17.90 on Aug 7, 2019 · $2.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Alector: Sold 492,364 at $17.90 on Aug 7, 2019 · $8.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Principia Biopharma: Sold 1,000,000 at $30.25 on May 21, 2019 · $30.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 290,231 at $57.75 on Mar 8, 2019 · $16.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 68,218 at $55.01 on Mar 7, 2019 · $3.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Inspire Medical Systems: Sold 614,772 at $37.60 on Dec 11, 2018 · $23.1M	Filing · EDGAR
—	—	—	Notice not machine-readable SteadyMed: Sold 2,123,098 at $4.46 on Aug 30, 2018 · $9.5M	Filing · EDGAR
—	—	—	Notice not machine-readable SteadyMed: Sold 2,123,098 at $4.46 on Aug 30, 2018 · $9.5M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 153,921 at $9.98 on Aug 20, 2018 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 153,921 at $9.98 on Aug 20, 2018 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 3,455 at $9.94 on Aug 16, 2018 · $34K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 362,765 at $9.94 on Aug 16, 2018 · $3.6M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 736 at $9.93 on Aug 15, 2018 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 77,314 at $9.93 on Aug 15, 2018 · $768K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 198 at $9.94 on Aug 14, 2018 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 20,777 at $9.94 on Aug 14, 2018 · $207K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 820 at $9.98 on Aug 13, 2018 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 86,103 at $9.98 on Aug 13, 2018 · $859K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 6,460 at $9.96 on Aug 10, 2018 · $64K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 678,333 at $9.96 on Aug 10, 2018 · $6.8M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 249 at $9.86 on Aug 9, 2018 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 26,139 at $9.86 on Aug 9, 2018 · $258K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 615 at $9.91 on Aug 9, 2018 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 64,575 at $9.91 on Aug 9, 2018 · $640K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 1,036 at $9.95 on Aug 9, 2018 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 108,729 at $9.95 on Aug 9, 2018 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 4,553 at $10.00 on Aug 8, 2018 · $46K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 478,107 at $10.00 on Aug 8, 2018 · $4.8M	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 478 at $10.01 on Aug 7, 2018 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 50,149 at $10.01 on Aug 7, 2018 · $502K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 1,125 at $11.71 on Aug 3, 2018 · $13K	Filing · EDGAR
—	—	—	Notice not machine-readable ViewRay: Sold 118,168 at $11.71 on Aug 3, 2018 · $1.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 1,600 at $13.49 on Jun 6, 2018 · $22K	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 17,100 at $13.57 on Jun 4, 2018 · $232K	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 50,000 at $13.49 on Jun 1, 2018 · $675K	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 121,000 at $13.52 on May 30, 2018 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Rhythm Pharmaceuticals: Sold 1,600 at $30.96 on May 22, 2018 · $50K	Filing · EDGAR
—	—	—	Notice not machine-readable Rhythm Pharmaceuticals: Sold 17,980 at $30.38 on May 22, 2018 · $546K	Filing · EDGAR
—	—	—	Notice not machine-readable Rhythm Pharmaceuticals: Sold 62,500 at $31.01 on May 21, 2018 · $1.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Rhythm Pharmaceuticals: Sold 69,136 at $30.77 on May 18, 2018 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 10,300 at $13.50 on May 14, 2018 · $139K	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 10,400 at $6.35 on Apr 30, 2018 · $66K	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 989,600 at $6.35 on Apr 30, 2018 · $6.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 31,983 at $11.53 on Mar 29, 2018 · $369K	Filing · EDGAR
—	—	—	Notice not machine-readable Adaptimmune Therapeutics: Sold 1,016,084 at $11.50 on Mar 27, 2018 · $11.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 16,937 at $34.92 on Mar 12, 2018 · $591K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 1,066 at $36.04 on Mar 12, 2018 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 11,305 at $36.44 on Mar 9, 2018 · $412K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 47,395 at $35.86 on Mar 9, 2018 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 21,300 at $34.67 on Mar 9, 2018 · $738K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 58,428 at $34.06 on Mar 8, 2018 · $2M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 445 at $32.06 on Mar 6, 2018 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 46,676 at $32.06 on Mar 6, 2018 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 192 at $30.77 on Mar 6, 2018 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 20,114 at $30.77 on Mar 6, 2018 · $619K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 886 at $30.01 on Mar 6, 2018 · $27K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 93,008 at $30.01 on Mar 6, 2018 · $2.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 11,372 at $33.03 on Mar 6, 2018 · $376K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 768 at $33.06 on Mar 5, 2018 · $25K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 80,516 at $33.06 on Mar 5, 2018 · $2.7M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,220 at $32.05 on Mar 5, 2018 · $39K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 128,092 at $32.05 on Mar 5, 2018 · $4.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 200 at $36.06 on Mar 5, 2018 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,851 at $32.80 on Mar 2, 2018 · $61K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 194,433 at $32.80 on Mar 2, 2018 · $6.4M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 2,533 at $31.92 on Mar 2, 2018 · $81K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 265,766 at $31.92 on Mar 2, 2018 · $8.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 35,558 at $36.33 on Mar 2, 2018 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 386,080 at $35.06 on Mar 2, 2018 · $13.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 75 at $8.98 on Feb 13, 2018 · $674	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 7,822 at $8.98 on Feb 13, 2018 · $70K	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 16,128 at $7.35 on Jan 3, 2018 · $119K	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 1,693,492 at $7.35 on Jan 3, 2018 · $12.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 1,392 at $5.70 on Dec 18, 2017 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Pieris Pharmaceuticals: Sold 146,243 at $5.70 on Dec 18, 2017 · $834K	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 250,000 at $82.50 on Dec 8, 2017 · $20.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 267,000 at $75.00 on Nov 22, 2017 · $20M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 8,377 at $76.23 on Nov 16, 2017 · $639K	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 71,598 at $75.37 on Nov 16, 2017 · $5.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 100,045 at $74.49 on Nov 16, 2017 · $7.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 43,300 at $73.48 on Nov 16, 2017 · $3.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 46,680 at $72.46 on Nov 16, 2017 · $3.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 1,899 at $0.68 on Oct 3, 2017 · $1K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 199,718 at $0.68 on Oct 3, 2017 · $136K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 888 at $0.74 on Sep 29, 2017 · $657	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 93,246 at $0.74 on Sep 29, 2017 · $69K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 672,000 at $28.25 on Sep 29, 2017 · $19M	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 3,592 at $0.72 on Sep 28, 2017 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 376,950 at $0.72 on Sep 28, 2017 · $271K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 498 at $0.92 on Sep 27, 2017 · $458	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 52,301 at $0.92 on Sep 27, 2017 · $48K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 706 at $1.03 on Sep 26, 2017 · $727	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 74,096 at $1.03 on Sep 26, 2017 · $76K	Filing · EDGAR
—	—	—	Notice not machine-readable Audentes Therapeutics: Sold 5,000 at $22.35 on Sep 7, 2017 · $112K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 553 at $40.77 on Sep 5, 2017 · $23K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 58,047 at $40.77 on Sep 5, 2017 · $2.4M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,808 at $39.63 on Sep 5, 2017 · $72K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 189,792 at $39.63 on Sep 5, 2017 · $7.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,651 at $37.94 on Sep 5, 2017 · $63K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 173,349 at $37.94 on Sep 5, 2017 · $6.6M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,038 at $37.72 on Sep 1, 2017 · $39K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 109,040 at $37.72 on Sep 1, 2017 · $4.1M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 424 at $37.82 on Aug 31, 2017 · $16K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 44,498 at $37.82 on Aug 31, 2017 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 125 at $1.50 on Aug 24, 2017 · $188	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 13,075 at $1.50 on Aug 24, 2017 · $20K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 10 at $1.50 on Aug 23, 2017 · $15	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 1,090 at $1.50 on Aug 23, 2017 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 52 at $1.52 on Aug 22, 2017 · $79	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 5,448 at $1.52 on Aug 22, 2017 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 28 at $1.49 on Aug 21, 2017 · $42	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 2,952 at $1.49 on Aug 21, 2017 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 630 at $1.52 on Aug 18, 2017 · $958	Filing · EDGAR
—	—	—	Notice not machine-readable Roka BioScience: Sold 66,166 at $1.52 on Aug 18, 2017 · $101K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 2,140 at $37.85 on Aug 17, 2017 · $81K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 224,780 at $37.85 on Aug 17, 2017 · $8.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 619 at $38.01 on Aug 16, 2017 · $24K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 64,961 at $38.01 on Aug 16, 2017 · $2.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 307 at $38.29 on Aug 15, 2017 · $12K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 32,193 at $38.29 on Aug 15, 2017 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 699 at $44.54 on Mar 14, 2017 · $31K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 73,401 at $44.54 on Mar 14, 2017 · $3.3M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 7 at $46.13 on Mar 13, 2017 · $323	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 693 at $46.13 on Mar 13, 2017 · $32K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,998 at $45.30 on Mar 13, 2017 · $91K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 208,712 at $45.30 on Mar 13, 2017 · $9.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 915 at $45.98 on Mar 10, 2017 · $42K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 96,113 at $45.98 on Mar 10, 2017 · $4.4M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 526 at $47.05 on Mar 3, 2017 · $25K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 55,246 at $47.05 on Mar 3, 2017 · $2.6M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 133 at $33.72 on Aug 12, 2016 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 13,967 at $33.72 on Aug 12, 2016 · $471K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,518 at $33.63 on Aug 11, 2016 · $51K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 159,382 at $33.63 on Aug 11, 2016 · $5.4M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 1,113 at $33.77 on Aug 10, 2016 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 116,825 at $33.77 on Aug 10, 2016 · $3.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Loxo Oncology: Sold 447,857 at $26.96 on Aug 10, 2016 · $12.1M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 4,010 at $30.59 on Aug 3, 2016 · $123K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS: Sold 420,990 at $30.59 on Aug 3, 2016 · $12.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 343,600 at $31.98 on Jul 25, 2016 · $11M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 3,700,000 at $32.00 on Jul 22, 2016 · $118.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 52,058 at $27.54 on Dec 23, 2015 · $1.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 47,942 at $26.78 on Dec 23, 2015 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 38,630 at $27.02 on Dec 22, 2015 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 111,370 at $26.39 on Dec 22, 2015 · $2.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 14,171 at $28.39 on Dec 21, 2015 · $402K	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 235,829 at $27.50 on Dec 21, 2015 · $6.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 590 at $29.22 on Nov 30, 2015 · $17K	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 2,716 at $28.64 on Nov 30, 2015 · $78K	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 29,000 at $28.97 on Nov 27, 2015 · $840K	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 34,800 at $28.91 on Nov 25, 2015 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 36,100 at $28.75 on Nov 24, 2015 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 80,800 at $28.45 on Nov 23, 2015 · $2.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 83,900 at $28.59 on Nov 20, 2015 · $2.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 127,300 at $28.60 on Nov 19, 2015 · $3.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 200 at $29.09 on Nov 17, 2015 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Otonomy: Sold 10,898 at $28.80 on Nov 17, 2015 · $314K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 2,785 at $5.98 on Oct 12, 2015 · $17K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 285,106 at $5.98 on Oct 12, 2015 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 2,041 at $7.03 on Oct 9, 2015 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 210,668 at $7.03 on Oct 9, 2015 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 3,837 at $7.24 on Oct 8, 2015 · $28K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 396,163 at $7.24 on Oct 8, 2015 · $2.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 454 at $7.36 on Oct 7, 2015 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 53,446 at $7.36 on Oct 7, 2015 · $393K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 59 at $7.80 on Oct 6, 2015 · $460	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 6,941 at $7.80 on Oct 6, 2015 · $54K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 1,163 at $8.19 on Oct 5, 2015 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 136,937 at $8.19 on Oct 5, 2015 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 403 at $10.34 on Oct 2, 2015 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 47,497 at $10.34 on Oct 2, 2015 · $491K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 400 at $10.34 on Oct 1, 2015 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 47,100 at $10.34 on Oct 1, 2015 · $487K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 369 at $10.17 on Sep 30, 2015 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 43,471 at $10.17 on Sep 30, 2015 · $442K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 89 at $10.08 on Sep 29, 2015 · $897	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 10,469 at $10.08 on Sep 29, 2015 · $106K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 89 at $10.30 on Sep 28, 2015 · $917	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 10,513 at $10.30 on Sep 28, 2015 · $108K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 311 at $11.07 on Sep 25, 2015 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 66,489 at $11.07 on Sep 25, 2015 · $736K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 800 at $10.07 on Sep 25, 2015 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 64,400 at $10.07 on Sep 25, 2015 · $649K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 8,152 at $11.00 on Sep 24, 2015 · $90K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 148 at $11.00 on Sep 24, 2015 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Sientra: Sold 6 at $9.78 on Sep 24, 2015 · $59	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 1,457,551 at $34.13 on May 18, 2015 · $49.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 90 at $294.82 on Mar 26, 2015 · $27K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 2,500 at $293.85 on Mar 26, 2015 · $735K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 6,000 at $292.13 on Mar 26, 2015 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,700 at $291.12 on Mar 26, 2015 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 13,974 at $290.02 on Mar 26, 2015 · $4.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 15,131 at $289.07 on Mar 26, 2015 · $4.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 26,028 at $288.11 on Mar 26, 2015 · $7.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 18,041 at $287.16 on Mar 26, 2015 · $5.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 7,611 at $286.24 on Mar 26, 2015 · $2.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 23,903 at $285.18 on Mar 26, 2015 · $6.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 16,845 at $284.20 on Mar 26, 2015 · $4.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 9,357 at $282.87 on Mar 26, 2015 · $2.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 8,397 at $282.13 on Mar 26, 2015 · $2.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 5,623 at $281.11 on Mar 26, 2015 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 2,800 at $270.23 on Mar 25, 2015 · $757K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,844 at $275.56 on Mar 24, 2015 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 12,066 at $275.00 on Mar 24, 2015 · $3.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 2,700 at $273.19 on Mar 24, 2015 · $738K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,050 at $272.13 on Mar 24, 2015 · $830K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 6,063 at $271.15 on Mar 24, 2015 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 9,574 at $270.13 on Mar 24, 2015 · $2.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,539 at $269.10 on Mar 24, 2015 · $414K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 6,764 at $268.13 on Mar 24, 2015 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,000 at $288.60 on Mar 23, 2015 · $289K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,400 at $286.04 on Mar 23, 2015 · $400K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 52 at $283.44 on Mar 23, 2015 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,548 at $283.29 on Mar 23, 2015 · $439K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,500 at $282.00 on Mar 23, 2015 · $987K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 6,306 at $281.01 on Mar 23, 2015 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 9,465 at $280.00 on Mar 23, 2015 · $2.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,668 at $279.00 on Mar 23, 2015 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 14,152 at $278.00 on Mar 23, 2015 · $3.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 8,195 at $276.96 on Mar 23, 2015 · $2.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 37,666 at $275.95 on Mar 23, 2015 · $10.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,579 at $274.86 on Mar 23, 2015 · $984K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 11,869 at $273.89 on Mar 23, 2015 · $3.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 8,638 at $272.79 on Mar 23, 2015 · $2.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 7,764 at $271.70 on Mar 23, 2015 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 40,598 at $270.70 on Mar 23, 2015 · $11M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 49,000 at $25.07 on Sep 17, 2014 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 2,600 at $26.06 on Sep 16, 2014 · $68K	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 42,400 at $25.45 on Sep 16, 2014 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 400 at $302.34 on Aug 26, 2014 · $121K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 5,400 at $301.36 on Aug 26, 2014 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 45,058 at $300.11 on Aug 26, 2014 · $13.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 10,400 at $299.13 on Aug 26, 2014 · $3.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,990 at $297.26 on Aug 25, 2014 · $592K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 10,010 at $296.59 on Aug 25, 2014 · $3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 25,442 at $295.52 on Aug 25, 2014 · $7.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 12,558 at $294.67 on Aug 25, 2014 · $3.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 990,000 at $26.35 on Aug 15, 2014 · $26.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 350 at $308.13 on Aug 14, 2014 · $108K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 14,640 at $307.06 on Aug 14, 2014 · $4.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 525 at $306.23 on Aug 14, 2014 · $161K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,732 at $305.14 on Aug 14, 2014 · $529K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,193 at $303.77 on Aug 14, 2014 · $362K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,100 at $302.55 on Aug 14, 2014 · $333K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 1,710 at $301.42 on Aug 14, 2014 · $515K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,985 at $300.21 on Aug 14, 2014 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 100 at $298.61 on Aug 14, 2014 · $30K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 9,985 at $297.76 on Aug 14, 2014 · $3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 6,192 at $296.86 on Aug 14, 2014 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 7,062 at $296.21 on Aug 14, 2014 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,254 at $294.96 on Aug 14, 2014 · $960K	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 4,468 at $293.85 on Aug 14, 2014 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 3,704 at $292.70 on Aug 14, 2014 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 5,000 at $20.04 on Jul 1, 2014 · $100K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 4,717 at $21.11 on Jun 30, 2014 · $100K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 9,283 at $20.33 on Jun 30, 2014 · $189K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 9,212 at $23.09 on Jun 27, 2014 · $213K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 79,120 at $21.79 on Jun 27, 2014 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 81,305 at $320.00 on Apr 9, 2014 · $26M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 40,088 at $62.50 on Oct 21, 2013 · $2.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intercept Pharmaceuticals: Sold 376,585 at $62.50 on Oct 15, 2013 · $23.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 41,100 at $7.58 on Feb 13, 2013 · $311K	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 108,900 at $7.58 on Feb 13, 2013 · $825K	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 41,483 at $7.52 on Feb 12, 2013 · $312K	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 110,700 at $7.52 on Feb 12, 2013 · $833K	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 100,000 at $7.08 on Dec 18, 2012 · $708K	Filing · EDGAR
—	—	—	Notice not machine-readable Supernus Pharmaceuticals: Sold 197,815 at $6.85 on Dec 17, 2012 · $1.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 2,244 at $14.43 on Sep 4, 2012 · $32K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 231,456 at $14.43 on Sep 4, 2012 · $3.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 3,456 at $14.61 on Jul 27, 2012 · $50K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 362,844 at $14.61 on Jul 27, 2012 · $5.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 4,500 at $2.51 on Jul 13, 2012 · $11K	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 474,800 at $2.51 on Jul 13, 2012 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 2,076 at $2.85 on Jul 12, 2012 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 218,624 at $2.85 on Jul 12, 2012 · $623K	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 4,792 at $2.90 on Jul 11, 2012 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable Complete Genomics: Sold 503,144 at $2.90 on Jul 11, 2012 · $1.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 1,283,300 at $0.73 on Jun 29, 2012 · $942K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 5,900 at $12.91 on Jun 19, 2012 · $76K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 611,200 at $12.91 on Jun 19, 2012 · $7.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 1,306,700 at $2.40 on Mar 22, 2012 · $3.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 125,000 at $2.87 on Mar 21, 2012 · $358K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 116,800 at $2.90 on Mar 20, 2012 · $339K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 700 at $11.03 on Mar 12, 2012 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 62,400 at $11.03 on Mar 12, 2012 · $688K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 300 at $11.25 on Mar 9, 2012 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 36,700 at $11.25 on Mar 9, 2012 · $413K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 3,000 at $10.86 on Feb 29, 2012 · $33K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 100 at $11.12 on Feb 28, 2012 · $1K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 10,000 at $11.12 on Feb 28, 2012 · $111K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 300 at $11.05 on Feb 27, 2012 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 28,700 at $11.05 on Feb 27, 2012 · $317K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 500 at $10.79 on Feb 3, 2012 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 49,500 at $10.79 on Feb 3, 2012 · $534K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 200 at $10.85 on Feb 2, 2012 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 23,100 at $10.85 on Feb 2, 2012 · $251K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 700 at $11.01 on Feb 1, 2012 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 69,300 at $11.01 on Feb 1, 2012 · $763K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 16,200 at $6.50 on Dec 13, 2011 · $105K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 40,000 at $6.75 on Dec 9, 2011 · $270K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 3,000 at $6.50 on Nov 18, 2011 · $20K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 24,000 at $6.67 on Nov 17, 2011 · $160K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 25,000 at $6.87 on Nov 16, 2011 · $172K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 50,000 at $6.93 on Nov 15, 2011 · $347K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 5,000 at $6.95 on Nov 14, 2011 · $35K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 5,000 at $7.14 on Nov 11, 2011 · $36K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 887 at $10.53 on Oct 31, 2011 · $9K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira Pharmaceuticals: Sold 96,554 at $10.53 on Oct 31, 2011 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 30,000 at $8.18 on Jun 10, 2011 · $245K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 37,000 at $8.11 on Jun 9, 2011 · $300K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 33,000 at $8.02 on Jun 8, 2011 · $265K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 34,200 at $8.53 on May 26, 2011 · $292K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 4,800 at $8.65 on May 25, 2011 · $42K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 69,334 at $8.03 on May 18, 2011 · $557K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 100,000 at $8.32 on May 17, 2011 · $832K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 12,000 at $7.20 on May 16, 2011 · $86K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 13,000 at $7.22 on May 11, 2011 · $94K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 106,400 at $7.23 on May 10, 2011 · $769K	Filing · EDGAR
—	—	—	Notice not machine-readable Anthera Pharmaceuticals: Sold 10,000 at $7.26 on May 9, 2011 · $73K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 300 at $16.30 on May 2, 2011 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 32,600 at $16.30 on May 2, 2011 · $531K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 1,000 at $16.01 on Apr 29, 2011 · $16K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 99,000 at $16.01 on Apr 29, 2011 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 75 at $2.90 on Apr 26, 2011 · $218	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 7,625 at $2.90 on Apr 26, 2011 · $22K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 350 at $2.90 on Apr 25, 2011 · $1K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 36,250 at $2.90 on Apr 25, 2011 · $105K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 25 at $2.90 on Apr 21, 2011 · $73	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 1,975 at $2.90 on Apr 21, 2011 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 4,733 at $16.91 on Apr 21, 2011 · $80K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 495,267 at $16.91 on Apr 21, 2011 · $8.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 2,367 at $16.18 on Apr 21, 2011 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 247,633 at $16.18 on Apr 21, 2011 · $4M	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 1,300 at $2.90 on Apr 20, 2011 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 7,600 at $15.79 on Apr 20, 2011 · $120K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 792,400 at $15.79 on Apr 20, 2011 · $12.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 100 at $2.93 on Apr 18, 2011 · $293	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 15,600 at $2.93 on Apr 18, 2011 · $46K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 10 at $16.26 on Apr 18, 2011 · $163 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 1,102 at $16.26 on Apr 18, 2011 · $18K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 11,522 at $15.65 on Apr 18, 2011 · $180K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 1,214,227 at $15.65 on Apr 18, 2011 · $19M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 16,668 at $14.86 on Apr 18, 2011 · $248K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 1,756,471 at $14.86 on Apr 18, 2011 · $26.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 300 at $2.90 on Apr 15, 2011 · $870	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 29,900 at $2.90 on Apr 15, 2011 · $87K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 200 at $2.91 on Apr 14, 2011 · $582	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 20,700 at $2.91 on Apr 14, 2011 · $60K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 500 at $2.94 on Apr 13, 2011 · $1K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 47,200 at $2.94 on Apr 13, 2011 · $139K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 100 at $2.90 on Apr 12, 2011 · $290	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 14,200 at $2.90 on Apr 12, 2011 · $41K	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 100 at $2.91 on Apr 11, 2011 · $291	Filing · EDGAR
—	—	—	Notice not machine-readable Athersys: Sold 12,900 at $2.91 on Apr 11, 2011 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 900 at $7.35 on Mar 28, 2011 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 92,200 at $7.35 on Mar 28, 2011 · $678K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 500 at $7.47 on Mar 25, 2011 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 56,400 at $7.47 on Mar 25, 2011 · $421K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 200 at $7.50 on Mar 24, 2011 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 22,800 at $7.50 on Mar 24, 2011 · $171K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 700 at $7.05 on Mar 21, 2011 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 76,300 at $7.05 on Mar 21, 2011 · $538K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 500 at $7.24 on Mar 15, 2011 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 49,500 at $7.24 on Mar 15, 2011 · $358K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 700 at $7.33 on Mar 14, 2011 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 74,300 at $7.33 on Mar 14, 2011 · $545K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 900 at $7.43 on Mar 11, 2011 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 99,100 at $7.43 on Mar 11, 2011 · $736K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 200 at $7.68 on Mar 7, 2011 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 24,800 at $7.68 on Mar 7, 2011 · $190K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 400 at $7.62 on Mar 4, 2011 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 42,600 at $7.62 on Mar 4, 2011 · $325K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 100 at $7.76 on Mar 3, 2011 · $776	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 6,900 at $7.76 on Mar 3, 2011 · $54K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 900 at $7.72 on Mar 2, 2011 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 94,100 at $7.72 on Mar 2, 2011 · $726K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 500 at $7.56 on Mar 1, 2011 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 49,500 at $7.56 on Mar 1, 2011 · $374K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 900 at $7.73 on Feb 28, 2011 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Amarin: Sold 99,100 at $7.73 on Feb 28, 2011 · $766K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 2,356 at $22.60 on Dec 9, 2010 · $53K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 54,000 at $16.23 on Sep 15, 2010 · $876K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 96,000 at $16.49 on Sep 14, 2010 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 100,000 at $16.70 on Sep 13, 2010 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 193,900 at $16.52 on Sep 10, 2010 · $3.2M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 8,800 at $16.36 on Sep 9, 2010 · $144K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 7,000 at $16.50 on Sep 8, 2010 · $116K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 40,100 at $16.79 on Sep 7, 2010 · $673K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 100,200 at $16.94 on Aug 18, 2010 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 288,000 at $17.06 on Aug 17, 2010 · $4.9M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 112,000 at $17.11 on Aug 16, 2010 · $1.9M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 101,100 at $16.31 on Aug 4, 2010 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 199,200 at $16.41 on Aug 3, 2010 · $3.3M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 17,400 at $16.39 on Aug 2, 2010 · $285K	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 128,000 at $16.66 on Jul 28, 2010 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable NxStage Medical: Sold 572,556 at $16.93 on Jul 27, 2010 · $9.7M	Filing · EDGAR
—	—	—	Notice not machine-readable Biodel: Sold 26,988 at $5.24 on Jun 10, 2009 · $141K	Filing · EDGAR
—	—	—	Notice not machine-readable ARYx Therapeutics: Sold 2,000,000 at $4.00 on May 22, 2009 · $8M	Filing · EDGAR
—	—	—	Notice not machine-readable Biodel: Sold 154,000 at $14.48 on Feb 12, 2008 · $2.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Avanir Pharmaceuticals: Sold 629,121 at $9.79 on May 31, 2006 · $6.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Given Imaging: Sold 22,500 at $18.14 on May 24, 2006 · $408K	Filing · EDGAR
—	—	—	Notice not machine-readable Dov Pharmaceutical: Sold 258,858 at $3.25 on May 16, 2006 · $841K	Filing · EDGAR
—	—	—	Notice not machine-readable Dov Pharmaceutical: Sold 11,422 at $3.25 on May 16, 2006 · $37K	Filing · EDGAR
—	—	—	Notice not machine-readable Dov Pharmaceutical: Sold 547,491 at $3.25 on May 16, 2006 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Dov Pharmaceutical: Sold 138,400 at $18.24 on Aug 15, 2005 · $2.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Dov Pharmaceutical: Sold 85,000 at $18.47 on Aug 12, 2005 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Given Imaging: Sold 170,000 at $30.08 on Jun 23, 2004 · $5.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Orthovita: Sold 200,000 at $3.95 on Jan 14, 2004 · $790K	Filing · EDGAR
—	—	—	Notice not machine-readable Lifecell: Sold 700,750 at $5.65 on Dec 23, 2003 · $4M	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Aspen Neuroscience ASPE Director, 10% owner · filings 2026 to 2026 · bought $15M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 2, 2026	Derivative converted	+196,541			196,541 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted	+642,745			839,286 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted	+616,984			1,456,270 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted	+625,743			2,082,013 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted	+507,119			2,589,132 See footnotes	Filing · EDGAR
Nov 2, 2026	Open-market or private purchase	+1,000,000	$15.00	$15M	3,589,132 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted Series Seed-2 Convertible Preferred Stock	−196,541			0 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted Series A-1 Convertible Preferred Stock	−642,745			0 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted Series A-2 Convertible Preferred Stock	−616,984			0 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted Series B Convertible Preferred Stock	−625,743			0 See footnotes	Filing · EDGAR
Nov 2, 2026	Derivative converted Series C Convertible Preferred Stock	−507,119			0 See footnotes	Filing · EDGAR

ADARx Pharmaceuticals ADRX Director, 10% owner · filings 2026 to 2026 · bought $16.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 28, 2026	Derivative converted	+10,690,530			10,690,530 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+2,000,962			12,691,492 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+769,601			13,461,093 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+564,187			14,025,280 See footnotes	Filing · EDGAR
Sep 28, 2026	Open-market or private purchase	+300,249	$17.00	$5.1M	14,325,529 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+7,127,019			7,127,019 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+1,333,975			8,460,994 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+513,067			8,974,061 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted	+256,448			9,230,509 See footnotes	Filing · EDGAR
Sep 28, 2026	Open-market or private purchase	+61,516	$17.00	$1M	9,292,025 See footnotes	Filing · EDGAR
Sep 28, 2026	Open-market or private purchase	+588,235	$17.00	$10M	588,235 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series A Preferred Stock	−10,690,530			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series B Preferred Stock	−2,000,962			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series B-1 Preferred Stock	−769,601			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series C Preferred Stock	−564,187			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series A Preferred Stock	−7,127,019			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series B Preferred Stock	−1,333,975			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series B-1 Preferred Stock	−513,067			0 See footnotes	Filing · EDGAR
Sep 28, 2026	Derivative converted Series C Preferred Stock	−256,448			0 See footnotes	Filing · EDGAR

Electra Therapeutics ETRA Director, 10% owner · filings 2026 to 2026 · bought $20M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 21, 2026	Derivative converted	+2,002,310			2,002,310 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted	+1,087,934			3,090,244 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted	+1,703,314			4,793,558 See footnotes	Filing · EDGAR
Sep 21, 2026	Open-market or private purchase	+333,333	$15.00	$5M	5,126,891 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted	+758,279			758,279 See footnotes	Filing · EDGAR
Sep 21, 2026	Open-market or private purchase	+1,000,000	$15.00	$15M	1,758,279 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted Series A Convertible Preferred Stock	−2,002,310			0 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted Series B Convertible Preferred Stock	−1,087,934			0 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted Series C Convertible Preferred Stock	−1,703,314			0 See footnotes	Filing · EDGAR
Sep 21, 2026	Derivative converted Series C Convertible Preferred Stock	−758,279			0 See footnotes	Filing · EDGAR

BlossomHill Therapeutics BLSM Director · filings 2026 to 2026 · bought $10M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 10, 2026	Derivative converted	+1,039,996			1,039,996 See footnotes	Filing · EDGAR
Aug 10, 2026	Derivative converted	+1,049,283			2,089,279 See footnotes	Filing · EDGAR
Aug 10, 2026	Open-market or private purchase	+625,000	$16.00	$10M	2,714,279 See footnotes	Filing · EDGAR
Aug 10, 2026	Derivative converted Series A Preferred Stock	−1,039,996			0 See footnotes	Filing · EDGAR
Aug 10, 2026	Derivative converted Series B Preferred Stock	−1,049,283			0 See footnotes	Filing · EDGAR

Braveheart Bio BRVE Director, 10% owner · filings 2026 to 2026 · bought $34.9M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 7, 2026	Derivative converted	+9,132,420			10,235,159 See footnotes	Filing · EDGAR
Aug 7, 2026	Open-market or private purchase	+1,666,667	$18.00	$30M	11,901,826 See footnotes	Filing · EDGAR
Aug 7, 2026	Open-market or private purchase	+273,333	$18.00	$4.9M	273,333 See footnotes	Filing · EDGAR
Aug 7, 2026	Derivative converted Series A Preferred Stock	−40,000,000			0 See footnotes	Filing · EDGAR

Scribe Therapeutics SCTX Director · filings 2026 to 2026 · bought $15M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 27, 2026	Derivative converted	+348,825			348,825 See footnotes	Filing · EDGAR
Jul 27, 2026	Open-market or private purchase	+1,000,000	$15.00	$15M	1,348,825 See footnotes	Filing · EDGAR
Jul 27, 2026	Derivative converted Series B Preferred Stock	−2,065,672			0 See footnotes	Filing · EDGAR

Yarrow Bioscience YARW Director · filings 2026 to 2026

No transactions in the filings read; Form 144 notices are listed above.

Sionna Therapeutics SION Director · filings 2025 to 2026 · sold $55.7M · bought $9.9M · $101.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 7, 2026	Sale under a 10b5-1 plan	−85,918	$44.86	$3.9M	2,469,959 See footnotes	Filing · EDGAR
Jun 30, 2026	Sale under a 10b5-1 plan	−115,844	$45.50	$5.3M	2,555,877 See footnotes	Filing · EDGAR
May 27, 2026	Sale under a 10b5-1 plan	−101	$44.49	$4K	2,671,721 See footnotes	Filing · EDGAR
May 11, 2026	Sale under a 10b5-1 plan	−184,639	$46.22	$8.5M	2,671,822 See footnotes(	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−59,767	$44.58	$2.7M	2,856,461 See footnotes(	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−48,546	$44.61	$2.2M	2,916,228 See footnotes(	Filing · EDGAR
Apr 18, 2026	Sale under a 10b5-1 plan	−2,948	$44.52	$131K	2,964,774 See footnotes	Filing · EDGAR
Apr 17, 2026	Sale under a 10b5-1 plan	−52,397	$44.68	$2.3M	2,967,722 See footnotes	Filing · EDGAR
Apr 16, 2026	Sale under a 10b5-1 plan	−226,906	$45.34	$10.3M	3,020,119 See footnotes	Filing · EDGAR
Apr 15, 2026	Sale under a 10b5-1 plan	−235,863	$44.64	$10.5M	3,247,025 See footnotes	Filing · EDGAR
Apr 14, 2026	Sale under a 10b5-1 plan	−47,814	$44.51	$2.1M	3,482,888 See footnotes	Filing · EDGAR
Feb 3, 2026	Sale under a 10b5-1 plan	−29,063	$44.58	$1.3M	3,530,702 See footnotes	Filing · EDGAR
Feb 2, 2026	Sale under a 10b5-1 plan	−1,890	$44.57	$84K	3,559,765 See footnotes	Filing · EDGAR
Dec 24, 2025	Sale under a 10b5-1 plan	−33,356	$44.55	$1.5M	3,561,655 See footnotes	Filing · EDGAR
Dec 19, 2025	Sale under a 10b5-1 plan	−875	$44.49	$39K	3,595,011 See footnotes	Filing · EDGAR
Dec 18, 2025	Sale under a 10b5-1 plan	−100	$44.49	$4K	3,595,886 See footnotes	Filing · EDGAR
Dec 17, 2025	Sale under a 10b5-1 plan	−900	$44.50	$40K	3,595,986 See footnotes	Filing · EDGAR
Nov 26, 2025	Sale under a 10b5-1 plan	−1,600	$44.49	$71K	3,596,886 See footnotes	Filing · EDGAR
Nov 25, 2025	Sale under a 10b5-1 plan	−11,890	$44.60	$530K	3,598,486 See footnotes	Filing · EDGAR
Nov 24, 2025	Sale under a 10b5-1 plan	−94,583	$44.54	$4.2M	3,610,376 See footnotes	Filing · EDGAR
Feb 10, 2025	Derivative converted	+3,154,959			3,154,959 See footnotes	Filing · EDGAR
Feb 10, 2025	Open-market or private purchase	+550,000	$18.00	$9.9M	3,704,959 See footnotes	Filing · EDGAR
Feb 10, 2025	Derivative converted Series B convertible preferred stock	−2,560,951			0 See footnotes	Filing · EDGAR
Feb 10, 2025	Derivative converted Series C convertible preferred stock	−2,048,760			0 See footnotes	Filing · EDGAR

Enliven Therapeutics IMRA 10% owner · filings 2020 to 2026 · sold $74.6M · bought $25M · $74.3M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 22, 2026	Open-market or private sale	−24,846	$45.38	$1.1M	220,882 See Footnotes	Filing · EDGAR
Jun 22, 2026	Open-market or private sale	−1,477	$45.00	$66K	219,405 See Footnotes	Filing · EDGAR
Jun 22, 2026	Open-market or private sale	−787,024	$45.38	$35.7M	6,601,878 See Footnotes	Filing · EDGAR
Jun 22, 2026	Open-market or private sale	−46,776	$45.00	$2.1M	6,555,102 See Footnotes	Filing · EDGAR
Jun 15, 2026	Open-market or private sale	−9,086	$45.02	$409K	245,728 See Footnotes	Filing · EDGAR
Jun 15, 2026	Open-market or private sale	−272,322	$45.02	$12.3M	7,388,902 See Footnotes	Filing · EDGAR
May 16, 2024	Open-market or private sale	−33,300	$22.14	$737K	254,814 See Footnotes	Filing · EDGAR
May 16, 2024	Open-market or private sale	−1,000,000	$22.14	$22.1M	7,663,349 See Footnotes	Filing · EDGAR
May 17, 2023	Option or RSU exercised or converted	+2,125	$4.28	$9K	8,663,349 See footnotes	Filing · EDGAR
May 17, 2023	Option or RSU exercised or converted Stock Options (Right to Buy)	−2,125			0 See footnotes	Filing · EDGAR
Feb 23, 2023	Grant or award from the company	+7,611,458			8,661,225 See footnotes	Filing · EDGAR
Feb 23, 2023	Grant or award from the company	+288,114			288,114 See footnotes	Filing · EDGAR
Jul 16, 2021	Open-market or private purchase	+1,666,666	$6.00	$10M	4,199,068 See footnotes	Filing · EDGAR
Mar 16, 2020	Derivative converted	+1,594,902			2,532,402 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Mar 16, 2020	Derivative converted Series B Preferred Stock	−10,046,294			0 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Mar 12, 2020	Open-market or private purchase	+937,500	$16.00	$15M	937,500 By OrbiMed Private Investments VII, LP	Filing · EDGAR

Shattuck Labs STTK Director · filings 2025 to 2026 · bought $5.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 11, 2026	Open-market or private purchase Pre-Funded Warrants (right to buy)	+1,041,667			26,519,541 See Footnote	Filing · EDGAR
Jun 11, 2026	Open-market or private purchase Pre-Funded Warrants (right to buy)	+208,333			5,303,908 See Footnote	Filing · EDGAR
Jun 8, 2026	Derivative converted Pre-Funded Warrants (right to buy)	+15,366,490			25,477,874 See Footnote	Filing · EDGAR
Jun 8, 2026	Derivative converted Pre-Funded Warrants (right to buy)	+3,073,298			5,095,575 See Footnote	Filing · EDGAR
Jun 8, 2026	Derivative converted Common Warrants (right to buy)	−15,366,490			0 See Footnote	Filing · EDGAR
Jun 8, 2026	Derivative converted Common Warrants (right to buy)	−3,073,298			0 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase	+5,255,106	$0.87	$4.6M	5,255,106 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase	+1,051,021	$0.87	$912K	1,051,021 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase Pre-Funded Warrants (right to buy)	+10,111,384			10,111,384 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase Pre-Funded Warrants (right to buy)	+2,022,277			2,022,277 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase Common Warrants (right to buy)	+15,366,490			15,366,490 See Footnote	Filing · EDGAR
Aug 25, 2025	Open-market or private purchase Common Warrants (right to buy)	+3,073,298			3,073,298 See Footnote	Filing · EDGAR

Q32 Bio QTTB Director, 10% owner · filings 2024 to 2026 · bought $15M

Date	Transaction	Shares	Price	Value	Held after	Source
May 28, 2026	Open-market or private purchase	+1,250,000	$8.00	$10M	3,502,987 See footnotes	Filing · EDGAR
May 28, 2026	Open-market or private purchase	+625,000	$8.00	$5M	625,000 See footnotes	Filing · EDGAR

Traws Pharma TRAW 10% owner · filings 2024 to 2026 · bought $998K

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 16, 2026	Open-market or private purchase	+597,729	$1.67	$998K	1,203,250 See Footnote	Filing · EDGAR
Apr 16, 2026	Open-market or private purchase Series A Warrants (right to buy)	+597,729			597,729 See Footnote	Filing · EDGAR
Apr 16, 2026	Open-market or private purchase Series B Warrants (right to buy)	+597,729			597,729 See Footnote	Filing · EDGAR
Apr 16, 2026	Open-market or private purchase Series C Warrants (right to buy)	+1,793,187			1,793,187 See Footnote	Filing · EDGAR
Dec 29, 2024	Open-market or private purchase Pre-Funded Warrant (right to buy)	+96,348			96,348 See Footnote	Filing · EDGAR
Dec 29, 2024	Open-market or private purchase Series A Warrant (right to buy)	+96,348			96,348 See Footnote	Filing · EDGAR

Prelude Therapeutics PRLD Director, 10% owner · filings 2020 to 2026 · bought $41M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 21, 2026	Open-market or private purchase	+1,689,189	$4.44	$7.5M	11,808,945 See footnotes	Filing · EDGAR
Apr 21, 2026	Open-market or private purchase	+1,126,126	$4.44	$5M	1,126,126 See footnotes	Filing · EDGAR
May 22, 2023	Open-market or private purchase	+869,565	$5.75	$5M	10,119,756 See footnotes	Filing · EDGAR
Jan 11, 2021	Open-market or private purchase Non-Voting Common Stock	+41,700	$60.00	$2.5M	5,596,886 See Footnotes	Filing · EDGAR
Sep 29, 2020	Derivative converted	+8,332,779			9,250,191 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series A Preferred Stock	−3,294,743			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series A Prefered Stock	−2,196,494			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series B Preferred Stock	−4,418,186			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series B Preferred Stock	−2,945,458			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series C Preferred Stock	−619,850			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series C Preferred Stock	−413,234			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Non-Voting Common Stock	+5,555,186			5,555,186 See footnote	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+526,300	$19.00	$10M	526,300 See footnote	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+710,500	$19.00	$13.5M	917,412 See footnote	Filing · EDGAR
Aug 21, 2020	Open-market or private purchase Series C Preferred Stock	+1,033,084			1,033,084 See footnote	Filing · EDGAR
Mar 27, 2020	Open-market or private purchase Series B Preferred Stock	+3,681,822			7,363,644 See footnote	Filing · EDGAR

ImageneBio IKNA Director · filings 2021 to 2026 · bought $6.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 14, 2026	Open-market or private purchase Pre-Funded Warrants (right to buy)	+336,603			336,603 See Footnote	Filing · EDGAR
Apr 14, 2026	Open-market or private purchase Pre-Funded Warrants (right to buy)	+384,689			384,689 See Footnote	Filing · EDGAR
Jul 25, 2025	Grant or award from the company	+83,611	$2.49	$208K	287,885 See Footnote	Filing · EDGAR
Aug 4, 2023	Grant or award from the company	+153,121			5,582,144 See Footnote	Filing · EDGAR
Aug 4, 2023	Grant or award from the company Series A Preferred Stock	+353,192			353,192 See Footnote	Filing · EDGAR
Aug 4, 2023	Grant or award from the company	+153,121			2,251,218 See Footnote	Filing · EDGAR
Jun 24, 2022	Open-market or private purchase	−65,965	$4.37	$288K	2,002,062 See Footnotes	Filing · EDGAR
Jun 24, 2022	Open-market or private purchase	−96,035	$5.37	$516K	2,098,097 See Footnotes	Filing · EDGAR
Jun 23, 2022	Open-market or private purchase	−23,419	$3.71	$87K	1,936,097 See Footnotes	Filing · EDGAR
Jun 22, 2022	Open-market or private purchase	−66,806	$3.55	$237K	1,912,678 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+1,470,872			1,470,872 See footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+42,614			42,614 See footnotes	Filing · EDGAR
Mar 30, 2021	Open-market or private purchase	+375,000	$16.00	$6M	1,845,872 See footnotes	Filing · EDGAR
Mar 30, 2021	Open-market or private purchase	+48,400	$16.00	$774K	91,014 See footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+5,429,023			5,429,023 See footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+157,288			157,288 See footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A Preferred Stock	−2,034,708			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A Preferred Stock	−551,259			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A-1 Preferred Stock	−2,411,260			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A-1 Preferred Stock	−653,277			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B Preferred Stock	−983,055			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B Preferred Stock	−266,336			0 See foonotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B Preferred Stock	−157,288			0 See footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B Preferred Stock	−42,614			0 See footnotes	Filing · EDGAR
Dec 21, 2020	Grant or award from the company Series B Preferred Stock	+8,938,148	$1.40	$12.5M	8,938,148 See foonotes	Filing · EDGAR
Dec 21, 2020	Grant or award from the company Series B Preferred Stock	+1,430,103	$1.40	$2M	1,430,103 See footnotes	Filing · EDGAR

Adicet Bio TORC 10% owner · filings 2018 to 2026 · sold $675K · bought $22.3M · $514K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 8, 2026	Open-market or private sale	−32,523	$6.29	$205K	0 See footnotes	Filing · EDGAR
Apr 8, 2026	Open-market or private sale	−40,416	$6.52	$264K	0 See footnotes	Filing · EDGAR
Apr 7, 2026	Open-market or private sale	−29,319	$6.53	$191K	34,923 See footnotes	Filing · EDGAR
Apr 7, 2026	Open-market or private sale	−2,400	$6.38	$15K	32,523 See footnotes	Filing · EDGAR
Oct 8, 2025	Open-market or private purchase	+1,500,000	$1.00	$1.5M	9,026,359 See footnotes	Filing · EDGAR
Oct 8, 2025	Open-market or private purchase	+3,500,000	$1.00	$3.5M	4,490,254 See footnotes	Filing · EDGAR
Jan 25, 2024	Open-market or private purchase	+1,841,100	$2.40	$4.4M	7,526,359 See footnotes	Filing · EDGAR
Jan 25, 2024	Open-market or private purchase	+242,200	$2.40	$581K	990,254 See footnotes	Filing · EDGAR
Jan 25, 2024	Open-market or private purchase	+1,041,700	$2.40	$2.5M	1,255,985 See footnotes	Filing · EDGAR
Jun 27, 2023	Open-market or private purchase	+125,000	$2.09	$261K	1,027,885 See footnotes	Filing · EDGAR
Jun 27, 2023	Open-market or private purchase	+250,000	$2.09	$522K	646,657 See footnotes	Filing · EDGAR
Jun 27, 2023	Open-market or private purchase	+442,000	$2.09	$924K	5,685,259 See footnotes	Filing · EDGAR
Jun 27, 2023	Open-market or private purchase	+58,000	$2.09	$121K	748,054 See footnotes	Filing · EDGAR
Dec 10, 2021	Grant or award from the company	+214,285	$14.00	$3M	242,285 See Footnotes	Filing · EDGAR
Feb 12, 2021	Grant or award from the company	+420,299	$13.00	$5.5M	5,243,259 See Footnotes	Filing · EDGAR
Feb 12, 2021	Grant or award from the company	+104,050	$13.00	$1.4M	396,657 See Footnotes	Filing · EDGAR
Sep 17, 2020	Grant or award from the company Stock Option (Right to Buy)	+30,000			30,000 See Footnote	Filing · EDGAR
Sep 17, 2020	Grant or award from the company Stock Option (Right to Buy)	+30,000			30,000 See Footnote	Filing · EDGAR
Sep 15, 2020	Grant or award from the company	+4,822,960			4,822,960 See Footnotes	Filing · EDGAR
Sep 15, 2020	Grant or award from the company	+902,885			902,855 See Footnotes	Filing · EDGAR
Sep 15, 2020	Grant or award from the company	+292,607			292,607 See Footnotes	Filing · EDGAR
Jan 30, 2018	Derivative converted	+2,425,485			2,425,485 See Footnotes	Filing · EDGAR
Jan 30, 2018	Derivative converted	+1,871,569			4,297,054 See Footnotes	Filing · EDGAR
Jan 30, 2018	Open-market or private purchase	+533,333	$15.00	$8M	4,830,387 See Footnotes	Filing · EDGAR
Jan 30, 2018	Derivative converted Series A Preferred Stock	−2,425,482			0 See Footnotes	Filing · EDGAR
Jan 30, 2018	Derivative converted Series B Preferred Stock	−1,871,569			0 See Footnotes	Filing · EDGAR

Keros Therapeutics KROS Shareholder; Director · filings 2020 to 2026 · sold $11M · bought $6M · $11.7M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 21, 2025	Returned to the company	−140,057	$17.75	$2.5M	759,155 See footnotes	Filing · EDGAR
Nov 21, 2025	Returned to the company	−74,465	$17.75	$1.3M	45,057 See footnotes	Filing · EDGAR
Aug 13, 2024	Open-market or private sale	−220,600	$44.01	$9.7M	899,212 See footnotes	Filing · EDGAR
Aug 13, 2024	Open-market or private sale	−29,400	$44.01	$1.3M	119,522 See footnotes	Filing · EDGAR
Apr 13, 2020	Derivative converted	+744,612			744,612 See footnote	Filing · EDGAR
Apr 13, 2020	Derivative converted	+148,922			148,922 See footnote	Filing · EDGAR
Apr 13, 2020	Open-market or private purchase	+375,200	$16.00	$6M	1,119,812 See footnote	Filing · EDGAR
Apr 13, 2020	Derivative converted Series C Preferred Stock	−744,612			0 See footnote	Filing · EDGAR
Apr 13, 2020	Derivative converted Series C Preferred Stock	−148,922			0 See footnote	Filing · EDGAR

PMV Pharmaceuticals PMVP 10% owner · filings 2020 to 2025 · sold $13.3M · bought $17.1M · $5.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 23, 2025	Open-market or private sale	−1,000,000	$1.52	$1.5M	4,975,291 See Footnotes	Filing · EDGAR
Sep 10, 2025	Open-market or private sale	−500,000	$1.80	$900K	5,975,291 See Footnotes	Filing · EDGAR
Nov 22, 2023	Open-market or private sale	−87,786	$2.23	$196K	0 See Footnotes	Filing · EDGAR
May 26, 2022	Open-market or private sale	−26,253	$15.93	$418K	87,786 See Footnotes	Filing · EDGAR
Mar 31, 2022	Open-market or private sale	−34,500	$21.17	$730K	0 See Footnotes	Filing · EDGAR
Mar 30, 2022	Open-market or private sale	−75,000	$22.39	$1.7M	34,500 See Footnotes	Filing · EDGAR
Mar 29, 2022	Open-market or private sale	−365,000	$21.52	$7.9M	109,500 See Footnotes	Filing · EDGAR
Sep 29, 2020	Derivative converted	+4,025,076			4,500,076 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted	+1,076,891			5,576,967 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted	+518,191			6,095,158 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted	+380,133			6,475,291 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted	+114,039			114,039 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series A Preferred Stock	−4,025,076			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series B Preferred Stock	−1,076,891			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series C Preferred Stock	−518,191			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series D Preferred Stock	−380,133			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series D Preferred Stock	−114,039			0 See footnote	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+475,000	$18.00	$8.6M	475,000 See footnote	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+475,000	$18.00	$8.6M	475,000 See footnote	Filing · EDGAR

Disc Medicine GMTX Shareholder · filings 2021 to 2025 · sold $52.7M · bought $5.5M · $328.1M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 24, 2025	Open-market or private sale	−1,956	$54.11	$106K	482,308 See Footnotes	Filing · EDGAR
Mar 24, 2025	Open-market or private sale	−3,026	$54.11	$164K	746,171 See Footnotes	Filing · EDGAR
Mar 24, 2025	Open-market or private sale	−756	$54.11	$41K	186,541 See Footnotes	Filing · EDGAR
Mar 21, 2025	Open-market or private sale	−3,412	$54.00	$184K	484,264 See Footnotes	Filing · EDGAR
Mar 21, 2025	Open-market or private sale	−5,279	$54.00	$285K	749,197 See Footnotes	Filing · EDGAR
Mar 21, 2025	Open-market or private sale	−1,320	$54.00	$71K	187,297 See Footnotes	Filing · EDGAR
Mar 20, 2025	Open-market or private sale	−941	$54.01	$51K	487,676 See Footnotes	Filing · EDGAR
Mar 20, 2025	Open-market or private sale	−1,457	$54.01	$79K	754,476 See Footnotes	Filing · EDGAR
Mar 20, 2025	Open-market or private sale	−364	$54.01	$20K	188,617 See Footnotes	Filing · EDGAR
Mar 19, 2025	Open-market or private sale	−13,517	$54.02	$730K	488,617 See Footnotes	Filing · EDGAR
Mar 19, 2025	Open-market or private sale	−20,911	$54.02	$1.1M	755,933 See Footnotes	Filing · EDGAR
Mar 19, 2025	Open-market or private sale	−5,228	$54.02	$282K	188,981 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−603	$55.05	$33K	529,884 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−933	$55.05	$51K	819,774 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−233	$55.05	$13K	204,942 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−27,750	$54.44	$1.5M	502,134 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−42,930	$54.44	$2.3M	776,844 See Footnotes	Filing · EDGAR
Mar 12, 2025	Open-market or private sale	−10,733	$54.44	$584K	194,209 See Footnotes	Filing · EDGAR
Mar 11, 2025	Open-market or private sale	−9,222	$54.01	$498K	530,487 See Footnotes	Filing · EDGAR
Mar 11, 2025	Open-market or private sale	−14,267	$54.01	$771K	820,707 See Footnotes	Filing · EDGAR
Mar 11, 2025	Open-market or private sale	−3,567	$54.01	$193K	205,175 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−68,766	$54.29	$3.7M	539,845 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−106,384	$54.29	$5.8M	835,185 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−26,596	$54.29	$1.4M	208,795 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−136	$55.01	$7K	539,709 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−211	$55.01	$12K	834,974 See Footnotes	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−53	$55.01	$3K	208,742 See Footnotes	Filing · EDGAR
Jun 17, 2024	Open-market or private purchase	+28,404	$36.00	$1M	608,611 See Footnotes	Filing · EDGAR
Jun 17, 2024	Open-market or private purchase	+43,944	$36.00	$1.6M	941,569 See Footnotes	Filing · EDGAR
Jun 17, 2024	Open-market or private purchase	+10,986	$36.00	$395K	235,391 See Footnotes	Filing · EDGAR
Dec 18, 2023	Option or RSU exercised or converted	+1,724	$38.00	$66K	1,724 direct	Filing · EDGAR
Dec 18, 2023	Open-market or private sale	−1,724	$59.24	$102K	0 direct	Filing · EDGAR
Dec 18, 2023	Option or RSU exercised or converted Stock Options (Right to Buy)	−1,724			0 direct	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−228,500	$56.75	$13M	897,625 See footnotes	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−147,600	$56.75	$8.4M	580,207 See footnotes	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−57,100	$56.75	$3.2M	224,405 See footnotes	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−100	$57.73	$6K	1,126,125 See footnotes	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−100	$57.73	$6K	727,807 See footnotes	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−56,200	$58.56	$3.3M	1,126,225 See footnotes	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−36,400	$58.56	$2.1M	727,907 See footnotes	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−14,100	$58.56	$826K	281,505 See footnotes	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−14,400	$60.16	$866K	1,182,425 See footnotes	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−9,300	$60.16	$559K	764,307 See footnotes	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−3,600	$60.16	$217K	295,605 See footnotes	Filing · EDGAR
Feb 15, 2023	Open-market or private purchase	+57,318	$23.00	$1.3M	1,196,825 See footnotes	Filing · EDGAR
Feb 15, 2023	Open-market or private purchase	+37,049	$23.00	$852K	773,607 See footnotes	Filing · EDGAR
Feb 15, 2023	Open-market or private purchase	+14,329	$23.00	$330K	299,205 See footnotes	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+284,876			284,876 See footnote	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+582,622			582,622 See footnote	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+153,936			736,558 See footnote	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+1,139,507			1,139,507 See footnote	Filing · EDGAR

Turnstone Biologics TSBX Director · filings 2023 to 2025 · bought $5M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 8, 2025	Tendered in a change of control	−3,099,265	$0.34	$1.1M	0 See Footnote	Filing · EDGAR
Jul 20, 2023	Derivative converted	+2,682,599			2,682,599 See Footnote	Filing · EDGAR
Jul 20, 2023	Open-market or private purchase	+416,666	$12.00	$5M	3,099,265 See Footnote	Filing · EDGAR
Jul 20, 2023	Derivative converted Series B-1 Preferred Stock	−937,372			0 See Footnotes	Filing · EDGAR
Jul 20, 2023	Derivative converted Series B-2 Preferred Stock	−1,249,829			0 See Footnotes	Filing · EDGAR
Jul 20, 2023	Derivative converted Series C Preferred Stock	−266,240			0 See Footnotes	Filing · EDGAR
Jul 20, 2023	Derivative converted Series D Preferred Stock	−229,158			0 See Footnotes	Filing · EDGAR

Passage BIO PASG Stockholder · filings 2020 to 2025 · sold $1M · bought $10.7M · $6.2M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 26, 2025	Open-market or private sale	−213,257	$0.33	$70K	6,066,343 See footnotes	Filing · EDGAR
Jun 25, 2025	Open-market or private sale	−138,800	$0.33	$46K	6,279,600 See footnotes	Filing · EDGAR
Jun 24, 2025	Open-market or private sale	−231,600	$0.35	$81K	6,418,400 See footnotes	Filing · EDGAR
Apr 24, 2025	Open-market or private sale	−68,195	$0.32	$22K	6,650,000 See footnotes	Filing · EDGAR
Apr 23, 2025	Open-market or private sale	−89,328	$0.34	$30K	6,718,195 See footnotes	Filing · EDGAR
Apr 22, 2025	Open-market or private sale	−78,049	$0.34	$27K	6,807,523 See footnotes	Filing · EDGAR
Apr 17, 2025	Open-market or private sale	−77,090	$0.33	$25K	6,885,572 See footnotes	Filing · EDGAR
Apr 16, 2025	Open-market or private sale	−61,638	$0.33	$20K	6,962,662 See footnotes	Filing · EDGAR
Apr 15, 2025	Open-market or private sale	−10,326	$0.38	$4K	7,024,300 See footnotes	Filing · EDGAR
Jan 14, 2025	Open-market or private sale	−79,024	$0.60	$47K	7,034,626 See footnotes	Filing · EDGAR
Jan 13, 2025	Open-market or private sale	−17,986	$0.64	$12K	7,113,650 See footnotes	Filing · EDGAR
Jan 10, 2025	Open-market or private sale	−126,209	$0.66	$83K	7,131,636 See footnotes	Filing · EDGAR
Jan 8, 2025	Open-market or private sale	−75,007	$0.68	$51K	7,257,845 See footnotes	Filing · EDGAR
Jan 7, 2025	Open-market or private sale	−52,536	$0.71	$37K	7,332,852 See footnotes	Filing · EDGAR
Jan 6, 2025	Open-market or private sale	−19,481	$0.77	$15K	7,385,388 See footnotes	Filing · EDGAR
Dec 20, 2024	Open-market or private sale	−230,321	$0.60	$138K	7,404,869 See footnotes	Filing · EDGAR
Dec 11, 2024	Open-market or private sale	−80	$0.80	$64	7,635,190 See footnotes	Filing · EDGAR
Dec 10, 2024	Open-market or private sale	−8,015	$0.80	$6K	7,635,270 See footnotes	Filing · EDGAR
Dec 9, 2024	Open-market or private sale	−54,181	$0.84	$46K	7,643,285 See footnotes	Filing · EDGAR
Dec 6, 2024	Open-market or private sale	−20,903	$0.82	$17K	7,697,466 See footnotes	Filing · EDGAR
Dec 4, 2024	Open-market or private sale	−76,200	$0.79	$60K	7,718,369 See footnotes	Filing · EDGAR
Sep 19, 2024	Open-market or private sale	−39,300	$0.71	$28K	7,794,569 See footnotes	Filing · EDGAR
Sep 18, 2024	Open-market or private sale	−25,631	$0.73	$19K	7,833,869 See footnotes	Filing · EDGAR
Sep 17, 2024	Open-market or private sale	−111,400	$0.73	$81K	7,859,500 See footnotes	Filing · EDGAR
Sep 16, 2024	Open-market or private sale	−63,100	$0.74	$47K	7,970,900 See footnotes	Filing · EDGAR
Jun 28, 2023	Open-market or private purchase	+575,195	$0.84	$483K	8,034,000 See footnotes	Filing · EDGAR
Jun 27, 2023	Open-market or private purchase	+617,382	$0.84	$519K	7,458,805 See footnotes	Filing · EDGAR
May 4, 2022	Open-market or private purchase	+303,500	$1.94	$589K	6,841,423 See Footnotes	Filing · EDGAR
May 3, 2022	Open-market or private purchase	+221,500	$1.93	$427K	6,537,923 See Footnotes	Filing · EDGAR
Jan 20, 2022	Open-market or private purchase	+50,800	$5.00	$254K	6,316,423 See Footnotes	Filing · EDGAR
Jan 19, 2022	Open-market or private purchase	+43,300	$5.11	$221K	6,265,623 See Footnotes	Filing · EDGAR
Jan 18, 2022	Open-market or private purchase	+114,700	$5.46	$626K	6,222,323 See Footnotes	Filing · EDGAR
Jan 14, 2022	Open-market or private purchase	+10,300	$5.60	$58K	6,107,623 See Footnotes	Filing · EDGAR
Jan 13, 2022	Open-market or private purchase	+41,800	$5.52	$231K	6,097,323 See Footnotes	Filing · EDGAR
Jan 12, 2022	Open-market or private purchase	+100,000	$5.65	$565K	6,055,523 See Footnotes	Filing · EDGAR
Jan 11, 2022	Open-market or private purchase	+8,200	$5.53	$45K	5,955,523 See Footnotes	Filing · EDGAR
Mar 3, 2020	Derivative converted	+3,721,552			4,094,852 See Footnote	Filing · EDGAR
Mar 3, 2020	Derivative converted	+1,311,469			5,406,321 See Footnote	Filing · EDGAR
Mar 3, 2020	Derivative converted	+541,002			5,947,323 See Footnote	Filing · EDGAR
Mar 3, 2020	Derivative converted Series A-1 Preferred Stock	−3,721,552			0 See Footnote	Filing · EDGAR
Mar 3, 2020	Derivative converted Series A-2 Preferred Stock	−1,311,469			0 See Footnote	Filing · EDGAR
Mar 3, 2020	Derivative converted Series B Preferred Stock	−541,002			0 See Footnote	Filing · EDGAR
Feb 28, 2020	Open-market or private purchase	+373,300	$18.00	$6.7M	373,300 See Footnote	Filing · EDGAR

Corvus Pharmaceuticals CRVS Director, 10% owner · filings 2016 to 2025 · sold $11.6M · bought $22.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 27, 2025	In-the-money option exercised	+1,397,684	$3.50	$4.9M	8,341,338 See Footnotes	Filing · EDGAR
Jun 27, 2025	Open-market or private sale	−1,176,332	$4.16	$4.9M	7,165,006 See Footnotes	Filing · EDGAR
Jun 27, 2025	In-the-money option exercised Common Warrants (right to buy)	−1,397,684			0 See Footnotes	Filing · EDGAR
May 6, 2024	Open-market or private purchase Pre-Funded Warrants (right to buy)	+1,444,085	$1.73	$2.5M	1,444,085 See Footnotes	Filing · EDGAR
May 6, 2024	Open-market or private purchase Common Warrants (right to buy)	+1,397,684			1,397,684 See Footnotes	Filing · EDGAR
Sep 20, 2021	Open-market or private sale	−1,109,644	$6.09	$6.8M	6,943,654 See Footnotes	Filing · EDGAR
Feb 17, 2021	Open-market or private purchase	+1,285,714	$3.50	$4.5M	8,053,298 See Footnotes	Filing · EDGAR
Aug 6, 2019	Open-market or private purchase	+142,656	$3.51	$501K	6,767,584 See Footnotes	Filing · EDGAR
Jul 1, 2019	Open-market or private purchase	+59,243	$3.91	$232K	6,624,928 See Footnotes	Filing · EDGAR
Jun 28, 2019	Open-market or private purchase	+565,178	$3.72	$2.1M	6,565,685 See Footnotes	Filing · EDGAR
Jun 27, 2019	Open-market or private purchase	+32,923	$3.34	$110K	6,000,507 See Footnotes	Filing · EDGAR
Mar 12, 2018	Open-market or private purchase	+588,235	$8.50	$5M	5,967,584 See Footnotes	Filing · EDGAR
Jun 24, 2016	Open-market or private purchase	+900	$12.99	$12K	5,379,349 See Footnotes	Filing · EDGAR
Jun 23, 2016	Open-market or private purchase	+100	$12.92	$1K	5,378,449 See Footnotes	Filing · EDGAR
Jun 21, 2016	Open-market or private purchase	+26,083	$12.87	$336K	5,378,349 See Footnotes	Filing · EDGAR
Jun 17, 2016	Open-market or private purchase	+12,300	$12.48	$154K	5,352,266 See Footnotes	Filing · EDGAR
Jun 16, 2016	Open-market or private purchase	+5,000	$12.04	$60K	5,339,966 See Footnotes	Filing · EDGAR
Jun 15, 2016	Open-market or private purchase	+5,000	$11.94	$60K	5,334,966 See Footnotes	Filing · EDGAR
Jun 14, 2016	Open-market or private purchase	+10,000	$12.71	$127K	5,329,966 See Footnotes	Filing · EDGAR
Jun 10, 2016	Open-market or private purchase	+20,000	$12.98	$260K	5,319,966 See Footnotes	Filing · EDGAR
Jun 9, 2016	Open-market or private purchase	+30,000	$12.95	$389K	5,299,966 See Footnotes	Filing · EDGAR
May 20, 2016	Open-market or private purchase	+4,716	$13.09	$62K	5,269,966 See Footnotes	Filing · EDGAR
May 19, 2016	Open-market or private purchase	+2,539	$12.11	$31K	5,265,189 See Footnotes	Filing · EDGAR
May 19, 2016	Open-market or private purchase	+61	$12.75	$778	5,265,250 See Footnotes	Filing · EDGAR
May 18, 2016	Open-market or private purchase	+4,200	$11.55	$49K	5,262,650 See Footnotes	Filing · EDGAR
Mar 29, 2016	Derivative converted	+3,994,674			3,994,674 See Footnotes	Filing · EDGAR
Mar 29, 2016	Derivative converted	+713,776			4,708,450 See Footnotes	Filing · EDGAR
Mar 29, 2016	Open-market or private purchase	+550,000	$15.00	$8.3M	5,258,450 See Footnotes	Filing · EDGAR
Mar 29, 2016	Derivative converted Series A Convertible Preferred Stock	−3,994,674			0 See Footnotes	Filing · EDGAR
Mar 29, 2016	Derivative converted Series B Convertible Preferred Stock	−713,776			0 See Footnotes	Filing · EDGAR

NeuroPace NPCE 10% owner · filings 2021 to 2025 · sold $11.4M · bought $4M · $2.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 14, 2025	Open-market or private sale	−134,136	$15.83	$2.1M	3,272,199 See Footnotes	Filing · EDGAR
May 14, 2025	Open-market or private sale	−34,000	$15.94	$542K	3,238,199 See Footnotes	Filing · EDGAR
May 3, 2024	Open-market or private sale	−4,674	$14.03	$66K	3,406,335 See Footnotes	Filing · EDGAR
May 2, 2024	Open-market or private sale	−8,842	$14.01	$124K	3,411,009 See Footnotes	Filing · EDGAR
May 1, 2024	Open-market or private sale	−15,690	$14.02	$220K	3,419,851 See Footnotes	Filing · EDGAR
Apr 24, 2024	Open-market or private sale	−1,781	$14.06	$25K	3,435,541 See Footnotes	Filing · EDGAR
Apr 23, 2024	Open-market or private sale	−21,791	$14.29	$311K	3,437,322 See Footnotes	Filing · EDGAR
Apr 22, 2024	Open-market or private sale	−24,609	$14.05	$346K	3,459,113 See Footnotes	Filing · EDGAR
Apr 19, 2024	Open-market or private sale	−18,253	$14.02	$256K	3,483,722 See Footnotes	Filing · EDGAR
Apr 18, 2024	Open-market or private sale	−2,623	$14.06	$37K	3,501,975 See Footnotes	Filing · EDGAR
Apr 17, 2024	Open-market or private sale	−300	$14.15	$4K	3,504,598 See Footnotes	Filing · EDGAR
Apr 16, 2024	Open-market or private sale	−14,069	$14.01	$197K	3,504,898 See Footnotes	Filing · EDGAR
Apr 12, 2024	Open-market or private sale	−23,101	$14.42	$333K	3,518,967 See Footnotes	Filing · EDGAR
Apr 11, 2024	Open-market or private sale	−461,899	$14.49	$6.7M	3,542,068 See Footnotes	Filing · EDGAR
Oct 3, 2023	Open-market or private sale	−700	$9.02	$6K	4,003,967 See Footnotes	Filing · EDGAR
Oct 2, 2023	Open-market or private sale	−7,614	$9.08	$69K	4,004,667 See Footnotes	Filing · EDGAR
Apr 26, 2021	Derivative converted	+3,777,281			4,012,281 See Footnotes	Filing · EDGAR
Apr 26, 2021	Derivative converted Series A' Preferred Stock	−171,895			0 See Footnotes	Filing · EDGAR
Apr 26, 2021	Derivative converted Series B' Preferred Stock	−3,605,386			0 See Footnotes	Filing · EDGAR
Apr 21, 2021	Open-market or private purchase	+235,000	$17.00	$4M	235,000 See Footnote	Filing · EDGAR

Xtant Medical Holdings XTNT 10% owner · filings 2018 to 2025 · sold $30.7M · bought $6.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 10, 2025	Open-market or private sale	−56,004,974	$0.42	$23.5M	0 See footnotes	Filing · EDGAR
Apr 10, 2025	Open-market or private sale	−17,109,618	$0.42	$7.2M	0 See footnotes	Filing · EDGAR
Aug 15, 2022	Other acquisition or disposition (see the filing)	+215,415			215,415 See Footnotes	Filing · EDGAR
Aug 15, 2022	Other acquisition or disposition (see the filing)	+215,415			215,415 See Footnotes	Filing · EDGAR
Aug 15, 2021	Other acquisition or disposition (see the filing)	+85,337			120,549 See Footnotes	Filing · EDGAR
Aug 15, 2021	Other acquisition or disposition (see the filing)	+85,337			120,549 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+765,992	$0.01	$8K	53,468,376 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+765,992	$0.01	$8K	54,234,368 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+1,531,984	$0.01	$15K	55,766,352 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+434,008	$0.01	$4K	15,734,696 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+434,008	$0.01	$4K	16,168,704 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised	+868,016	$0.01	$9K	17,036,720 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−765,992			0 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−434,008			0 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−765,992			0 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−434,008			0 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−1,531,984			0 See Footnotes	Filing · EDGAR
Nov 17, 2020	In-the-money option exercised Warrant (right to buy)	−868,016			0 See Footnotes	Filing · EDGAR
Oct 1, 2020	Grant or award from the company	+46,784,775	$1.07	$50.1M	52,702,384 See Footnotes	Filing · EDGAR
Oct 1, 2020	Grant or award from the company	+11,969,619	$1.07	$12.8M	15,300,688 See Footnotes	Filing · EDGAR
May 6, 2020	Grant or award from the company Warrant (right to buy)	+1,531,984			1,531,984 See footnotes	Filing · EDGAR
May 6, 2020	Grant or award from the company Warrant (right to buy)	+868,016			868,016 See footnotes	Filing · EDGAR
Feb 5, 2020	Other acquisition or disposition (see the filing)	+70,423			91,256 See footnote	Filing · EDGAR
Feb 5, 2020	Other acquisition or disposition (see the filing)	+70,423			91,256 See footnote	Filing · EDGAR
Oct 30, 2019	Other acquisition or disposition (see the filing)	+20,833			20,833 See Footnote	Filing · EDGAR
Oct 30, 2019	Other acquisition or disposition (see the filing)	+20,833			20,833 See Footnote	Filing · EDGAR
Apr 1, 2019	Grant or award from the company Warrant (right to buy)	+765,992			765,992 See Footnotes	Filing · EDGAR
Apr 1, 2019	Grant or award from the company Warrant (right to buy)	+434,008			434,008 See Footnotes	Filing · EDGAR
Sep 17, 2018	Grant or award from the company Warrant (right to buy)	+765,992			765,992 See Footnotes	Filing · EDGAR
Sep 17, 2018	Grant or award from the company Warrant (right to buy)	+434,008			434,008 See Footnotes	Filing · EDGAR
Feb 14, 2018	Grant or award from the company	+5,126,534	$7.20	$36.9M	5,287,197 See Footnotes	Filing · EDGAR
Feb 14, 2018	Grant or award from the company	+2,905,396	$7.20	$20.9M	2,973,996 See Footnotes	Filing · EDGAR
Feb 14, 2018	Open-market or private purchase	+603,687	$7.20	$4.3M	5,890,884 See Footnotes	Filing · EDGAR
Feb 14, 2018	Open-market or private purchase	+342,132	$7.20	$2.5M	3,316,128 See Footnotes	Filing · EDGAR
Feb 14, 2018	Returned to the company Convertible Note	+33,190,000	$46.56	$1.5B	0 See Footnotes	Filing · EDGAR
Feb 14, 2018	Returned to the company Convertible Note	+18,810,000	$46.56	$875.8M	0 See Footnotes	Filing · EDGAR
Feb 14, 2018	Returned to the company Convertible Note	+1,428,553	$34.80	$49.7M	0 See Footnotes	Filing · EDGAR
Feb 14, 2018	Returned to the company Convertible Note	+809,614	$34.80	$28.2M	0 See Footnotes	Filing · EDGAR

Compass Therapeutics CMPX Director, 10% owner · filings 2020 to 2025 · sold $5.7M · bought $27.9M · $5.7M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 9, 2025	Open-market or private sale	−3,571,428	$1.59	$5.7M	0 See footnotes	Filing · EDGAR
Nov 8, 2022	Open-market or private purchase	+402,000	$3.21	$1.3M	15,219,994 See Footnotes	Filing · EDGAR
May 13, 2022	Open-market or private purchase	+30,722	$2.49	$76K	14,817,994 See Footnotes	Filing · EDGAR
May 12, 2022	Open-market or private purchase	+97,094	$2.35	$228K	14,787,272 See Footnotes	Filing · EDGAR
May 11, 2022	Open-market or private purchase	+64,700	$1.79	$116K	14,690,178 See Footnotes	Filing · EDGAR
May 10, 2022	Open-market or private purchase	+24,447	$1.60	$39K	14,625,478 See Footnotes	Filing · EDGAR
May 9, 2022	Open-market or private purchase	+90,712	$1.56	$142K	14,601,031 See Footnotes	Filing · EDGAR
May 6, 2022	Open-market or private purchase	+10,200	$1.63	$17K	14,510,319 See Footnotes	Filing · EDGAR
Nov 4, 2021	Open-market or private purchase	+1,785,715	$3.50	$6.3M	14,500,119 See Footnotes	Filing · EDGAR
Nov 4, 2021	Open-market or private purchase	+3,571,428	$3.50	$12.5M	3,571,428 See Footnotes	Filing · EDGAR
Jun 19, 2020	Open-market or private purchase	+1,455,132	$5.00	$7.3M	12,714,404 direct	Filing · EDGAR

Edgewise Therapeutics EWTX Director, 10% owner · filings 2021 to 2025 · bought $26.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 3, 2025	Open-market or private purchase	+372,578	$20.13	$7.5M	14,809,075 See footnotes	Filing · EDGAR
Apr 3, 2025	Open-market or private purchase	+124,193	$20.13	$2.5M	443,792 See footnotes	Filing · EDGAR
Jan 23, 2024	Open-market or private purchase	+454,545	$11.00	$5M	14,436,497 See footnotes	Filing · EDGAR
Sep 16, 2022	Open-market or private purchase	+484,496	$10.32	$5M	13,981,952 See Footnotes	Filing · EDGAR
May 18, 2022	Open-market or private purchase	+138,000	$7.21	$995K	13,497,456 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+12,730,036			13,046,956 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted	+272,724			272,724 See Footnotes	Filing · EDGAR
Mar 30, 2021	Open-market or private purchase	+46,875	$16.00	$750K	319,599 See Footnotes	Filing · EDGAR
Mar 30, 2021	Open-market or private purchase	+312,500	$16.00	$5M	13,359,456 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A Preferred Stock	−8,187,100			0 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B-1 Preferred Stock	−1,572,960			0 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B-2 Preferred Stock	−1,301,626			0 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series C Preferred Stock	−1,668,350			0 See Footnotes	Filing · EDGAR
Mar 30, 2021	Derivative converted Series C Preferred Stock	−272,724			0 See Footnotes	Filing · EDGAR

MBX Biosciences MBX Director, 10% owner · filings 2024 to 2025 · bought $14M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 18, 2025	Open-market or private purchase	+49,070	$10.84	$532K	3,255,000 See footnotes	Filing · EDGAR
Feb 18, 2025	Open-market or private purchase	+94,100	$10.84	$1M	747,887 See footnotes	Filing · EDGAR
Feb 14, 2025	Open-market or private purchase	+17,962	$9.90	$178K	3,176,390 See footnotes	Filing · EDGAR
Feb 14, 2025	Open-market or private purchase	+29,540	$9.85	$291K	3,205,930 See footnotes	Filing · EDGAR
Sep 16, 2024	Derivative converted	+2,658,428			2,658,428 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Sep 16, 2024	Derivative converted	+403,787			403,787 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR
Sep 16, 2024	Open-market or private purchase	+500,000	$16.00	$8M	3,158,428 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Sep 16, 2024	Open-market or private purchase	+250,000	$16.00	$4M	653,787 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR
Sep 16, 2024	Derivative converted Series A Convertible Preferred Stock	−12,372,634			0 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Sep 16, 2024	Derivative converted Series B Convertible Preferred Stock	−19,587,284			0 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Sep 16, 2024	Derivative converted Series C Convertible Preferred Stock	−4,854,368			0 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR

Lomond Therapeutics Holdings Director · filings 2024 to 2024

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 1, 2024	Derivative converted	+323,916	$3.20	$1M	323,916 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted	+215,146	$3.20	$688K	539,062 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted	+389,078	$3.60	$1.4M	928,140 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted	+230,753	$3.60	$831K	1,158,893 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted	+74,613	$3.60	$269K	1,233,506 See Footnote	Filing · EDGAR
Nov 1, 2024	Grant or award from the company	+808,894	$4.00	$3.2M	2,042,400 See Footnote	Filing · EDGAR
Nov 1, 2024	Grant or award from the company	+479,736	$4.00	$1.9M	2,522,136 See Footnote	Filing · EDGAR
Nov 1, 2024	Grant or award from the company	+155,120	$4.00	$620K	2,677,256 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted Simple Agreement for Future Equity	−323,916			0 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted Simple Agreement for Future Equity	−215,146			0 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted Simple Agreement for Future Equity	−389,078			0 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted Simple Agreement for Future Equity	−230,753			0 See Footnote	Filing · EDGAR
Nov 1, 2024	Derivative converted Simple Agreement for Future Equity	−74,613			0 See Footnote	Filing · EDGAR

Upstream Bio Director, 10% owner · filings 2024 to 2024 · bought $14M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 15, 2024	Derivative converted	+721,956			973,716 See Footnote	Filing · EDGAR
Oct 15, 2024	Open-market or private purchase	+165,000	$17.00	$2.8M	1,138,716 See Footnote	Filing · EDGAR
Oct 15, 2024	Derivative converted	+2,887,833			3,894,873 See Footnote	Filing · EDGAR
Oct 15, 2024	Open-market or private purchase	+660,000	$17.00	$11.2M	4,554,873 See Footnote	Filing · EDGAR
Oct 15, 2024	Derivative converted Series A redeemable convertible preferred stock	−524,500			0 See Footnote	Filing · EDGAR
Oct 15, 2024	Derivative converted Series A redeemable convertible preferred stock	−2,098,000			0 See Footnote	Filing · EDGAR
Oct 15, 2024	Derivative converted Series B redeemable convertible preferred stock	−197,456			0 See Footnote	Filing · EDGAR
Oct 15, 2024	Derivative converted Series B redeemable convertible preferred stock	−789,833			0 See Footnote	Filing · EDGAR

ARS Pharmaceuticals Director · filings 2020 to 2024 · sold $12.6M · bought $28.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 26, 2024	Open-market or private sale	−83,695	$13.00	$1.1M	0 See Footnote	Filing · EDGAR
Aug 23, 2024	Open-market or private sale	−69,500	$13.03	$906K	83,695 See Footnote	Filing · EDGAR
Aug 22, 2024	Open-market or private sale	−391,482	$12.94	$5.1M	153,195 See Footnote	Filing · EDGAR
Aug 21, 2024	Open-market or private sale	−394,400	$13.52	$5.3M	557,977 See Footnote	Filing · EDGAR
Aug 21, 2024	Open-market or private sale	−13,300	$14.61	$194K	544,677 See Footnote	Filing · EDGAR
Aug 29, 2023	Open-market or private purchase	+500,000	$6.20	$3.1M	8,019,187 See Footnote	Filing · EDGAR
Dec 8, 2020	Open-market or private purchase	+238,100	$21.00	$5M	507,423 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Derivative converted	+3,462,737			3,970,160 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Derivative converted	+2,493,741			6,463,901 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Derivative converted	+1,055,287			7,519,188 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Open-market or private purchase	+952,377	$21.00	$20M	952,377 By OrbiMed Partners Master Fund Limited	Filing · EDGAR
Dec 8, 2020	Derivative converted Series A Preferred Stock	−12,857,142			0 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Derivative converted Series B Preferred Stock	−9,259,259			0 By OrbiMed Private Investments VI, LP	Filing · EDGAR
Dec 8, 2020	Derivative converted Series C Preferred Stock	−3,918,279			0 By OrbiMed Private Investments VI, LP	Filing · EDGAR

scPharmaceuticals 10% owner · filings 2017 to 2024 · bought $29.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 13, 2024	Open-market or private purchase	+478,342	$4.00	$1.9M	5,806,670 See footnotes	Filing · EDGAR
Aug 13, 2024	Open-market or private purchase	+21,658	$4.00	$87K	252,858 See footnotes	Filing · EDGAR
Nov 25, 2022	Open-market or private purchase	+762,380	$5.25	$4M	5,328,328 See Footnotes	Filing · EDGAR
May 21, 2020	Open-market or private purchase	+1,156,083	$8.65	$10M	4,565,948 See Footnotes	Filing · EDGAR
May 21, 2020	Open-market or private purchase	+231,200	$8.65	$2M	231,200 See Footnotes	Filing · EDGAR
Nov 21, 2017	Derivative converted	+2,576,532			2,576,532 See Footnotes	Filing · EDGAR
Nov 21, 2017	Open-market or private purchase	+833,333	$14.00	$11.7M	3,409,865 See Footnotes	Filing · EDGAR
Nov 21, 2017	Derivative converted Series B Preferred Stock	−18,500,000			0 See Footnotes	Filing · EDGAR

Terns Pharmaceuticals Director, 10% owner · filings 2021 to 2024 · sold $562K · bought $18M · $11.7M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 16, 2024	Sale under a 10b5-1 plan	−4,009	$10.00	$40K	4,839,412 See footnotes	Filing · EDGAR
Jul 16, 2024	Sale under a 10b5-1 plan	−556	$10.00	$6K	1,967,924 See footnotes	Filing · EDGAR
Jul 16, 2024	Sale under a 10b5-1 plan	−623	$10.00	$6K	755,635 See footnotes	Filing · EDGAR
Jul 15, 2024	Sale under a 10b5-1 plan	−39,433	$10.00	$394K	4,843,421 See footnotes	Filing · EDGAR
Jul 15, 2024	Sale under a 10b5-1 plan	−5,401	$10.00	$54K	1,968,480 See footnotes	Filing · EDGAR
Jul 15, 2024	Sale under a 10b5-1 plan	−6,142	$10.00	$61K	756,258 See footnotes	Filing · EDGAR
Dec 23, 2022	Open-market or private purchase	+137,931	$7.25	$1M	4,882,854 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase	+2,470,200	$2.42	$6M	4,744,923 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase	+457,400	$2.42	$1.1M	1,973,881 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase	+762,400	$2.42	$1.8M	762,400 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase Pre-Funded Warrant	+207,500			207,500 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase Pre-Funded Warrant	+38,450			38,450 See footnotes	Filing · EDGAR
Aug 16, 2022	Open-market or private purchase Pre-Funded Warrant	+64,050			64,050 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted	+1,326,481			1,326,481 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted	+1,989,723			1,989,723 See footnotes	Filing · EDGAR
Feb 9, 2021	Open-market or private purchase	+190,000	$17.00	$3.2M	1,516,481 See footnotes	Filing · EDGAR
Feb 9, 2021	Open-market or private purchase	+285,000	$17.00	$4.8M	2,274,723 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted Series B Preferred Stock	−714,285			0 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted Series B Preferred Stock	−1,071,428			0 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted Series C Preferred Stock	−612,196			0 See footnotes	Filing · EDGAR
Feb 9, 2021	Derivative converted Series C Preferred Stock	−918,295			0 See footnotes	Filing · EDGAR

TELA Bio 10% owner · filings 2019 to 2024 · sold $3.8M · bought $5M · $4.2M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 2, 2024	Open-market or private sale	−36,600	$4.54	$166K	2,407,242 See footnotes	Filing · EDGAR
Jul 1, 2024	Open-market or private sale	−13,700	$4.68	$64K	2,443,842 See footnotes	Filing · EDGAR
Jun 28, 2024	Open-market or private sale	−378,000	$4.74	$1.8M	2,457,542 See footnotes	Filing · EDGAR
Apr 21, 2023	Open-market or private sale	−27,700	$9.41	$261K	2,835,542 See footnotes	Filing · EDGAR
Apr 20, 2023	Open-market or private sale	−28,300	$9.43	$267K	2,863,242 See footnotes	Filing · EDGAR
Apr 19, 2023	Open-market or private sale	−136,000	$9.30	$1.3M	2,891,542 See footnotes	Filing · EDGAR
Nov 13, 2019	Derivative converted	+481,095			2,049,722 direct	Filing · EDGAR
Nov 13, 2019	Derivative converted	+977,820			3,027,542 direct	Filing · EDGAR
Nov 13, 2019	Derivative converted Series A Preferred Stock	−11,878,249			0 direct	Filing · EDGAR
Nov 13, 2019	Derivative converted Series B Preferred Stock	−24,142,419			0 direct	Filing · EDGAR
Nov 13, 2019	Derivative converted Warrant (right to buy)	−758,623			0 direct	Filing · EDGAR
Nov 13, 2019	Derivative converted Warrant (right to buy)	+758,623			758,623 direct	Filing · EDGAR
Nov 8, 2019	Open-market or private purchase	+384,615	$13.00	$5M	1,568,627 direct	Filing · EDGAR

Alpine Immune Sciences Director · filings 2017 to 2024 · sold $37.2M · bought $11.5M · $31.3M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 18, 2024	Tendered in a change of control	−2,416,181	$0.00	$2K	0 See footnotes	Filing · EDGAR
May 18, 2024	Tendered in a change of control	−264,315	$0.00	$264	0 See footnotes	Filing · EDGAR
Jan 11, 2024	In-the-money option exercised	+145,251	$12.74	$1.9M	2,416,181 See footnotes	Filing · EDGAR
Jan 11, 2024	In-the-money option exercised Warrant (Right to Buy)	−145,251			0 See footnotes	Filing · EDGAR
Dec 28, 2023	Open-market or private sale	−26,872	$19.82	$533K	3,466,613 See footnotes	Filing · EDGAR
Dec 28, 2023	Open-market or private sale	−3,128	$19.82	$62K	403,481 See footnotes	Filing · EDGAR
Dec 28, 2023	Open-market or private sale	−1,195,683	$18.32	$21.9M	2,270,930 See footnotes	Filing · EDGAR
Dec 28, 2023	Open-market or private sale	−139,166	$18.32	$2.5M	264,315 See footnotes	Filing · EDGAR
Dec 27, 2023	Open-market or private sale	−162,576	$19.96	$3.2M	3,493,485 See footnotes	Filing · EDGAR
Dec 27, 2023	Open-market or private sale	−18,922	$19.96	$378K	406,609 See footnotes	Filing · EDGAR
Sep 17, 2021	Open-market or private purchase	+585,106	$9.40	$5.5M	3,656,061 See Footnotes	Filing · EDGAR
Sep 17, 2021	Open-market or private purchase	+425,531	$9.40	$4M	425,531 See Footnotes	Filing · EDGAR
Dec 28, 2020	Open-market or private sale	−600,000	$14.25	$8.6M	3,070,955 See Footnotes	Filing · EDGAR
Jan 18, 2019	Open-market or private purchase	+372,439	$5.37	$2M	3,670,955 See Footnotes	Filing · EDGAR
Jan 18, 2019	Open-market or private purchase Warrants to Purchase Common Stock	+145,251			145,251 See Footnotes	Filing · EDGAR
Jul 24, 2017	Grant or award from the company	+3,298,516			3,298,516 See Footnotes	Filing · EDGAR

Kinnate Biopharma Director, 10% owner · filings 2020 to 2024 · bought $24.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 3, 2024	Returned to the company	−1,368,339			0 See footnotes	Filing · EDGAR
Apr 3, 2024	Returned to the company	−4,738,453			0 See footnotes	Filing · EDGAR
Apr 3, 2024	Returned to the company	−1,368,338			0 See footnotes	Filing · EDGAR
Apr 3, 2024	Returned to the company	−84,599			0 See footnotes	Filing · EDGAR
Apr 3, 2024	Returned to the company	−450,000			0 See footnotes	Filing · EDGAR
May 5, 2023	Open-market or private purchase	+490,512	$2.82	$1.4M	1,368,339 See footnotes	Filing · EDGAR
May 5, 2023	Open-market or private purchase	+490,511	$2.82	$1.4M	1,368,338 See footnotes	Filing · EDGAR
May 4, 2023	Open-market or private purchase	+83,459	$2.75	$230K	877,827 See footnotes	Filing · EDGAR
May 4, 2023	Open-market or private purchase	+312,991	$2.75	$861K	4,738,453 See footnotes	Filing · EDGAR
May 4, 2023	Open-market or private purchase	+83,459	$2.75	$230K	877,827 See footnotes	Filing · EDGAR
May 2, 2023	Open-market or private purchase	+58,826	$2.67	$157K	794,368 See footnotes	Filing · EDGAR
May 2, 2023	Open-market or private purchase	+220,610	$2.67	$589K	4,425,462 See footnotes	Filing · EDGAR
May 2, 2023	Open-market or private purchase	+58,826	$2.67	$157K	794,368 See footnotes	Filing · EDGAR
May 1, 2023	Open-market or private purchase	+124,544	$2.62	$326K	735,542 See footnotes	Filing · EDGAR
May 1, 2023	Open-market or private purchase	+467,068	$2.62	$1.2M	4,204,852 See footnotes	Filing · EDGAR
May 1, 2023	Open-market or private purchase	+124,545	$2.62	$326K	735,542 See footnotes	Filing · EDGAR
Apr 28, 2023	Open-market or private purchase	+60,998	$2.55	$156K	610,998 See footnotes	Filing · EDGAR
Apr 28, 2023	Open-market or private purchase	+228,754	$2.55	$583K	3,737,784 See footnotes	Filing · EDGAR
Apr 28, 2023	Open-market or private purchase	+60,997	$2.55	$156K	610,997 See footnotes	Filing · EDGAR
Feb 17, 2023	Grant or award from the company	+550,000			550,000 See footnotes	Filing · EDGAR
Feb 17, 2023	Grant or award from the company	+550,000			550,000 See footnotes	Filing · EDGAR
Feb 15, 2022	Open-market or private purchase	+9,000	$9.96	$90K	3,509,030 See Footnotes	Filing · EDGAR
Feb 14, 2022	Open-market or private purchase	+20,700	$9.98	$207K	3,490,030 See Footnotes	Filing · EDGAR
Feb 14, 2022	Open-market or private purchase	+10,000	$9.89	$99K	3,500,030 See Footnotes	Filing · EDGAR
Feb 11, 2022	Open-market or private purchase	+156,000	$10.22	$1.6M	3,469,330 See Footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+243,494			543,494 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+2,651,042			3,194,536 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+118,794			3,313,330 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+50,501			50,501 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+9,461			59,962 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted	+24,637			84,599 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series A Preferred Stock	−243,494			0 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series B Preferred Stock	−2,651,042			0 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series C Preferred Stock	−118,398			0 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series A Preferred Stock	−50,501			0 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series B Preferred Stock	−9,461			0 See footnotes	Filing · EDGAR
Dec 7, 2020	Derivative converted Series C Preferred Stock	−24,555			0 See footnotes	Filing · EDGAR
Dec 2, 2020	Open-market or private purchase	+300,000	$20.00	$6M	300,000 See footnotes	Filing · EDGAR
Dec 2, 2020	Open-market or private purchase	+450,000	$20.00	$9M	450,000 See footnotes	Filing · EDGAR

Verona Pharma Shareholder · filings 2021 to 2024 · sold $145.9M · $78.5M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 15, 2023	Open-market or private sale	−14,400	$21.96	$316K	4,123,091 See footnotes	Filing · EDGAR
May 15, 2023	Open-market or private sale	−345,313	$20.00	$6.9M	3,777,778 See footnotes	Filing · EDGAR
May 12, 2023	Open-market or private sale	−43,200	$21.64	$935K	4,137,491 See footnotes	Filing · EDGAR
May 11, 2023	Open-market or private sale	−80,000	$22.26	$1.8M	4,180,691 See footnotes	Filing · EDGAR
Dec 23, 2022	Open-market or private sale	−961,328	$22.27	$21.4M	35,294,568 See footnotes	Filing · EDGAR
Dec 23, 2022	Open-market or private sale	−1,116,048	$23.23	$25.9M	34,178,520 See footnotes	Filing · EDGAR
Dec 23, 2022	Open-market or private sale	−92,992	$24.11	$2.2M	34,085,528 See footnotes	Filing · EDGAR
Dec 22, 2022	Open-market or private sale	−3,284,800	$21.71	$71.3M	36,940,592 See footnotes	Filing · EDGAR
Dec 22, 2022	Open-market or private sale	−684,696	$22.07	$15.1M	36,255,896 See footnotes	Filing · EDGAR

Theseus Pharmaceuticals Director, 10% owner · filings 2021 to 2024 · bought $14.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 14, 2024	Tendered in a change of control	−17,063,000	$4.05	$69.1M	0 See Footnotes	Filing · EDGAR
Feb 14, 2024	Tendered in a change of control	−650,600	$4.05	$2.6M	0 See Footnotes	Filing · EDGAR
Jul 17, 2023	Open-market or private purchase	+328,482	$3.05	$1M	17,063,000 See Footnotes	Filing · EDGAR
Jul 17, 2023	Open-market or private purchase	+151,450	$3.05	$462K	650,600 See Footnotes	Filing · EDGAR
Nov 7, 2022	Open-market or private purchase	+192,000	$5.21	$1M	16,734,518 See Footnotes	Filing · EDGAR
Jan 21, 2022	Open-market or private purchase	+111,896	$9.97	$1.1M	16,542,652 See Footnotes	Filing · EDGAR
Jan 20, 2022	Open-market or private purchase	+35,000	$9.95	$348K	16,430,756 See Footnotes	Filing · EDGAR
Jan 19, 2022	Open-market or private purchase	+11,521	$9.97	$115K	16,395,756 See Footnotes	Filing · EDGAR
Jan 13, 2022	Open-market or private purchase	+17,320	$9.43	$163K	16,384,235 See Footnotes	Filing · EDGAR
Jan 12, 2022	Open-market or private purchase	+18,897	$10.06	$190K	16,366,915 See Footnotes	Filing · EDGAR
Jan 11, 2022	Open-market or private purchase	+1,600	$9.81	$16K	16,341,118 See Footnotes	Filing · EDGAR
Jan 11, 2022	Open-market or private purchase	+6,900	$10.67	$74K	16,348,018 See Footnotes	Filing · EDGAR
Oct 12, 2021	Derivative converted	+15,777,018			15,777,018 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Oct 12, 2021	Derivative converted	+436,650			436,650 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR
Oct 12, 2021	Open-market or private purchase	+562,500	$16.00	$9M	16,339,518 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Oct 12, 2021	Open-market or private purchase	+62,500	$16.00	$1M	499,150 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR
Oct 12, 2021	Derivative converted Series A Convertible Preferred Stock	−14,903,718			0 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Oct 12, 2021	Derivative converted Series B Convertible Preferred Stock	−873,300			0 By OrbiMed Private Investments VII, LP	Filing · EDGAR
Oct 12, 2021	Derivative converted Series B Convertible Preferred Stock	−436,650			0 By OrbiMed Genesis Master Fund, L.P.	Filing · EDGAR

ArriVent Biopharma Director, 10% owner · filings 2024 to 2024 · bought $8M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 30, 2024	Derivative converted	+821,827			821,827 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted	+821,827			821,827 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted	+469,615			1,291,442 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted	+469,615			1,291,442 See footnotes	Filing · EDGAR
Jan 30, 2024	Open-market or private purchase	+222,222	$18.00	$4M	1,513,664 See footnotes	Filing · EDGAR
Jan 30, 2024	Open-market or private purchase	+222,222	$18.00	$4M	1,513,664 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted Series A Preferred Stock	−821,827			0 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted Series A Preferred Stock	−821,827			0 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted Series B Preferred Stock	−469,615			0 See footnotes	Filing · EDGAR
Jan 30, 2024	Derivative converted Series B Preferred Stock	−469,615			0 See footnotes	Filing · EDGAR

Galecto Shareholder · filings 2020 to 2023 · sold $2.3M · bought $11M · $7.2M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 15, 2023	Open-market or private sale	−38,327	$0.75	$29K	97,204 See footnotes	Filing · EDGAR
Aug 15, 2023	Open-market or private sale	−248,819	$0.75	$187K	631,048 See footnotes	Filing · EDGAR
Aug 15, 2023	Open-market or private sale	−535,534	$0.75	$402K	1,510,375 See footnotes	Filing · EDGAR
Jul 31, 2023	Open-market or private sale	−26,622	$3.00	$80K	135,531 See footnotes	Filing · EDGAR
Jul 31, 2023	Open-market or private sale	−29,700	$3.00	$89K	879,867 See footnotes	Filing · EDGAR
Jul 31, 2023	Open-market or private sale	−153,078	$3.00	$459K	2,105,909 See footnotes	Filing · EDGAR
Jul 25, 2023	Open-market or private sale	−7,800	$2.92	$23K	162,153 See footnotes	Filing · EDGAR
Jul 25, 2023	Open-market or private sale	−4,700	$2.92	$14K	909,567 See footnotes	Filing · EDGAR
Jul 25, 2023	Open-market or private sale	−26,700	$2.92	$78K	2,258,987 See footnotes	Filing · EDGAR
Jul 13, 2023	Open-market or private sale	−9,800	$2.40	$24K	169,953 See footnotes	Filing · EDGAR
Jul 13, 2023	Open-market or private sale	−52,800	$2.40	$127K	914,267 See footnotes	Filing · EDGAR
Jul 13, 2023	Open-market or private sale	−132,100	$2.40	$317K	2,285,687 See footnotes	Filing · EDGAR
Apr 17, 2023	Open-market or private sale	−660	$1.97	$1K	179,753 See footnotes	Filing · EDGAR
Apr 17, 2023	Open-market or private sale	−3,551	$1.97	$7K	967,067 See footnotes	Filing · EDGAR
Apr 17, 2023	Open-market or private sale	−8,878	$1.97	$17K	2,417,787 See footnotes	Filing · EDGAR
Apr 14, 2023	Open-market or private sale	−2,091	$1.86	$4K	180,413 See footnotes	Filing · EDGAR
Apr 14, 2023	Open-market or private sale	−11,245	$1.86	$21K	970,618 See footnotes	Filing · EDGAR
Apr 14, 2023	Open-market or private sale	−28,110	$1.86	$52K	2,426,665 See footnotes	Filing · EDGAR
Apr 13, 2023	Open-market or private sale	−703	$1.82	$1K	182,504 See footnotes	Filing · EDGAR
Apr 13, 2023	Open-market or private sale	−3,784	$1.82	$7K	981,863 See footnotes	Filing · EDGAR
Apr 13, 2023	Open-market or private sale	−9,459	$1.82	$17K	2,454,775 See footnotes	Filing · EDGAR
Apr 12, 2023	Open-market or private sale	−119	$1.81	$215	183,207 See footnotes	Filing · EDGAR
Apr 12, 2023	Open-market or private sale	−641	$1.81	$1K	985,647 See footnotes	Filing · EDGAR
Apr 12, 2023	Open-market or private sale	−1,603	$1.81	$3K	2,464,234 See footnotes	Filing · EDGAR
Apr 11, 2023	Open-market or private sale	−703	$1.82	$1K	183,326 See footnotes	Filing · EDGAR
Apr 11, 2023	Open-market or private sale	−3,784	$1.82	$7K	986,288 See footnotes	Filing · EDGAR
Apr 11, 2023	Open-market or private sale	−9,459	$1.82	$17K	2,465,837 See footnotes	Filing · EDGAR
Apr 10, 2023	Open-market or private sale	−2,584	$1.79	$5K	185,910 See footnotes	Filing · EDGAR
Apr 10, 2023	Open-market or private sale	−13,899	$1.79	$25K	1,000,187 See footnotes	Filing · EDGAR
Apr 10, 2023	Open-market or private sale	−34,745	$1.79	$62K	2,500,582 See footnotes	Filing · EDGAR
Apr 6, 2023	Open-market or private sale	−487	$2.00	$974	186,613 See footnotes	Filing · EDGAR
Apr 6, 2023	Open-market or private sale	−2,620	$2.00	$5K	1,003,971 See footnotes	Filing · EDGAR
Apr 6, 2023	Open-market or private sale	−6,558	$2.00	$13K	2,510,041 See footnotes	Filing · EDGAR
Apr 5, 2023	Open-market or private sale	−4,687	$2.18	$10K	187,100 See footnotes	Filing · EDGAR
Apr 5, 2023	Open-market or private sale	−25,220	$2.18	$55K	1,006,591 See footnotes	Filing · EDGAR
Apr 5, 2023	Open-market or private sale	−63,058	$2.18	$137K	2,516,599 See footnotes	Filing · EDGAR
Nov 2, 2020	Derivative converted	+2,055,824			2,055,824 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted	+822,311			822,311 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted	+191,787			191,787 See footnote	Filing · EDGAR
Nov 2, 2020	Open-market or private purchase	+523,833	$15.00	$7.9M	2,579,657 See footnote	Filing · EDGAR
Nov 2, 2020	Open-market or private purchase	+209,500	$15.00	$3.1M	1,031,811 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-2 Preferred Stock	−291,999			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-2 Preferred Stock	−116,800			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-4 Preferred Stock	−272,533			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-4 Preferred Stock	−109,013			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-5 Preferred Stock	−77,866			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series C-5 Preferred Stock	−31,147			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series D Preferred Stock	−148,395			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series D Preferred Stock	−59,350			0 See footnote	Filing · EDGAR
Nov 2, 2020	Derivative converted Series D Preferred Stock	−73,773			0 See footnote	Filing · EDGAR
Sep 25, 2020	Grant or award from the company Series D Preferred Stock	−148,395	$27.11	$4M	148,395 See footnote	Filing · EDGAR
Sep 25, 2020	Grant or award from the company Series D Preferred Stock	−59,350	$27.11	$1.6M	59,350 See footnote	Filing · EDGAR
Sep 25, 2020	Grant or award from the company Series D Preferred Stock	−73,773	$27.11	$2M	73,773 See footnote	Filing · EDGAR

Gracell Biotechnologies Shareholder · filings 2023 to 2023 · $1.8M noticed on Form 144

No transactions in the filings read; Form 144 notices are listed above.

Tricida Director, 10% owner · filings 2018 to 2022 · sold $62.2M · bought $15.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 25, 2022	Open-market or private sale	−3,629,226	$0.22	$798K	0 See Footnotes	Filing · EDGAR
Nov 23, 2022	Open-market or private sale	−5,617,300	$0.21	$1.2M	3,629,226 See Footnotes	Filing · EDGAR
Nov 22, 2022	Open-market or private sale	−1,034,421	$0.22	$228K	9,246,526 See Footnotes	Filing · EDGAR
Nov 15, 2021	Grant or award from the company	+666,667	$6.00	$4M	10,280,947 See Footnotes	Filing · EDGAR
Nov 15, 2021	Grant or award from the company Comm on Warrants to Purchase Common Stock	+666,667			666,667 See footnotes	Filing · EDGAR
Dec 11, 2019	Open-market or private sale	−1,500,000	$40.00	$60M	9,614,280 By OrbiMed Private Investments V, LP	Filing · EDGAR
Apr 3, 2019	Open-market or private purchase	+225,000	$36.00	$8.1M	11,114,280 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted	+1,559,716			1,559,716 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted	+4,300,774			5,860,490 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted	+3,591,194			9,451,684 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted	+1,069,175			10,520,859 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Open-market or private purchase	+368,421	$19.00	$7M	10,889,280 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted Series A Convertible Preferred Stock	−6,207,674			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted Series B Convertible Preferred Stock	−17,117,085			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted Series C Convertible Preferred Stock	−14,292,958			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jul 2, 2018	Derivative converted Series D Convertible Preferred Stock	−4,255,319			0 By OrbiMed Private Investments V, LP	Filing · EDGAR

Third Harmonic Bio Director, 10% owner · filings 2022 to 2022 · bought $5.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 19, 2022	Derivative converted	+5,479,071			5,479,071 See Footnote	Filing · EDGAR
Sep 19, 2022	Open-market or private purchase	+300,000	$17.00	$5.1M	5,779,071 See Footnote	Filing · EDGAR
Sep 19, 2022	Derivative converted Series A-2 Preferred Stock	−8,593,750			0 See Footnote	Filing · EDGAR
Sep 19, 2022	Derivative converted Series A-3 Preferred Stock	−2,441,407			0 See Footnote	Filing · EDGAR
Sep 19, 2022	Derivative converted Series B Preferred Stock	−1,342,065			0 See Footnote	Filing · EDGAR

SpringWorks Therapeutics 10% owner · filings 2019 to 2022 · sold $130.3M · bought $5M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 12, 2022	Open-market or private sale	−123,897	$31.96	$4M	5,629,842 See Footnotes	Filing · EDGAR
Sep 12, 2022	Open-market or private sale	−30,000	$31.98	$959K	5,599,842 See Footnotes	Filing · EDGAR
Aug 9, 2022	Open-market or private sale	−69,568	$37.47	$2.6M	5,753,739 See Footnotes	Filing · EDGAR
Aug 8, 2022	Open-market or private sale	−205,000	$38.33	$7.9M	5,823,307 See Footnotes	Filing · EDGAR
Jul 1, 2021	Sale under a 10b5-1 plan	−15,959	$85.01	$1.4M	6,028,307 See Footnotes	Filing · EDGAR
Jun 28, 2021	Sale under a 10b5-1 plan	−6,502	$85.17	$554K	6,044,266 See Footnotes	Filing · EDGAR
Jun 25, 2021	Sale under a 10b5-1 plan	−22,334	$85.14	$1.9M	6,050,768 See Footnotes	Filing · EDGAR
Jun 24, 2021	Sale under a 10b5-1 plan	−34,200	$85.22	$2.9M	6,073,102 See Footnotes	Filing · EDGAR
Jun 23, 2021	Sale under a 10b5-1 plan	−100	$85.00	$9K	6,107,302 See Footnotes	Filing · EDGAR
Jun 10, 2021	Sale under a 10b5-1 plan	−30,852	$85.09	$2.6M	6,107,402 See Footnotes	Filing · EDGAR
Jun 9, 2021	Sale under a 10b5-1 plan	−5,049	$85.33	$431K	6,138,254 See Footnotes	Filing · EDGAR
Jun 8, 2021	Sale under a 10b5-1 plan	−42,633	$85.37	$3.6M	6,143,303 See Footnotes	Filing · EDGAR
Jun 7, 2021	Sale under a 10b5-1 plan	−371	$84.90	$31K	6,185,936 See Footnotes	Filing · EDGAR
Mar 1, 2021	Open-market or private sale	−1,220,000	$83.19	$101.5M	6,186,307 See Footnotes	Filing · EDGAR
Sep 17, 2019	Derivative converted	+6,078,103			6,078,103 See footnote	Filing · EDGAR
Sep 17, 2019	Derivative converted	+1,053,204			7,131,307 See footnote	Filing · EDGAR
Sep 17, 2019	Open-market or private purchase	+275,000	$18.00	$5M	7,406,307 See footnote	Filing · EDGAR
Sep 17, 2019	Derivative converted Series A Convertible Preferred Stock	−6,078,103			0 See footnote	Filing · EDGAR
Sep 17, 2019	Derivative converted Series B Convertible Preferred Stock	−1,053,204			0 See footnote	Filing · EDGAR

Sierra Oncology Director, 10% owner · filings 2015 to 2022 · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 1, 2022	Returned to the company	−1,511,362	$55.00	$83.1M	0 See footnotes	Filing · EDGAR
Jul 1, 2022	Returned to the company	−226,704	$55.00	$12.5M	0 See footnotes	Filing · EDGAR
Jul 1, 2022	Returned to the company	−226,704	$55.00	$12.5M	0 See footnotes	Filing · EDGAR
Jul 1, 2022	Returned to the company Series A Warrants	−1,136,250			0 See footnotes	Filing · EDGAR
Jul 1, 2022	Returned to the company Series A Warrants	−170,437			0 See footnotes	Filing · EDGAR
Jul 1, 2022	Returned to the company Series A Warrants	−170,437			0 See footnotes	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised	+374,962	$13.20	$4.9M	1,511,362 See footnote (4),	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised	+56,244	$13.20	$742K	226,704 See footnote (4),	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised	+56,244	$13.20	$742K	226,704 See footnote	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised Series B Warrants	−374,962			0 See footnote	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised Series B Warrants	−56,244			0 See footnote	Filing · EDGAR
Jan 26, 2022	In-the-money option exercised Series B Warrants	−56,244			0 See footnote	Filing · EDGAR
Jan 29, 2020	Derivative converted	+1,477,320			1,477,320 See footnotes	Filing · EDGAR
Jan 29, 2020	Derivative converted Series A Convertible Voting Preferred Stock	−19,500			0 See footnotes	Filing · EDGAR
Jul 21, 2015	Derivative converted	+1,725,790			1,725,790 See Footnotes	Filing · EDGAR
Jul 21, 2015	Other acquisition or disposition (see the filing)	+89,159	$5.22	$465K	1,814,949 See Footnotes	Filing · EDGAR
Jul 21, 2015	Open-market or private purchase	+175,000	$17.00	$3M	1,989,949 See Footnotes	Filing · EDGAR
Jul 21, 2015	Derivative converted Series D Preferred Stock	−1,725,790			0 See Footnotes	Filing · EDGAR

Arcutis Biotherapeutics 10% owner · filings 2020 to 2022 · sold $25.5M · bought $21.9M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 24, 2022	Open-market or private sale	−306,027	$21.31	$6.5M	3,534,537 See Footnotes	Filing · EDGAR
Jun 24, 2022	Open-market or private sale	−35,944	$21.31	$766K	415,142 See Footnotes	Filing · EDGAR
Apr 8, 2022	Open-market or private sale	−97,200	$20.71	$2M	3,840,564 See Footnotes	Filing · EDGAR
Apr 8, 2022	Open-market or private sale	−102,800	$20.71	$2.1M	451,086 See Footnotes	Filing · EDGAR
Apr 7, 2022	Open-market or private sale	−167,800	$20.66	$3.5M	3,937,764 See Footnotes	Filing · EDGAR
Apr 7, 2022	Open-market or private sale	−177,196	$20.66	$3.7M	553,886 See Footnotes	Filing · EDGAR
Apr 6, 2022	Open-market or private sale	−162,000	$20.69	$3.4M	4,105,564 See Footnotes	Filing · EDGAR
Apr 6, 2022	Open-market or private sale	−171,204	$20.69	$3.5M	731,082 See Footnotes	Filing · EDGAR
Oct 2, 2020	Open-market or private purchase	+200,000	$25.00	$5M	4,267,564 See Footnotes	Filing · EDGAR
Oct 2, 2020	Open-market or private purchase	+296,000	$25.00	$7.4M	902,286 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted	+2,825,603			3,207,991 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted	+859,573			4,067,564 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted	+429,786			606,286 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted Series B Preferred Stock	−2,825,603			0 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted Series C Preferred Stock	−859,573			0 See Footnotes	Filing · EDGAR
Feb 4, 2020	Derivative converted Series C Preferred Stock	−429,786			0 See Footnotes	Filing · EDGAR
Feb 3, 2020	Open-market or private purchase	+382,388	$17.00	$6.5M	382,388 See Footnotes	Filing · EDGAR
Feb 3, 2020	Open-market or private purchase	+176,500	$17.00	$3M	176,500 See Footnotes	Filing · EDGAR

89bio 10% owner · filings 2019 to 2022 · sold $8.3M · bought $13.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 26, 2022	Open-market or private sale	−10,742	$8.38	$90K	1,829,433 See Footnotes	Filing · EDGAR
Jan 26, 2022	Open-market or private sale	−10,740	$8.38	$90K	1,829,436 See Footnotes	Filing · EDGAR
Jan 25, 2022	Open-market or private sale	−24,546	$8.40	$206K	1,840,175 See Footnotes	Filing · EDGAR
Jan 25, 2022	Open-market or private sale	−24,545	$8.40	$206K	1,840,176 See Footnotes	Filing · EDGAR
Sep 21, 2020	Open-market or private sale	−137,500	$28.00	$3.9M	1,864,721 See Footnotes	Filing · EDGAR
Sep 21, 2020	Open-market or private sale	−137,500	$28.00	$3.9M	1,864,721 See Footnotes	Filing · EDGAR
Nov 13, 2019	Derivative converted	+1,277,858			2,002,221 See footnote	Filing · EDGAR
Nov 13, 2019	Derivative converted	+1,277,858			2,002,221 See footnote	Filing · EDGAR
Nov 13, 2019	Derivative converted Series A Preferred Stock	−7,944,444			0 See footnote	Filing · EDGAR
Nov 13, 2019	Derivative converted Series A Preferred Stock	−7,944,444			0 See footnote	Filing · EDGAR
Nov 11, 2019	Open-market or private purchase	+418,750	$16.00	$6.7M	724,363 See footnote	Filing · EDGAR
Nov 11, 2019	Open-market or private purchase	+418,750	$16.00	$6.7M	724,363 See footnote	Filing · EDGAR

Janux Therapeutics Director · filings 2021 to 2021 · sold $10.6M · bought $12M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 29, 2021	Open-market or private sale	−36,700	$20.30	$745K	2,258,566 See Footnotes	Filing · EDGAR
Dec 29, 2021	Open-market or private sale	−3,700	$20.30	$75K	231,098 See Footnotes	Filing · EDGAR
Dec 21, 2021	Open-market or private sale	−108,300	$19.00	$2.1M	2,295,266 See Footnotes	Filing · EDGAR
Dec 21, 2021	Open-market or private sale	−11,100	$19.00	$211K	234,798 See Footnotes	Filing · EDGAR
Dec 16, 2021	Open-market or private sale	−356,800	$19.07	$6.8M	2,403,566 See Footnotes	Filing · EDGAR
Dec 16, 2021	Open-market or private sale	−36,500	$19.07	$696K	245,898 See Footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted	+1,348,421			1,348,421 See footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted	+823,742			2,172,163 See footnotes	Filing · EDGAR
Jun 15, 2021	Open-market or private purchase	+588,203	$17.00	$10M	2,760,366 See footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted	+164,748			164,748 See footnotes	Filing · EDGAR
Jun 15, 2021	Open-market or private purchase	+117,650	$17.00	$2M	282,398 See footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted Series A Convertible Preferred Stock	−1,052,632			0 See footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted Series B Convertible Preferred Stock	−643,046			0 See footnotes	Filing · EDGAR
Jun 15, 2021	Derivative converted Series B Convertible Preferred Stock	−128,609			0 See footnotes	Filing · EDGAR

Repare Therapeutics Director · filings 2020 to 2021 · sold $3.5M · bought $15.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 7, 2021	Sale under a 10b5-1 plan	−861	$33.93	$29K	3,177,041 See Footnotes	Filing · EDGAR
Sep 7, 2021	Sale under a 10b5-1 plan	−26	$33.93	$882	96,190 See Footnotes	Filing · EDGAR
Sep 3, 2021	Sale under a 10b5-1 plan	−6,985	$34.00	$237K	3,177,902 See Footnotes	Filing · EDGAR
Sep 3, 2021	Sale under a 10b5-1 plan	−212	$34.00	$7K	96,216 See Footnotes	Filing · EDGAR
Sep 2, 2021	Sale under a 10b5-1 plan	−15,941	$34.24	$546K	3,184,887 See Footnotes	Filing · EDGAR
Sep 2, 2021	Sale under a 10b5-1 plan	−483	$34.24	$17K	96,428 See Footnotes	Filing · EDGAR
Sep 1, 2021	Sale under a 10b5-1 plan	−12,586	$33.98	$428K	3,200,828 See Footnotes	Filing · EDGAR
Sep 1, 2021	Sale under a 10b5-1 plan	−382	$33.98	$13K	96,911 See Footnotes	Filing · EDGAR
Aug 31, 2021	Sale under a 10b5-1 plan	−8,223	$33.94	$279K	3,213,414 See Footnotes	Filing · EDGAR
Aug 31, 2021	Sale under a 10b5-1 plan	−249	$33.94	$8K	97,293 See Footnotes	Filing · EDGAR
Aug 30, 2021	Sale under a 10b5-1 plan	−6,500	$33.92	$220K	3,221,637 See Footnotes	Filing · EDGAR
Aug 30, 2021	Sale under a 10b5-1 plan	−197	$33.92	$7K	97,542 See Footnotes	Filing · EDGAR
Aug 27, 2021	Sale under a 10b5-1 plan	−6,884	$33.94	$234K	3,228,137 See Footnotes	Filing · EDGAR
Aug 27, 2021	Sale under a 10b5-1 plan	−209	$33.94	$7K	97,739 See Footnotes	Filing · EDGAR
Aug 26, 2021	Sale under a 10b5-1 plan	−4,157	$34.52	$143K	3,235,021 See Footnotes	Filing · EDGAR
Aug 26, 2021	Sale under a 10b5-1 plan	−126	$34.52	$4K	97,948 See Footnotes	Filing · EDGAR
Aug 25, 2021	Sale under a 10b5-1 plan	−6,874	$34.34	$236K	3,239,178 See Footnotes	Filing · EDGAR
Aug 25, 2021	Sale under a 10b5-1 plan	−208	$34.34	$7K	98,074 See Footnotes	Filing · EDGAR
Aug 24, 2021	Sale under a 10b5-1 plan	−3,920	$34.07	$134K	3,246,052 See Footnotes	Filing · EDGAR
Aug 24, 2021	Sale under a 10b5-1 plan	−119	$34.07	$4K	98,282 See Footnotes	Filing · EDGAR
Aug 23, 2021	Sale under a 10b5-1 plan	−6,885	$34.06	$235K	3,249,972 See Footnotes	Filing · EDGAR
Aug 23, 2021	Sale under a 10b5-1 plan	−209	$34.06	$7K	98,401 See Footnotes	Filing · EDGAR
Aug 18, 2021	Sale under a 10b5-1 plan	−2,852	$33.99	$97K	3,256,857 See Footnotes	Filing · EDGAR
Aug 18, 2021	Sale under a 10b5-1 plan	−78	$33.99	$3K	98,610 See Footnotes	Filing · EDGAR
Aug 17, 2021	Sale under a 10b5-1 plan	−16,886	$34.12	$576K	3,259,439 See Footnotes	Filing · EDGAR
Aug 17, 2021	Sale under a 10b5-1 plan	−512	$34.12	$17K	98,688 See Footnotes	Filing · EDGAR
Jun 23, 2020	Derivative converted	+2,601,325			2,601,325 See Footnotes	Filing · EDGAR
Jun 23, 2020	Open-market or private purchase	+675,000	$20.00	$13.5M	3,276,325 See Footnotes	Filing · EDGAR
Jun 23, 2020	Open-market or private purchase	+99,200	$20.00	$2M	99,200 See Footnote	Filing · EDGAR
Jun 23, 2020	Derivative converted Class B Preferred Shares	−2,601,325			0 See Footnotes	Filing · EDGAR

Acutus Medical Director, 10% owner · filings 2020 to 2021 · bought $22.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 19, 2021	Open-market or private purchase	+714,285	$14.00	$10M	4,872,025 See Footnotes	Filing · EDGAR
Jul 19, 2021	Open-market or private purchase	+357,143	$14.00	$5M	1,677,361 See Footnotes	Filing · EDGAR
Aug 10, 2020	Open-market or private purchase	+373,500	$18.00	$6.7M	373,500 See footnotes	Filing · EDGAR
Aug 10, 2020	Open-market or private purchase	+41,500	$18.00	$747K	41,500 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted	+3,784,240			4,157,740 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted	+1,278,718			1,320,218 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series B Convertible Preferred Stock	−872,302			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series B Convertible Preferred Stock	−673,123			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series C Convertible Preferred Stock	−647,582			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series C Convertible Preferred Stock	−899,985			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series D Convertible Preferred Stock	−389,116			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series D Convertible Preferred Stock	−1,202,117			0 See footnotes	Filing · EDGAR
Aug 10, 2020	Derivative converted Series D Convertible Preferred Stock	−378,733			0 See footnotes	Filing · EDGAR

Synlogic Director · filings 2017 to 2021

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 20, 2021	Grant or award from the company	+1,666,666	$3.00	$5M	3,696,662 See Footnotes	Filing · EDGAR
Jan 26, 2018	Grant or award from the company	+715,000	$9.75	$7M	2,029,996 See Footnotes	Filing · EDGAR

Oric Pharmaceuticals Director · filings 2020 to 2021 · sold $15.2M · bought $4.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 30, 2021	Sale under a 10b5-1 plan	−27,869	$23.93	$667K	2,212,571 See Footnotes	Filing · EDGAR
Mar 29, 2021	Sale under a 10b5-1 plan	−75,555	$23.31	$1.8M	2,240,440 See Footnotes	Filing · EDGAR
Mar 26, 2021	Sale under a 10b5-1 plan	−27,816	$23.88	$664K	2,315,995 See Footnotes	Filing · EDGAR
Mar 25, 2021	Sale under a 10b5-1 plan	−51,523	$24.70	$1.3M	2,343,811 See Footnotes	Filing · EDGAR
Mar 24, 2021	Sale under a 10b5-1 plan	−32,959	$24.80	$817K	2,395,334 See Footnotes	Filing · EDGAR
Mar 23, 2021	Sale under a 10b5-1 plan	−3,992	$24.32	$97K	2,428,293 See Footnotes	Filing · EDGAR
Mar 22, 2021	Sale under a 10b5-1 plan	−7,673	$26.47	$203K	2,432,285 See Footnotes	Filing · EDGAR
Mar 19, 2021	Sale under a 10b5-1 plan	−21,275	$26.47	$563K	2,439,958 See Footnotes	Filing · EDGAR
Mar 18, 2021	Sale under a 10b5-1 plan	−6,059	$28.03	$170K	2,461,233 See Footnotes	Filing · EDGAR
Mar 17, 2021	Sale under a 10b5-1 plan	−18,790	$28.43	$534K	2,467,292 See Footnotes	Filing · EDGAR
Mar 16, 2021	Sale under a 10b5-1 plan	−41,353	$27.72	$1.1M	2,486,082 See Footnotes	Filing · EDGAR
Mar 15, 2021	Sale under a 10b5-1 plan	−89,210	$29.14	$2.6M	2,527,435 See Footnotes	Filing · EDGAR
Mar 12, 2021	Sale under a 10b5-1 plan	−90,521	$30.29	$2.7M	2,616,645 See Footnotes	Filing · EDGAR
Mar 11, 2021	Sale under a 10b5-1 plan	−58,551	$33.04	$1.9M	2,707,166 See Footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted	+1,875,000			2,156,250 See footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted	+373,356			2,529,606 See footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted	+236,111			2,765,717 See footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted Series B Preferred Stock	−1,875,000			0 See footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted Series C Preferred Stock	−373,356			0 See footnotes	Filing · EDGAR
Apr 28, 2020	Derivative converted Series D Preferred Stock	−236,111			0 See footnotes	Filing · EDGAR
Apr 24, 2020	Open-market or private purchase	+281,250	$16.00	$4.5M	281,250 See footnotes	Filing · EDGAR

Decibel Therapeutics Director, 10% owner · filings 2021 to 2021 · bought $30M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 17, 2021	Derivative converted	+2,732,106			2,732,106 See footnotes	Filing · EDGAR
Feb 17, 2021	Derivative converted	+327,852			327,852 See footnotes	Filing · EDGAR
Feb 17, 2021	Derivative converted	+218,568			218,568 See footnotes	Filing · EDGAR
Feb 17, 2021	Open-market or private purchase	+1,111,100	$18.00	$20M	3,843,206 See footnotes	Filing · EDGAR
Feb 17, 2021	Open-market or private purchase	+555,566	$18.00	$10M	883,418 See footnotes	Filing · EDGAR
Feb 17, 2021	Derivative converted Series D Preferred Stock	−14,480,162			0 See footnotes	Filing · EDGAR
Feb 17, 2021	Derivative converted Series D Preferred Stock	−1,737,619			0 See footnotes	Filing · EDGAR
Feb 17, 2021	Derivative converted Series D Preferred Stock	−1,158,412			0 See footnotes	Filing · EDGAR

Prevail Therapeutics Director, 10% owner · filings 2019 to 2021 · bought $15M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 22, 2021	Tendered in a change of control	−13,822,463	$22.50	$311M	0 See Footnotes	Filing · EDGAR
Jun 24, 2019	Derivative converted	+10,510,111			12,940,111 See Footnotes	Filing · EDGAR
Jun 24, 2019	Open-market or private purchase	+882,352	$17.00	$15M	13,822,463 See Footnotes	Filing · EDGAR
Jun 24, 2019	Derivative converted Series Seed Preferred Stock	−6,399,000			0 See Footnotes	Filing · EDGAR
Jun 24, 2019	Derivative converted Series A Preferred Stock	−3,099,612			0 See Footnotes	Filing · EDGAR
Jun 24, 2019	Derivative converted Series B Preferred Stock	−1,011,499			0 See Footnotes	Filing · EDGAR

Cti Biopharma 10% owner · filings 2017 to 2021 · sold $7M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 7, 2021	Open-market or private sale	−2,000,000	$3.50	$7M	7,520,600 See Footnotes	Filing · EDGAR
Jun 13, 2017	Derivative converted	+5,000,000			5,000,000 See Footnotes	Filing · EDGAR
Jun 13, 2017	Derivative converted Series N-3 Preferred Stock	−7,500			0 See Footnotes	Filing · EDGAR

Aerpio Pharmaceuticals 10% owner · filings 2017 to 2020 · sold $42K · bought $6.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 8, 2020	In-the-money option exercised	+21,400	$0.96	$21K	21,400 See Footnotes	Filing · EDGAR
Dec 8, 2020	Open-market or private sale	−21,400	$1.96	$42K	0 See Footnotes	Filing · EDGAR
Dec 8, 2020	In-the-money option exercised Stock Option (Right to Buy)	−21,400			0 See Footnotes	Filing · EDGAR
Jun 28, 2018	Open-market or private purchase	+777,500	$3.85	$3M	5,193,946 See Footnotes	Filing · EDGAR
Mar 15, 2017	Open-market or private purchase	+762,995	$5.00	$3.8M	4,416,446 See Footnotes	Filing · EDGAR

LogicBio Therapeutics Director, 10% owner · filings 2018 to 2020 · bought $20.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 1, 2020	Open-market or private purchase	+545,974	$6.00	$3.3M	3,524,997 See Footnotes	Filing · EDGAR
Oct 1, 2020	Open-market or private purchase	+639,212	$6.00	$3.8M	4,126,972 See Footnotes	Filing · EDGAR
Oct 1, 2020	Open-market or private purchase	+296,296	$6.00	$1.8M	296,296 See Footnotes	Filing · EDGAR
Oct 23, 2018	Derivative converted	+2,997,760			2,997,760 See Footnotes	Filing · EDGAR
Oct 23, 2018	Derivative converted	+2,279,023			5,276,783 See Footnotes	Filing · EDGAR
Oct 23, 2018	Open-market or private purchase	+490,000	$10.00	$4.9M	5,766,783 See Footnotes	Filing · EDGAR
Oct 23, 2018	Open-market or private purchase	+700,000	$10.00	$7M	6,466,783 See Footnotes	Filing · EDGAR
Oct 23, 2018	Derivative converted Series A Convertible Preferred Stock	−2,678,571			0 See Footnotes	Filing · EDGAR
Oct 23, 2018	Derivative converted Series B Convertible Preferred Stock	−3,046,943			2,279,023 See Footnotes	Filing · EDGAR
Oct 23, 2018	Derivative converted Series B Convertible Preferred Stock	−4,352,775			0 See Footnotes	Filing · EDGAR

Graybug Vision 10% owner · filings 2020 to 2020 · bought $9M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 29, 2020	Derivative converted	+3,600,847			4,163,347 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series B Preferred Stock	−2,754,273			0 See footnote	Filing · EDGAR
Sep 29, 2020	Derivative converted Series C Preferred Stock	−846,574			0 See footnote	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+562,500	$16.00	$9M	562,500 See footnote	Filing · EDGAR

Inspire Medical Systems Director · filings 2018 to 2020 · sold $173.5M · bought $5M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 18, 2020	Open-market or private sale	−43,543	$108.54	$4.7M	0 See Footnotes	Filing · EDGAR
Aug 17, 2020	Open-market or private sale	−94,900	$107.49	$10.2M	43,543 See Footnotes	Filing · EDGAR
Aug 14, 2020	Open-market or private sale	−20,257	$109.03	$2.2M	138,443 See Footnotes	Filing · EDGAR
Aug 13, 2020	Open-market or private sale	−29,251	$109.93	$3.2M	158,500 See Footnotes	Filing · EDGAR
Aug 12, 2020	Open-market or private sale	−42,679	$107.45	$4.6M	187,751 See Footnotes	Filing · EDGAR
Aug 11, 2020	Open-market or private sale	−39,877	$105.78	$4.2M	230,430 See Footnotes	Filing · EDGAR
Aug 10, 2020	Open-market or private sale	−47,700	$105.23	$5M	270,307 See Footnotes	Filing · EDGAR
Aug 7, 2020	Open-market or private sale	−28,993	$106.18	$3.1M	318,007 See Footnotes	Filing · EDGAR
Mar 6, 2020	Open-market or private sale	−500,000	$83.52	$41.8M	347,000 See Footnotes	Filing · EDGAR
Mar 3, 2020	Open-market or private sale	−75,000	$83.21	$6.2M	1,272,000 See Footnotes	Filing · EDGAR
Mar 3, 2020	Open-market or private sale	−25,000	$84.55	$2.1M	1,247,000 See Footnotes	Filing · EDGAR
Mar 3, 2020	Open-market or private sale	−400,000	$84.42	$33.8M	847,000 See Footnotes	Filing · EDGAR
Nov 27, 2019	Sale under a 10b5-1 plan	−3,100	$70.60	$219K	1,398,613 See Footnotes	Filing · EDGAR
Nov 27, 2019	Sale under a 10b5-1 plan	−47,981	$71.67	$3.4M	1,350,632 See Footnotes	Filing · EDGAR
Nov 27, 2019	Sale under a 10b5-1 plan	−2,306	$72.13	$166K	1,348,326 See Footnotes	Filing · EDGAR
Nov 26, 2019	Sale under a 10b5-1 plan	−20,135	$69.55	$1.4M	1,452,191 See Footnotes	Filing · EDGAR
Nov 26, 2019	Sale under a 10b5-1 plan	−50,478	$70.16	$3.5M	1,401,713 See Footnotes	Filing · EDGAR
Mar 8, 2019	Open-market or private sale	−290,231	$57.75	$16.8M	1,471,725 See Footnotes	Filing · EDGAR
Mar 7, 2019	Open-market or private sale	−68,218	$55.01	$3.8M	1,761,956 See Footnotes	Filing · EDGAR
Dec 11, 2018	Open-market or private sale	−614,772	$37.60	$23.1M		Filing · EDGAR
May 7, 2018	Derivative converted	+1,582,904			1,582,904 direct	Filing · EDGAR
May 7, 2018	Derivative converted	+548,817			2,131,721 direct	Filing · EDGAR
May 7, 2018	Open-market or private purchase	+312,500	$16.00	$5M	2,444,221 direct	Filing · EDGAR
May 7, 2018	Derivative converted Series E Convertible Preferred Stock	−9,160,305			0 direct	Filing · EDGAR
May 7, 2018	Derivative converted Series F Convertible Preferred Stock	−3,649,635			0 direct	Filing · EDGAR

Pandion Therapeutics 10% owner · filings 2020 to 2020

No transactions in the filings read; Form 144 notices are listed above.

Fusion Pharmaceuticals Director · filings 2020 to 2020 · bought $15.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 30, 2020	Derivative converted	+2,224,770			2,224,770 By OrbiMed Private Investments VII, L.P.	Filing · EDGAR
Jun 30, 2020	Open-market or private purchase	+705,900	$17.00	$12M	2,930,670 By OrbiMed Private Investments VII, L.P.	Filing · EDGAR
Jun 30, 2020	Open-market or private purchase	+192,100	$17.00	$3.3M	192,100 By OrbiMed Partners Master Fund Limited	Filing · EDGAR
Jun 30, 2020	Derivative converted Class B Preferred Shares	−11,878,051			0 By OrbiMed Private Investments VII, L.P.	Filing · EDGAR

Alector 10% owner · filings 2019 to 2020 · sold $116.2M · bought $7.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 16, 2020	Open-market or private sale	−47,097	$23.53	$1.1M	5,955,674 See Footnotes	Filing · EDGAR
Apr 16, 2020	Open-market or private sale	−15,086	$23.53	$355K	1,906,718 See Footnotes	Filing · EDGAR
Apr 14, 2020	Open-market or private sale	−17,595	$23.52	$414K	6,002,771 See Footnotes	Filing · EDGAR
Apr 14, 2020	Open-market or private sale	−5,636	$23.52	$133K	1,921,804 See Footnotes	Filing · EDGAR
Apr 9, 2020	Open-market or private sale	−218,208	$23.79	$5.2M	6,020,366 See Footnotes	Filing · EDGAR
Apr 9, 2020	Open-market or private sale	−69,893	$23.79	$1.7M	1,927,440 See Footnotes	Filing · EDGAR
Apr 8, 2020	Open-market or private sale	−62,573	$23.65	$1.5M	6,238,574 See Footnotes	Filing · EDGAR
Apr 8, 2020	Open-market or private sale	−20,041	$23.65	$474K	1,997,333 See Footnotes	Filing · EDGAR
Apr 7, 2020	Open-market or private sale	−6,946	$23.10	$160K	6,301,147 See Footnotes	Filing · EDGAR
Apr 7, 2020	Open-market or private sale	−2,224	$23.10	$51K	2,017,374 See Footnotes	Filing · EDGAR
Mar 31, 2020	Open-market or private sale	−189,355	$24.50	$4.6M	6,308,093 See Footnotes	Filing · EDGAR
Mar 31, 2020	Open-market or private sale	−60,645	$24.50	$1.5M	2,019,598 See Footnotes	Filing · EDGAR
Mar 25, 2020	Open-market or private sale	−42,727	$24.66	$1.1M	6,497,448 See Footnotes	Filing · EDGAR
Mar 25, 2020	Open-market or private sale	−13,684	$24.66	$337K	2,080,243 See Footnotes	Filing · EDGAR
Mar 24, 2020	Open-market or private sale	−51,235	$24.45	$1.3M	6,540,175 See Footnotes	Filing · EDGAR
Mar 24, 2020	Open-market or private sale	−16,409	$24.45	$401K	2,093,927 See Footnotes	Filing · EDGAR
Mar 23, 2020	Open-market or private sale	−11,057	$26.05	$288K	6,591,410 See Footnotes	Filing · EDGAR
Mar 23, 2020	Open-market or private sale	−3,541	$26.05	$92K	2,110,336 See Footnotes	Filing · EDGAR
Mar 2, 2020	Open-market or private sale	−1,390,309	$26.00	$36.1M	6,602,467 See Footnotes	Filing · EDGAR
Mar 2, 2020	Open-market or private sale	−445,086	$26.00	$11.6M	2,113,877 See Footnotes	Filing · EDGAR
Mar 2, 2020	Open-market or private sale	−38,808	$26.00	$1M	0 See Footnotes	Filing · EDGAR
Jan 9, 2020	Open-market or private sale	−286,787	$19.50	$5.6M	7,992,776 See Footnotes	Filing · EDGAR
Jan 9, 2020	Open-market or private sale	−91,818	$19.50	$1.8M	2,558,963 See Footnotes	Filing · EDGAR
Jan 9, 2020	Open-market or private sale	−1,392	$19.50	$27K	38,808 See Footnotes	Filing · EDGAR
Dec 26, 2019	Open-market or private sale	−7,275	$18.60	$135K	8,279,563 See Footnotes	Filing · EDGAR
Dec 26, 2019	Open-market or private sale	−2,325	$18.60	$43K	2,650,781 See Footnotes	Filing · EDGAR
Dec 26, 2019	Open-market or private sale	−1,200	$18.60	$22K	40,200 See Footnotes	Filing · EDGAR
Dec 24, 2019	Open-market or private sale	−48,324	$19.59	$947K	8,286,838 See Footnotes	Filing · EDGAR
Dec 24, 2019	Open-market or private sale	−15,476	$19.59	$303K	2,653,106 See Footnotes	Filing · EDGAR
Dec 24, 2019	Open-market or private sale	−8,000	$19.59	$157K	41,400 See Footnotes	Filing · EDGAR
Dec 23, 2019	Open-market or private sale	−63,535	$19.82	$1.3M	8,335,162 See Footnotes	Filing · EDGAR
Dec 23, 2019	Open-market or private sale	−20,350	$19.82	$403K	2,668,582 See Footnotes	Filing · EDGAR
Dec 23, 2019	Open-market or private sale	−10,400	$19.82	$206K	49,400 See Footnotes	Filing · EDGAR
Dec 20, 2019	Open-market or private sale	−230,721	$19.66	$4.5M	8,398,697 See Footnotes	Filing · EDGAR
Dec 20, 2019	Open-market or private sale	−73,879	$19.66	$1.5M	2,688,932 See Footnotes	Filing · EDGAR
Dec 20, 2019	Open-market or private sale	−37,900	$19.66	$745K	59,800 See Footnotes	Filing · EDGAR
Dec 17, 2019	Open-market or private sale	−642,807	$18.52	$11.9M	8,629,418 See Footnotes	Filing · EDGAR
Dec 17, 2019	Open-market or private sale	−205,793	$18.52	$3.8M	2,762,811 See Footnotes	Filing · EDGAR
Dec 17, 2019	Open-market or private sale	−105,500	$18.52	$2M	97,700 See Footnotes	Filing · EDGAR
Aug 7, 2019	Open-market or private sale	−492,364	$17.90	$8.8M	9,272,225 See Footnotes	Filing · EDGAR
Aug 7, 2019	Open-market or private sale	−157,636	$17.90	$2.8M	2,968,604 See Footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+405,925			405,925 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+4,282,288			4,688,213 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+2,029,626			6,717,839 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+2,280,479			8,998,318 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+1,012,282			10,010,600 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+266,437			10,277,037 See footnotes	Filing · EDGAR
Feb 11, 2019	Open-market or private purchase	+157,939	$19.00	$3M	10,434,976 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+94,075			94,075 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+992,437			1,086,512 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+470,374			1,556,886 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+528,510			2,085,396 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+234,601			2,319,997 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted	+85,295			2,405,292 See footnotes	Filing · EDGAR
Feb 11, 2019	Open-market or private purchase	+50,561	$19.00	$961K	2,455,853 See footnotes	Filing · EDGAR
Feb 11, 2019	Open-market or private purchase	+203,200	$19.00	$3.9M	203,200 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted Series A-1 Preferred Stock	−405,925			0 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted Series A-1 Preferred Stock	−94,075			0 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted Series A-2 Preferred Stock	−4,282,288			0 See footnotes	Filing · EDGAR
Feb 11, 2019	Derivative converted Series A-2 Preferred Stock	−992,437			0 See footnotes	Filing · EDGAR

8 earlier transactions are in the filing list below.

Principia Biopharma 10% owner · filings 2018 to 2019 · sold $30.3M · bought $4.3M

Date	Transaction	Shares	Price	Value	Held after	Source
May 21, 2019	Open-market or private sale	−1,000,000	$30.25	$30.3M	1,605,713 See Footnotes	Filing · EDGAR
Sep 18, 2018	Derivative converted	+1,070,771			1,070,771 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted	+312,741			1,383,512 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted	+260,617			1,644,129 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted	+544,047			2,188,176 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted	+167,537			2,355,713 See footnote	Filing · EDGAR
Sep 18, 2018	Open-market or private purchase	+250,000	$17.00	$4.3M	2,605,713 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted Series A Convertible Preferred Stock	−1,070,771			0 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted Series B-1 Convertible Preferred Stock	−312,741			0 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted Series B-2 Convertible Preferred Stock	−260,617			0 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted Series B-3 Convertible Preferred Stock	−544,047			0 See footnote	Filing · EDGAR
Sep 18, 2018	Derivative converted Series C Convertible Preferred Stock	−167,537			0 See footnote	Filing · EDGAR

NextCure Director, 10% owner · filings 2019 to 2019 · bought $5.3M

Date	Transaction	Shares	Price	Value	Held after	Source
May 13, 2019	Derivative converted	+445,866			445,866 By OrbiMed Private Investments VI, LP	Filing · EDGAR
May 13, 2019	Derivative converted	+743,110			1,188,976 By OrbiMed Private Investments VI, LP	Filing · EDGAR
May 13, 2019	Derivative converted	+729,599			1,918,575 By OrbiMed Private Investments VI, LP	Filing · EDGAR
May 13, 2019	Derivative converted	+442,438			2,361,013 By OrbiMed Private Investments VI, LP	Filing · EDGAR
May 13, 2019	Open-market or private purchase	+350,000	$15.00	$5.3M	2,711,013 By OrbiMed Private Investments VI, LP	Filing · EDGAR
May 13, 2019	Derivative converted Series A-1 Preferred Stock	−3,582,000			0 See footnotes	Filing · EDGAR
May 13, 2019	Derivative converted Series A-2 Preferred Stock	−5,970,000			0 See footnotes	Filing · EDGAR
May 13, 2019	Derivative converted Series A-3 Preferred Stock	−5,861,455			0 See footnotes	Filing · EDGAR
May 13, 2019	Derivative converted Series B-1 Preferred Stock	−3,554,466			0 See footnotes	Filing · EDGAR

Turning Point Therapeutics Director · filings 2019 to 2019 · bought $6.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 22, 2019	Derivative converted	+1,120,730			1,120,730 See footnote	Filing · EDGAR
Apr 22, 2019	Derivative converted	+546,820			1,667,550 See footnote	Filing · EDGAR
Apr 22, 2019	Open-market or private purchase	+360,000	$18.00	$6.5M	2,027,550 See footnote	Filing · EDGAR
Apr 22, 2019	Derivative converted Series C Preferred Stock	−4,314,809			0 See footnote	Filing · EDGAR
Apr 22, 2019	Derivative converted Series D Preferred Stock	−2,105,259			0 See footnote	Filing · EDGAR

Avedro 10% owner · filings 2019 to 2019

Date	Transaction	Shares	Held after	Source
Feb 19, 2019	Derivative converted	+3,370,786	3,523,204 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted	+333,178	3,856,382 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted	+383,746	4,240,128 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted Series AA Convertible Preferred Stock	−3,370,786	0 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted Series BB Convertible Preferred Stock	−333,178	0 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted Series CC Convertible Preferred Stock	−383,746	0 See Footnote	Filing · EDGAR

Synthorx Director, 10% owner · filings 2018 to 2018 · bought $15M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 11, 2018	Open-market or private purchase	+1,363,636	$11.00	$15M	1,363,636 See Footnote	Filing · EDGAR
Dec 11, 2018	Derivative converted	+3,952,719			5,316,355 See Footnote	Filing · EDGAR
Dec 11, 2018	Derivative converted Series C Preferred Stock	−6,333,206			0 See Footnote	Filing · EDGAR

SI-BONE Director · filings 2018 to 2018 · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 19, 2018	Derivative converted	+605,964			605,964 By OrbiMed Private Investments V, LP	Filing · EDGAR
Oct 19, 2018	Derivative converted	+179,404			785,368 By OrbiMed Private Investments V, LP	Filing · EDGAR
Oct 19, 2018	Open-market or private purchase	+200,000	$15.00	$3M	985,368 By OrbiMed Private Investments V, LP	Filing · EDGAR
Oct 19, 2018	Derivative converted Series 6 Preferred Stock	−572,326			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Oct 19, 2018	Derivative converted Series 7 Preferred Stock	−179,404			0 By OrbiMed Private Investments V, LP	Filing · EDGAR

Guardant Health 10% owner · filings 2018 to 2018

Date	Transaction	Shares	Held after	Source
Oct 9, 2018	Derivative converted	+1,525,492	1,525,492 By OrbiMed Royalties Opportunities II, LP	Filing · EDGAR
Oct 9, 2018	Derivative converted	+8,972	8,972 By OrbiMed Royalties Opportunities II, LP	Filing · EDGAR
Oct 9, 2018	Derivative converted SERIES D PREFERRED STOCK	−1,525,492	0 By OrbiMed Royalties Opportunities II, LP	Filing · EDGAR
Oct 9, 2018	Derivative converted SERIES E PREFERRED STOCK	−8,972	0 By OrbiMed Royalties Opportunities II, LP	Filing · EDGAR

Arvinas Holding Company 10% owner · filings 2018 to 2018

No transactions in the filings read; Form 144 notices are listed above.

SteadyMed 10% owner · filings 2016 to 2018 · sold $18.9M · bought $6.9M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 30, 2018	Open-market or private sale	−2,123,098	$4.46	$9.5M	0 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private sale	−2,123,098	$4.46	$9.5M	0 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private purchase Warrants to Purchase Ordinary Shares	+55,000	$3.85	$212K	348,500 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private purchase Warrants to Purchase Ordinary Shares	+55,000	$3.85	$212K	348,500 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private sale Warrants to Purchase Ordinary Shares	−1,536,098			0 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private sale Warrants to Purchase Ordinary Shares				0 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private sale Warrants to Purchase Ordinary Shares	−348,500			0 See Footnotes	Filing · EDGAR
Aug 30, 2018	Open-market or private sale Warrants to Purchase Ordinary Shares	−348,500			0 See Footnotes	Filing · EDGAR
Apr 25, 2017	Open-market or private purchase	+587,000	$5.90	$3.5M	2,123,098 See Footnotes	Filing · EDGAR
Apr 25, 2017	Open-market or private purchase	+587,000	$5.90	$3.5M	2,123,098 See Footnotes	Filing · EDGAR
Apr 25, 2017	Open-market or private purchase Warrants to Purchase Ordinary Shares	+293,500	$0.13	$37K	293,500 See Footnotes	Filing · EDGAR
Apr 25, 2017	Open-market or private purchase Warrants to Purchase Ordinary Shares	+293,500	$0.13	$37K	293,500 See Footnotes	Filing · EDGAR

ViewRay 10% owner · filings 2016 to 2018 · sold $24.1M · bought $4.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 20, 2018	Open-market or private sale	−153,921	$9.98	$1.5M	7,234,976 See Footnotes	Filing · EDGAR
Aug 20, 2018	Open-market or private sale	−153,921	$9.98	$1.5M	68,898 See Footnotes	Filing · EDGAR
Aug 16, 2018	Open-market or private sale	−362,765	$9.94	$3.6M	7,388,897 See Footnotes	Filing · EDGAR
Aug 16, 2018	Open-market or private sale	−3,455	$9.94	$34K	70,364 See Footnotes	Filing · EDGAR
Aug 15, 2018	Open-market or private sale	−77,314	$9.93	$768K	7,751,662 See Footnotes	Filing · EDGAR
Aug 15, 2018	Open-market or private sale	−736	$9.93	$7K	73,819 See Footnotes	Filing · EDGAR
Aug 14, 2018	Open-market or private sale	−20,777	$9.94	$207K	7,828,976 See Footnotes	Filing · EDGAR
Aug 14, 2018	Open-market or private sale	−198	$9.94	$2K	74,555 See Footnotes	Filing · EDGAR
Aug 13, 2018	Open-market or private sale	−86,103	$9.98	$859K	7,849,753 See Footnotes	Filing · EDGAR
Aug 13, 2018	Open-market or private sale	−820	$9.98	$8K	74,753 See Footnotes	Filing · EDGAR
Aug 10, 2018	Open-market or private sale	−678,333	$9.96	$6.8M	7,935,856 See Footnotes	Filing · EDGAR
Aug 10, 2018	Open-market or private sale	−6,460	$9.96	$64K	75,573 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−108,729	$9.95	$1.1M	8,640,328 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−1,036	$9.95	$10K	82,282 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted	+19,372	$5.00	$97K	8,659,700 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted	+184	$5.00	$920	82,466 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted	+45,203	$5.00	$226K	8,704,903 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted	+431	$5.00	$2K	82,897 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−64,575	$9.91	$640K	8,640,328 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−615	$9.91	$6K	82,282 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−26,139	$9.86	$258K	8,614,189 See Footnotes	Filing · EDGAR
Aug 9, 2018	Open-market or private sale	−249	$9.86	$2K	82,033 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−19,372			0 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−184			0 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−45,203			0 See Footnotes	Filing · EDGAR
Aug 9, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−431			0 See Footnotes	Filing · EDGAR
Aug 8, 2018	Open-market or private sale	−478,107	$10.00	$4.8M	8,749,057 See Footnotes	Filing · EDGAR
Aug 8, 2018	Open-market or private sale	−4,553	$10.00	$46K	83,318 See Footnotes	Filing · EDGAR
Aug 7, 2018	Option or RSU exercised or converted	+26,139			9,227,164 See Footnotes	Filing · EDGAR
Aug 7, 2018	Option or RSU exercised or converted	+249			87,871 See Footnotes	Filing · EDGAR
Aug 7, 2018	Option or RSU exercised or converted Restricted Stock Unit	−26,139			0 See Footnotes	Filing · EDGAR
Aug 7, 2018	Option or RSU exercised or converted Restricted Stock Unit	−249			0 See Footnotes	Filing · EDGAR
Aug 7, 2018	Open-market or private sale	−50,149	$10.01	$502K	9,201,025 See Footnotes	Filing · EDGAR
Aug 7, 2018	Open-market or private sale	−478	$10.01	$5K	87,622 See Footnotes	Filing · EDGAR
Aug 3, 2018	Open-market or private sale	−118,168	$11.71	$1.4M	9,251,174 See Footnotes	Filing · EDGAR
Aug 3, 2018	Open-market or private sale	−1,125	$11.71	$13K	88,100 See Footnotes	Filing · EDGAR
Jan 18, 2017	Open-market or private purchase	+327,459	$3.00	$982K	9,369,342 See Footnotes	Filing · EDGAR
Jan 18, 2017	Open-market or private purchase	+3,118	$3.00	$9K	89,225 See Footnotes	Filing · EDGAR
Jan 18, 2017	Open-market or private purchase Warrants to purchase common stock	+65,491	$0.13	$8K	403,692 See Footnotes	Filing · EDGAR
Jan 18, 2017	Open-market or private purchase Warrants to purchase common stock	+623	$0.13	$78	3,843 See Footnotes	Filing · EDGAR
Aug 22, 2016	Open-market or private purchase	+1,127,338	$2.95	$3.3M	9,041,883 See Footnotes	Filing · EDGAR
Aug 22, 2016	Open-market or private purchase	+10,736	$2.95	$32K	86,107 See Footnotes	Filing · EDGAR
Aug 22, 2016	Open-market or private purchase Warrants to purchase common stock	+338,201	$0.13	$42K	338,201 See Footnotes	Filing · EDGAR
Aug 22, 2016	Open-market or private purchase Warrants to purchase common stock	+3,220	$0.13	$403	3,220 See Footnotes	Filing · EDGAR

Constellation Pharmaceuticals 10% owner · filings 2018 to 2018 · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 23, 2018	Derivative converted	+317,921			317,921 See footnote	Filing · EDGAR
Jul 23, 2018	Open-market or private purchase	+100,000	$15.00	$1.5M	417,921 See footnote	Filing · EDGAR
Jul 23, 2018	Derivative converted	+317,921			317,921 See footnote	Filing · EDGAR
Jul 23, 2018	Open-market or private purchase	+100,000	$15.00	$1.5M	417,921 See footnote	Filing · EDGAR
Jul 23, 2018	Derivative converted Series F Preferred Stock	−3,500,000			0 See footnote	Filing · EDGAR
Jul 23, 2018	Derivative converted Series F Preferred Stock	−3,500,000			0 See footnote	Filing · EDGAR

Crinetics Pharmaceuticals 10% owner · filings 2018 to 2018

No transactions in the filings read; Form 144 notices are listed above.

ARMO BioSciences Director, 10% owner · filings 2018 to 2018

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 22, 2018	Tendered in a change of control	−3,709,356	$50.00	$185.5M	3,709,356 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jun 22, 2018	Tendered in a change of control	−409,547	$50.00	$20.5M	409,547 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted	+3,709,356			3,709,356 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted	+409,547			409,547 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series A Convertible Preferred Stock	−1,783,704			0 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series B Convertible Preferred Stock	−1,226,156			0 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series C Convertible Preferred Stock	−415,869			0 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series C-1 Convertible Preferred Stock	−283,627			0 By OrbiMed Private Investments IV, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series B-1 Convertible Preferred Stock	−332,271			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series C Convertible Preferred Stock	−45,961			0 By OrbiMed Private Investments V, LP	Filing · EDGAR
Jan 30, 2018	Derivative converted Series C-1 Convertible Preferred Stock	−31,315			0 By OrbiMed Private Investments V, LP	Filing · EDGAR

Adaptimmune Therapeutics Director · filings 2016 to 2018 · sold $14.8M · bought $22.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 6, 2018	Open-market or private sale	−1,600	$13.49	$22K	4,901,310 See Footnotes	Filing · EDGAR
Jun 4, 2018	Open-market or private sale	−17,100	$13.57	$232K	4,902,910 See Footnotes	Filing · EDGAR
Jun 1, 2018	Open-market or private sale	−50,000	$13.49	$675K	4,920,010 See Footnotes	Filing · EDGAR
May 30, 2018	Open-market or private sale	−121,000	$13.52	$1.6M	4,970,010 See Footnotes	Filing · EDGAR
May 14, 2018	Open-market or private sale	−10,300	$13.50	$139K	5,091,010 See Footnotes	Filing · EDGAR
Mar 29, 2018	Open-market or private sale	−31,983	$11.53	$369K	5,101,310 See Footnotes	Filing · EDGAR
Mar 27, 2018	Open-market or private sale	−1,016,084	$11.50	$11.7M	5,133,293 See Footnotes	Filing · EDGAR
Mar 27, 2017	Open-market or private purchase	+1,190,476	$4.20	$5M	6,149,377 See Footnotes	Filing · EDGAR
May 24, 2016	Open-market or private purchase	+518,400	$10.48	$5.4M	29,753,404 See Footnotes	Filing · EDGAR
May 23, 2016	Open-market or private purchase	+1,191,600	$10.40	$12.4M	29,235,004 See Footnotes	Filing · EDGAR
May 20, 2016	Open-market or private purchase	+2,400	$10.04	$24K	28,043,404 See Footnotes	Filing · EDGAR

Rhythm Pharmaceuticals 10% owner, Other · filings 2017 to 2018 · sold $4.7M · bought $6M

Date	Transaction	Shares	Price	Value	Held after	Source
May 22, 2018	Open-market or private sale	−17,980	$30.38	$546K	2,751,679 See Footnotes	Filing · EDGAR
May 22, 2018	Open-market or private sale	−1,600	$30.96	$50K	2,750,079 See Footnotes	Filing · EDGAR
May 21, 2018	Open-market or private sale	−62,500	$31.01	$1.9M	2,769,659 See Footnotes	Filing · EDGAR
May 18, 2018	Open-market or private sale	−69,136	$30.77	$2.1M	2,832,159 See Footnotes	Filing · EDGAR
Oct 10, 2017	Derivative converted	+2,546,295			2,546,295 See Footnotes	Filing · EDGAR
Oct 10, 2017	Open-market or private purchase	+355,000	$17.00	$6M	2,901,295 See Footnotes	Filing · EDGAR
Oct 10, 2017	Derivative converted Series A Convertible Preferred Stock	−2,546,295			0 See Footnotes	Filing · EDGAR

Pieris Pharmaceuticals 10% owner, Other · filings 2015 to 2018 · sold $19.8M · bought $1.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 30, 2018	Open-market or private sale	−989,600	$6.35	$6.3M	4,511,130 See Footnotes	Filing · EDGAR
Apr 30, 2018	Open-market or private sale	−10,400	$6.35	$66K	38,870 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted	+6,057	$4.68	$28K	5,506,787 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted	+58	$4.68	$271	49,328 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted	+1,765	$5.08	$9K	5,508,552 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted	+17	$5.08	$86	49,345 See Footnotes	Filing · EDGAR
Feb 13, 2018	Open-market or private sale	−7,822	$8.98	$70K	5,500,730 See Footnotes	Filing · EDGAR
Feb 13, 2018	Open-market or private sale	−75	$8.98	$674	49,270 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−6,057			0 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−58			0 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−1,765			0 See Footnotes	Filing · EDGAR
Feb 13, 2018	Option or RSU exercised or converted Stock Option (right to buy)	−17			0 See Footnotes	Filing · EDGAR
Jan 3, 2018	Open-market or private sale	−1,693,492	$7.35	$12.4M	5,500,730 See Footnotes	Filing · EDGAR
Jan 3, 2018	Open-market or private sale	−16,128	$7.35	$119K	49,270 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+27,241	$2.00	$54K	7,221,463 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+259	$2.00	$518	65,657 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+5,227	$3.00	$16K	7,226,690 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+50	$3.00	$150	65,707 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+6,654	$2.62	$17K	7,233,344 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+63	$2.62	$165	65,770 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+8,717	$1.94	$17K	7,242,061 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+83	$1.94	$161	65,853 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+10,180	$1.62	$16K	7,252,241 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+97	$1.62	$157	65,950 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+19,811	$1.59	$31K	7,272,052 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+189	$1.59	$301	66,139 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+8,097	$2.05	$17K	7,280,149 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+77	$2.05	$158	66,216 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+9,642	$1.73	$17K	7,289,791 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+92	$1.73	$159	66,308 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+10,182	$1.64	$17K	7,299,973 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+97	$1.64	$159	66,405 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+14,858	$2.01	$30K	7,314,831 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+142	$2.01	$285	66,547 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+10,216	$2.01	$21K	7,325,047 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+97	$2.01	$195	66,644 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+10,447	$2.32	$24K	7,335,494 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+99	$2.32	$230	66,743 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+4,971	$5.64	$28K	7,340,465 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted	+47	$5.64	$265	66,790 See Footnotes	Filing · EDGAR
Dec 18, 2017	Open-market or private sale	−146,243	$5.70	$834K	7,194,222 See Footnotes	Filing · EDGAR
Dec 18, 2017	Open-market or private sale	−1,392	$5.70	$8K	65,398 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−27,241			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−259			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−5,227			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−50			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−6,654			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−63			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−8,717			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−83			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−10,180			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−97			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−19,811			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−189			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−8,097			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−77			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−9,642			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−92			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−10,182			0 See Footnotes	Filing · EDGAR
Dec 18, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−97			0 See Footnotes	Filing · EDGAR

10 earlier transactions are in the filing list below.

Audentes Therapeutics 10% owner · filings 2016 to 2018 · sold $39.8M · bought $500K

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 12, 2018	Open-market or private sale	−1,066	$36.04	$38K	3,556,934 See Footnotes	Filing · EDGAR
Mar 12, 2018	Open-market or private sale	−16,937	$34.92	$591K	3,539,997 See Footnotes	Filing · EDGAR
Mar 9, 2018	Open-market or private sale	−21,300	$34.67	$738K	3,616,700 See Footnotes	Filing · EDGAR
Mar 9, 2018	Open-market or private sale	−47,395	$35.86	$1.7M	3,569,305 See Footnotes	Filing · EDGAR
Mar 9, 2018	Open-market or private sale	−11,305	$36.44	$412K	3,558,000 See Footnotes	Filing · EDGAR
Mar 8, 2018	Open-market or private sale	−58,428	$34.06	$2M	3,638,000 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−11,372	$33.03	$376K	3,696,428 See Footnotes	Filing · EDGAR
Mar 5, 2018	Open-market or private sale	−200	$36.06	$7K	3,707,800 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−386,080	$35.06	$13.5M	3,743,558 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−35,558	$36.33	$1.3M	3,708,000 See Footnotes	Filing · EDGAR
Sep 29, 2017	Open-market or private sale	−672,000	$28.25	$19M	4,129,638 See Footnotes	Filing · EDGAR
Sep 7, 2017	In-the-money option exercised	+5,000	$15.03	$75K	4,806,638 See Footnotes	Filing · EDGAR
Sep 7, 2017	Open-market or private sale	−5,000	$22.35	$112K	4,801,638 See Footnotes	Filing · EDGAR
Sep 7, 2017	In-the-money option exercised Stock Option (right to buy)	−5,000			0 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted	+627,867			852,105 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted	+2,511,441			3,363,546 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted	+1,071,992			4,435,538 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted	+332,766			4,768,304 See Footnotes	Filing · EDGAR
Jul 25, 2016	Open-market or private purchase	+33,334	$15.00	$500K	4,801,638 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted Series Seed Preferred Stock	−627,867			0 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted Series A Preferred Stock	−2,511,441			0 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted Series B Preferred Stock	−1,071,992			0 See Footnotes	Filing · EDGAR
Jul 25, 2016	Derivative converted Series C Preferred Stock	−332,766			0 See Footnotes	Filing · EDGAR

GLAUKOS Director · filings 2015 to 2018 · sold $104.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 6, 2018	Open-market or private sale	−93,008	$30.01	$2.8M	66,790 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−886	$30.01	$27K	637 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−20,114	$30.77	$619K	46,676 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−192	$30.77	$6K	445 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−46,676	$32.06	$1.5M	0 See Footnotes	Filing · EDGAR
Mar 6, 2018	Open-market or private sale	−445	$32.06	$14K	0 See Footnotes	Filing · EDGAR
Mar 5, 2018	Open-market or private sale	−128,092	$32.05	$4.1M	240,314 See Footnotes	Filing · EDGAR
Mar 5, 2018	Open-market or private sale	−1,220	$32.05	$39K	2,291 See Footnotes	Filing · EDGAR
Mar 5, 2018	Open-market or private sale	−80,516	$33.06	$2.7M	159,798 See Footnotes	Filing · EDGAR
Mar 5, 2018	Open-market or private sale	−768	$33.06	$25K	1,523 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−265,766	$31.92	$8.5M	562,839 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−2,533	$31.92	$81K	5,362 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−194,433	$32.80	$6.4M	368,406 See Footnotes	Filing · EDGAR
Mar 2, 2018	Open-market or private sale	−1,851	$32.80	$61K	3,511 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−173,349	$37.94	$6.6M	1,076,444 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−1,651	$37.94	$63K	10,256 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−189,792	$39.63	$7.5M	886,652 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−1,808	$39.63	$72K	8,448 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−58,047	$40.77	$2.4M	828,605 See Footnotes	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−553	$40.77	$23K	7,895 See Footnotes	Filing · EDGAR
Sep 1, 2017	Open-market or private sale	−109,040	$37.72	$4.1M	1,249,793 See Footnotes	Filing · EDGAR
Sep 1, 2017	Open-market or private sale	−1,038	$37.72	$39K	11,907 See Footnotes	Filing · EDGAR
Aug 31, 2017	Open-market or private sale	−44,498	$37.82	$1.7M	1,358,833 See Footnotes	Filing · EDGAR
Aug 31, 2017	Open-market or private sale	−424	$37.82	$16K	12,945 See Footnotes	Filing · EDGAR
Aug 17, 2017	Open-market or private sale	−224,780	$37.85	$8.5M	1,403,331 See Footnotes	Filing · EDGAR
Aug 17, 2017	Open-market or private sale	−2,140	$37.85	$81K	13,369 See Footnotes	Filing · EDGAR
Aug 16, 2017	Open-market or private sale	−64,961	$38.01	$2.5M	1,628,111 See Footnotes	Filing · EDGAR
Aug 16, 2017	Open-market or private sale	−619	$38.01	$24K	15,509 See Footnotes	Filing · EDGAR
Aug 15, 2017	Open-market or private sale	−32,193	$38.29	$1.2M	1,693,072 See Footnotes	Filing · EDGAR
Aug 15, 2017	Open-market or private sale	−307	$38.29	$12K	16,128 See Footnotes	Filing · EDGAR
Mar 14, 2017	Open-market or private sale	−73,401	$44.54	$3.3M	1,725,265 See Footnotes	Filing · EDGAR
Mar 14, 2017	Open-market or private sale	−699	$44.54	$31K	16,435 See Footnotes	Filing · EDGAR
Mar 13, 2017	Open-market or private sale	−208,712	$45.30	$9.5M	1,799,359 See Footnotes	Filing · EDGAR
Mar 13, 2017	Open-market or private sale	−1,998	$45.30	$91K	17,141 See Footnotes	Filing · EDGAR
Mar 13, 2017	Open-market or private sale	−693	$46.13	$32K	1,798,666 See Footnotes	Filing · EDGAR
Mar 13, 2017	Open-market or private sale	−7	$46.13	$323	17,134 See Footnotes	Filing · EDGAR
Mar 10, 2017	Open-market or private sale	−96,113	$45.98	$4.4M	2,008,071 See Footnotes	Filing · EDGAR
Mar 10, 2017	Open-market or private sale	−915	$45.98	$42K	19,129 See Footnotes	Filing · EDGAR
Mar 3, 2017	Open-market or private sale	−55,246	$47.05	$2.6M	2,104,184 See Footnotes	Filing · EDGAR
Mar 3, 2017	Open-market or private sale	−526	$47.05	$25K	20,044 See Footnotes	Filing · EDGAR
Aug 12, 2016	Open-market or private sale	−13,967	$33.72	$471K	2,159,430 See Footnotes	Filing · EDGAR
Aug 12, 2016	Open-market or private sale	−133	$33.72	$4K	20,570 See Footnotes	Filing · EDGAR
Aug 11, 2016	Open-market or private sale	−159,382	$33.63	$5.4M	2,173,397 See Footnotes	Filing · EDGAR
Aug 11, 2016	Open-market or private sale	−1,518	$33.63	$51K	20,703 See Footnotes	Filing · EDGAR
Aug 10, 2016	Open-market or private sale	−116,825	$33.77	$3.9M	2,332,779 See Footnotes	Filing · EDGAR
Aug 10, 2016	Open-market or private sale	−1,113	$33.77	$38K	22,221 See Footnotes	Filing · EDGAR
Aug 3, 2016	Open-market or private sale	−420,990	$30.59	$12.9M	2,449,604 See Footnotes	Filing · EDGAR
Aug 3, 2016	Open-market or private sale	−4,010	$30.59	$123K	23,334 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted	+2,854,870			2,854,870 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted	+27,194			27,194 See Footnotes	Filing · EDGAR
Jun 30, 2015	Option or RSU exercised or converted	+27,346			2,882,216 See Footnotes	Filing · EDGAR
Jun 30, 2015	Shares withheld for tax or exercise price	−11,623	$18.00	$209K	2,870,593 See Footnotes	Filing · EDGAR
Jun 30, 2015	Option or RSU exercised or converted	+261			27,455 See Footnotes	Filing · EDGAR
Jun 30, 2015	Shares withheld for tax or exercise price	−111	$18.00	$2K	27,344 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series D Convertible Preferred Stock	−2,406,441			0 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series D Convertible Preferred Stock	−22,923			0 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series E Convertible Preferred Stock	−167,898			0 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series E Convertible Preferred Stock	−1,599			0 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series F Convertible Preferred Stock	−280,531			0 See Footnotes	Filing · EDGAR
Jun 30, 2015	Derivative converted Series F Convertible Preferred Stock	−2,672			0 See Footnotes	Filing · EDGAR

2 earlier transactions are in the filing list below.

Kala Pharmaceuticals 10% owner · filings 2017 to 2018 · bought $19.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 8, 2018	Open-market or private purchase	+25,000	$12.93	$323K	3,447,840 See Footnotes	Filing · EDGAR
Feb 2, 2018	Open-market or private purchase	+37,840	$14.73	$557K	3,422,840 See Footnotes	Filing · EDGAR
Feb 1, 2018	Open-market or private purchase	+22,840	$14.99	$342K	3,385,000 See Footnotes	Filing · EDGAR
Jan 31, 2018	Open-market or private purchase	+339,400	$15.00	$5.1M	3,362,160 See Footnotes	Filing · EDGAR
Jan 29, 2018	Open-market or private purchase	+50,000	$14.99	$750K	3,022,760 See Footnotes	Filing · EDGAR
Jan 26, 2018	Open-market or private purchase	+22,760	$14.93	$340K	2,972,760 See Footnotes	Filing · EDGAR
Jan 24, 2018	Open-market or private purchase	+64,637	$14.91	$964K	2,950,000 See Footnotes	Filing · EDGAR
Jan 23, 2018	Open-market or private purchase	+4,363	$14.99	$65K	2,885,363 See Footnotes	Filing · EDGAR
Jan 22, 2018	Open-market or private purchase	+75,000	$14.98	$1.1M	2,881,000 See Footnotes	Filing · EDGAR
Jan 19, 2018	Open-market or private purchase	+74,931	$14.95	$1.1M	2,806,000 See Footnotes	Filing · EDGAR
Jan 12, 2018	Open-market or private purchase	+38,354	$14.50	$556K	2,731,069 See Footnotes	Filing · EDGAR
Jan 12, 2018	Open-market or private purchase	+28,446	$15.40	$438K	2,692,715 See Footnotes	Filing · EDGAR
Jan 11, 2018	Open-market or private purchase	+41,700	$13.65	$569K	2,664,269 See Footnotes	Filing · EDGAR
Jan 10, 2018	Open-market or private purchase	+170,338	$12.83	$2.2M	2,622,569 See Footnotes	Filing · EDGAR
Jul 25, 2017	Derivative converted	+2,055,946			2,055,946 See Footnotes	Filing · EDGAR
Jul 25, 2017	Open-market or private purchase	+319,333	$15.00	$4.8M	2,375,279 See Footnotes	Filing · EDGAR
Jul 25, 2017	Derivative converted Series C Preferred Stock	−10,707,985			0 See Footnotes	Filing · EDGAR

Loxo Oncology Director · filings 2014 to 2017 · sold $72.8M · bought $3.6M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 8, 2017	Open-market or private sale	−250,000	$82.50	$20.6M	941,000 See Footnotes	Filing · EDGAR
Nov 22, 2017	Open-market or private sale	−267,000	$75.00	$20M	1,191,000 See Footnotes	Filing · EDGAR
Nov 16, 2017	Open-market or private sale	−46,680	$72.46	$3.4M	1,681,320 See Footnotes	Filing · EDGAR
Nov 16, 2017	Open-market or private sale	−43,300	$73.48	$3.2M	1,638,020 See Footnotes	Filing · EDGAR
Nov 16, 2017	Open-market or private sale	−100,045	$74.49	$7.5M	1,537,975 See Footnotes	Filing · EDGAR
Nov 16, 2017	Open-market or private sale	−71,598	$75.37	$5.4M	1,466,377 See Footnotes	Filing · EDGAR
Nov 16, 2017	Open-market or private sale	−8,377	$76.23	$639K	1,458,000 See Footnotes	Filing · EDGAR
Aug 10, 2016	Open-market or private sale	−447,857	$26.96	$12.1M	1,728,000 See Footnotes	Filing · EDGAR
Aug 6, 2014	Derivative converted	+1,562,499			1,562,499 See Footnotes	Filing · EDGAR
Aug 6, 2014	Derivative converted	+337,973			1,900,472 See Footnotes	Filing · EDGAR
Aug 6, 2014	Open-market or private purchase	+275,385	$13.00	$3.6M	2,175,857 See Footnotes	Filing · EDGAR
Aug 6, 2014	Derivative converted Series A Convertible Preferred Stock	−1,562,499			0 See Footnotes	Filing · EDGAR
Aug 6, 2014	Derivative converted Series B Convertible Preferred Stock	−337,973			0 See Footnotes	Filing · EDGAR

Arsanis 10% owner · filings 2017 to 2017

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 20, 2017	Derivative converted	+19,533			19,533 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted	+252,230			271,763 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted	+328,909			600,672 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted	+114,320			714,992 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted	+653,974			1,368,966 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted	+500,000	$10.00	$5M	1,868,966 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted Series A-1 Convertible Preferred Stock	−66,667			0 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted Series A-2 Convertible Preferred Stock	−704,846			0 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted Series B Convertible Preferred Stock	−736,648			0 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted Series C Convertible Preferred Stock	−229,412			0 See Footnotes	Filing · EDGAR
Nov 20, 2017	Derivative converted Series D Convertible Preferred Stock	−2,232,014			0 See Footnotes	Filing · EDGAR

Roka BioScience 10% owner · filings 2014 to 2017 · sold $742K · bought $4.6M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 3, 2017	Open-market or private sale	−199,718	$0.68	$136K	0 See Footnotes	Filing · EDGAR
Oct 3, 2017	Open-market or private sale	−1,899	$0.68	$1K	0 See Footnotes	Filing · EDGAR
Sep 29, 2017	Open-market or private sale	−93,246	$0.74	$69K	199,718 See Footnotes	Filing · EDGAR
Sep 29, 2017	Open-market or private sale	−888	$0.74	$657	1,899 See Footnotes	Filing · EDGAR
Sep 28, 2017	Open-market or private sale	−376,950	$0.72	$271K	292,964 See Footnotes	Filing · EDGAR
Sep 28, 2017	Open-market or private sale	−3,592	$0.72	$3K	2,787 See Footnotes	Filing · EDGAR
Sep 27, 2017	Open-market or private sale	−52,301	$0.92	$48K	669,914 See Footnotes	Filing · EDGAR
Sep 27, 2017	Open-market or private sale	−498	$0.92	$458	6,379 See Footnotes	Filing · EDGAR
Sep 26, 2017	Open-market or private sale	−74,096	$1.03	$76K	722,215 See Footnotes	Filing · EDGAR
Sep 26, 2017	Open-market or private sale	−706	$1.03	$727	6,877 See Footnotes	Filing · EDGAR
Aug 24, 2017	Open-market or private sale	−13,075	$1.50	$20K	796,311 See Footnotes	Filing · EDGAR
Aug 24, 2017	Open-market or private sale	−125	$1.50	$188	7,583 See Footnotes	Filing · EDGAR
Aug 23, 2017	Open-market or private sale	−1,090	$1.50	$2K	809,386 See Footnotes	Filing · EDGAR
Aug 23, 2017	Open-market or private sale	−10	$1.50	$15	7,708 See Footnotes	Filing · EDGAR
Aug 22, 2017	Open-market or private sale	−5,448	$1.52	$8K	810,476 See Footnotes	Filing · EDGAR
Aug 22, 2017	Open-market or private sale	−52	$1.52	$79	7,718 See Footnotes	Filing · EDGAR
Aug 21, 2017	Open-market or private sale	−2,952	$1.49	$4K	815,924 See Footnotes	Filing · EDGAR
Aug 21, 2017	Open-market or private sale	−28	$1.49	$42	7,770 See Footnotes	Filing · EDGAR
Aug 18, 2017	Open-market or private sale	−66,166	$1.52	$101K	818,876 See Footnotes	Filing · EDGAR
Aug 18, 2017	Open-market or private sale	−630	$1.52	$958	7,798 See Footnotes	Filing · EDGAR
Sep 21, 2016	Open-market or private purchase Series A Convertible Preferred Stock	+3,962.26			3,962.26 See Footnotes	Filing · EDGAR
Sep 21, 2016	Open-market or private purchase Series A Convertible Preferred Stock	+37.74			37.74 See Footnotes	Filing · EDGAR
Sep 21, 2016	Open-market or private purchase Warrants	+5,660,377			5,660,377 See Footnotes	Filing · EDGAR
Sep 21, 2016	Open-market or private purchase Warrants	+53,909			53,909 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+1,112,592			1,117,280 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+10,596			10,640 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+361,612			1,478,892 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+3,443			14,083 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+794,178			2,273,070 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+7,563			21,646 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+537,264			2,810,334 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted	+5,116			26,762 See Footnotes	Filing · EDGAR
Jul 22, 2014	Open-market or private purchase	+379,717	$12.00	$4.6M	3,190,051 See Footnotes	Filing · EDGAR
Jul 22, 2014	Open-market or private purchase	+3,616	$12.00	$43K	30,378 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series B Convertible Preferred Stock	−12,238,019			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series B Convertible Preferred Stock	−116,981			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series C Convertible Preferred Stock	−3,992,203			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series C Convertible Preferred Stock	−38,021			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series D Convertible Preferred Stock	−8,475,069			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series D Convertible Preferred Stock	−80,715			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series E Convertible Preferred Stock	−5,931,402			0 See Footnotes	Filing · EDGAR
Jul 22, 2014	Derivative converted Series E Convertible Preferred Stock	−56,490			0 See Footnotes	Filing · EDGAR

Aeglea BioTherapeutics 10% owner · filings 2016 to 2017 · bought $564K

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 21, 2017	Open-market or private purchase	+7,000	$5.36	$38K	1,469,524 See Footnotes	Filing · EDGAR
Feb 17, 2017	Open-market or private purchase	+71,800	$5.19	$373K	1,462,524 See Footnotes	Filing · EDGAR
Feb 16, 2017	Open-market or private purchase	+30,500	$5.04	$154K	1,390,724 See Footnotes	Filing · EDGAR

Nabriva Therapeutics Director, 10% owner · filings 2016 to 2016

No transactions in the filings read; Form 144 notices are listed above.

Response Biomedical Director, 10% owner · filings 2012 to 2016 · bought $2.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 29, 2016	Other acquisition or disposition (see the filing)	−3,604,266			0 See Footnotes	Filing · EDGAR
Nov 29, 2016	Other acquisition or disposition (see the filing)	−34,291			0 See Footnotes	Filing · EDGAR
Nov 29, 2016	Other acquisition or disposition (see the filing)	−2,149,902			0 See Footnotes	Filing · EDGAR
Jun 16, 2016	Open-market or private purchase	+556,339	$0.56	$312K	3,604,266 See Footnotes	Filing · EDGAR
Jun 16, 2016	Open-market or private purchase	+5,294	$0.56	$3K	34,291 See Footnotes	Filing · EDGAR
Jun 16, 2016	Open-market or private purchase	+331,225	$0.56	$185K	2,149,902 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase	+508,244	$2.45	$1.2M	3,047,927 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase	+4,816	$2.45	$12K	28,997 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase	+303,265	$2.45	$743K	1,818,677 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase Warrant	+254,122			254,122 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase Warrant	+2,408			2,408 See Footnotes	Filing · EDGAR
Nov 7, 2013	Open-market or private purchase Warrant	+151,632			151,632 See Footnotes	Filing · EDGAR

Relypsa 10% owner · filings 2013 to 2016 · sold $221.2M · bought $14.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 25, 2016	Open-market or private sale	−343,600	$31.98	$11M	3,356,400 See Footnotes	Filing · EDGAR
Jul 22, 2016	Open-market or private sale	−3,700,000	$32.00	$118.4M	3,700,000 See Footnotes	Filing · EDGAR
Dec 23, 2015	Open-market or private sale	−47,942	$26.78	$1.3M	7,452,058 See Footnotes	Filing · EDGAR
Dec 23, 2015	Open-market or private sale	−52,058	$27.54	$1.4M	7,400,000 See Footnotes	Filing · EDGAR
Dec 22, 2015	Open-market or private sale	−111,370	$26.39	$2.9M	7,538,630 See Footnotes	Filing · EDGAR
Dec 22, 2015	Open-market or private sale	−38,630	$27.02	$1M	7,500,000 See Footnotes	Filing · EDGAR
Dec 21, 2015	Open-market or private sale	−235,829	$27.50	$6.5M	7,664,171 See Footnotes	Filing · EDGAR
Dec 21, 2015	Open-market or private sale	−14,171	$28.39	$402K	7,650,000 See Footnotes	Filing · EDGAR
Oct 22, 2015	Open-market or private purchase	+189,300	$11.97	$2.3M	7,589,300 See Footnotes	Filing · EDGAR
Oct 22, 2015	Open-market or private purchase	+310,700	$12.92	$4M	7,900,000 See Footnotes	Filing · EDGAR
May 18, 2015	Open-market or private sale	−1,457,551	$34.13	$49.7M	7,400,000 See Footnotes	Filing · EDGAR
Sep 17, 2014	Open-market or private sale	−49,000	$25.07	$1.2M	8,857,551 See footnotes	Filing · EDGAR
Sep 16, 2014	Open-market or private sale	−42,400	$25.45	$1.1M	8,909,151 See footnotes	Filing · EDGAR
Sep 16, 2014	Open-market or private sale	−2,600	$26.06	$68K	8,906,551 See footnotes	Filing · EDGAR
Aug 15, 2014	Open-market or private sale	−990,000	$26.35	$26.1M	8,951,551 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted	+1,904,940			1,904,940 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted	+1,905,702			3,810,642 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted	+3,007,297			6,817,939 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted	+693,991			7,511,930 See footnotes	Filing · EDGAR
Nov 20, 2013	Option or RSU exercised or converted	+1,417,578	$0.17	$241K	8,929,508 See footnotes	Filing · EDGAR
Nov 20, 2013	Shares withheld for tax or exercise price	−22,166	$11.00	$244K	8,907,342 See footnotes	Filing · EDGAR
Nov 20, 2013	Option or RSU exercised or converted	+327,133	$0.17	$56K	9,234,475 See footnotes	Filing · EDGAR
Nov 20, 2013	Shares withheld for tax or exercise price	−5,116	$11.00	$56K	9,229,359 See footnotes	Filing · EDGAR
Nov 20, 2013	Open-market or private purchase	+712,192	$11.00	$7.8M	9,941,551 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted Series B-1 Preferred Stock	−1,295,845			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted Series B-2 Preferred Stock	−1,905,702			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted Series C-1 Preferred Stock	−3,007,297			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Derivative converted Series C-2 Preferred Stock	−693,991			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Other acquisition or disposition (see the filing) Warrant to Purchase Preferred Stock	−1,417,578			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Other acquisition or disposition (see the filing) Warrant to Purchase Common Stock	+1,417,578			1,417,578 See footnotes	Filing · EDGAR
Nov 20, 2013	Option or RSU exercised or converted Warrant to Purchase Common Stock	−1,417,578			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Other acquisition or disposition (see the filing) Warrant to Purchase Preferred Stock	−327,133			0 See footnotes	Filing · EDGAR
Nov 20, 2013	Other acquisition or disposition (see the filing) Warrant to Purchase Common Stock	+327,133			327,133 See footnotes	Filing · EDGAR
Nov 20, 2013	Option or RSU exercised or converted Warrant to Purchase Common Stock	−327,133			0 See footnotes	Filing · EDGAR

Selecta Biosciences Director, 10% owner · filings 2016 to 2016 · bought $15.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 27, 2016	Derivative converted	+11,111			12,193 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted	+1,166,884			1,280,604 See Footnote	Filing · EDGAR
Jun 27, 2016	Open-market or private purchase	+5,189	$14.00	$73K	17,382 See Footnote	Filing · EDGAR
Jun 27, 2016	Open-market or private purchase	+544,811	$14.00	$7.6M	1,825,415 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series C Convertible Preferred Stock	−3,628			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series C Convertible Preferred Stock	−380,986			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series D Convertible Preferred Stock	−739			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series D Convertible Preferred Stock	−77,697			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series E Convertible Preferred Stock	−4,351			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series E Convertible Preferred Stock	−456,870			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted	+11,111			12,193 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted	+1,166,884			1,280,604 See Footnote	Filing · EDGAR
Jun 27, 2016	Open-market or private purchase	+5,189	$14.00	$73K	17,382 See Footnote	Filing · EDGAR
Jun 27, 2016	Open-market or private purchase	+544,811	$14.00	$7.6M	1,825,415 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series C Convertible Preferred Stock	−3,628			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series C Convertible Preferred Stock	−380,986			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series D Convertible Preferred Stock	−739			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series D Convertible Preferred Stock	−77,697			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series E Convertible Preferred Stock	−4,351			0 See Footnote	Filing · EDGAR
Jun 27, 2016	Derivative converted Series E Convertible Preferred Stock	−456,870			0 See Footnote	Filing · EDGAR

Intellia Therapeutics Director · filings 2016 to 2016 · bought $4.5M

Date	Transaction	Shares	Price	Value	Held after	Source
May 11, 2016	Derivative converted	+1,847,400			1,847,400 See Footnote	Filing · EDGAR
May 11, 2016	Derivative converted	+564,780			2,412,180 See Footnote	Filing · EDGAR
May 11, 2016	Open-market or private purchase	+191,466	$18.00	$3.4M	2,603,646 See Footnote	Filing · EDGAR
May 11, 2016	Open-market or private purchase	+58,534	$18.00	$1.1M	2,662,180 See Footnote	Filing · EDGAR
May 11, 2016	Derivative converted Series B Preferred Stock	−2,857,143			0 See Footnote	Filing · EDGAR
May 11, 2016	Derivative converted Series B Preferred Stock	−873,475			0 See Footnote	Filing · EDGAR

Otonomy Director · filings 2014 to 2015 · sold $11.6M · bought $2.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 30, 2015	Open-market or private sale	−2,716	$28.64	$78K	1,850,684 See Footnotes	Filing · EDGAR
Nov 30, 2015	Open-market or private sale	−590	$29.22	$17K	1,850,094 See Footnotes	Filing · EDGAR
Nov 27, 2015	Open-market or private sale	−29,000	$28.97	$840K	1,853,400 See Footnotes	Filing · EDGAR
Nov 25, 2015	Open-market or private sale	−34,800	$28.91	$1M	1,882,400 See Footnotes	Filing · EDGAR
Nov 24, 2015	Open-market or private sale	−36,100	$28.75	$1M	1,917,200 See Footnotes	Filing · EDGAR
Nov 23, 2015	Open-market or private sale	−80,800	$28.45	$2.3M	1,953,300 See Footnotes	Filing · EDGAR
Nov 20, 2015	Open-market or private sale	−83,900	$28.59	$2.4M	2,034,100 See Footnotes	Filing · EDGAR
Nov 19, 2015	Open-market or private sale	−127,300	$28.60	$3.6M	2,118,000 See Footnotes	Filing · EDGAR
Nov 17, 2015	Open-market or private sale	−10,898	$28.80	$314K	2,245,500 See Footnotes	Filing · EDGAR
Nov 17, 2015	Open-market or private sale	−200	$29.09	$6K	2,245,300 See Footnotes	Filing · EDGAR
Aug 18, 2014	Derivative converted	+2,084,523			2,084,523 See footnotes	Filing · EDGAR
Aug 18, 2014	Open-market or private purchase	+171,875	$16.00	$2.8M	2,256,398 See footnotes	Filing · EDGAR
Aug 18, 2014	Derivative converted Series C Preferred Stock	−1,706,484			0 See footnotes	Filing · EDGAR
Aug 18, 2014	Derivative converted Series D Preferred Stock	−378,039			0 See footnotes	Filing · EDGAR

Dimension Therapeutics Director, 10% owner · filings 2015 to 2015 · bought $2.6M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 27, 2015	Derivative converted	+3,250,085			3,250,085 See Footnotes	Filing · EDGAR
Oct 27, 2015	Derivative converted	+1,947,613			5,197,698 See Footnotes	Filing · EDGAR
Oct 27, 2015	Open-market or private purchase	+200,000	$13.00	$2.6M	5,397,698 See Footnotes	Filing · EDGAR
Oct 27, 2015	Derivative converted Series A Preferred Stock	−9,500,000			0 See Footnotes	Filing · EDGAR
Oct 27, 2015	Derivative converted Series B Preferred Stock	−5,692,874			0 See Footnotes	Filing · EDGAR

Sientra 10% owner · filings 2014 to 2015 · sold $10.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 12, 2015	Open-market or private sale	−285,106	$5.98	$1.7M	1,767,902 See Footnotes	Filing · EDGAR
Oct 12, 2015	Open-market or private sale	−2,785	$5.98	$17K	17,100 See Footnotes	Filing · EDGAR
Oct 9, 2015	Open-market or private sale	−210,668	$7.03	$1.5M	2,053,008 See Footnotes	Filing · EDGAR
Oct 9, 2015	Open-market or private sale	−2,041	$7.03	$14K	19,885 See Footnotes	Filing · EDGAR
Oct 8, 2015	Open-market or private sale	−396,163	$7.24	$2.9M	2,263,676 See Footnotes	Filing · EDGAR
Oct 8, 2015	Open-market or private sale	−3,837	$7.24	$28K	21,926 See Footnotes	Filing · EDGAR
Oct 7, 2015	Open-market or private sale	−53,446	$7.36	$393K	2,659,839 See Footnotes	Filing · EDGAR
Oct 7, 2015	Open-market or private sale	−454	$7.36	$3K	25,763 See Footnotes	Filing · EDGAR
Oct 6, 2015	Open-market or private sale	−6,941	$7.80	$54K	2,713,285 See Footnotes	Filing · EDGAR
Oct 6, 2015	Open-market or private sale	−59	$7.80	$460	26,217 See Footnotes	Filing · EDGAR
Oct 5, 2015	Open-market or private sale	−136,937	$8.19	$1.1M	2,720,226 See Footnotes	Filing · EDGAR
Oct 5, 2015	Open-market or private sale	−1,163	$8.19	$10K	26,276 See Footnotes	Filing · EDGAR
Oct 2, 2015	Open-market or private sale	−47,497	$10.34	$491K	2,857,163 See Footnotes	Filing · EDGAR
Oct 2, 2015	Open-market or private sale	−403	$10.34	$4K	27,439 See Footnotes	Filing · EDGAR
Oct 1, 2015	Open-market or private sale	−47,100	$10.34	$487K	2,904,660 See Footnotes	Filing · EDGAR
Oct 1, 2015	Open-market or private sale	−400	$10.34	$4K	27,842 See Footnotes	Filing · EDGAR
Sep 30, 2015	Open-market or private sale	−43,471	$10.17	$442K	2,951,760 See Footnotes	Filing · EDGAR
Sep 30, 2015	Open-market or private sale	−369	$10.17	$4K	28,242 See Footnotes	Filing · EDGAR
Sep 29, 2015	Open-market or private sale	−10,469	$10.08	$106K	2,995,231 See Footnotes	Filing · EDGAR
Sep 29, 2015	Open-market or private sale	−89	$10.08	$897	28,611 See Footnotes	Filing · EDGAR
Sep 28, 2015	Open-market or private sale	−10,513	$10.30	$108K	3,005,700 See Footnotes	Filing · EDGAR
Sep 28, 2015	Open-market or private sale	−89	$10.30	$917	28,700 See Footnotes	Filing · EDGAR
Sep 25, 2015	Open-market or private sale	−64,400	$10.07	$649K	3,082,702 See Footnotes	Filing · EDGAR
Sep 25, 2015	Open-market or private sale	−800	$10.07	$8K	29,100 See Footnotes	Filing · EDGAR
Sep 25, 2015	Open-market or private sale	−66,489	$11.07	$736K	3,016,213 See Footnotes	Filing · EDGAR
Sep 25, 2015	Open-market or private sale	−311	$11.07	$3K	28,789 See Footnotes	Filing · EDGAR
Sep 24, 2015	Open-market or private sale	−6	$9.78	$59	3,155,254 See Footnotes	Filing · EDGAR
Sep 24, 2015	Open-market or private sale	−148	$11.00	$2K	29,900 See Footnotes	Filing · EDGAR
Sep 24, 2015	Open-market or private sale	−8,152	$11.00	$90K	3,147,102 See Footnotes	Filing · EDGAR

Intercept Pharmaceuticals Director · filings 2012 to 2015 · sold $205.3M · bought $5M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 17, 2015	Grant or award from the company	+285			1,120,609 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−5,623	$281.11	$1.6M	1,271,901 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−8,397	$282.13	$2.4M	1,263,504 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−9,357	$282.87	$2.6M	1,254,147 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−16,845	$284.20	$4.8M	1,237,302 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−23,903	$285.18	$6.8M	1,213,399 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−7,611	$286.24	$2.2M	1,205,788 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−18,041	$287.16	$5.2M	1,187,747 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−26,028	$288.11	$7.5M	1,161,719 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−15,131	$289.07	$4.4M	1,146,588 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−13,974	$290.02	$4.1M	1,132,614 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−3,700	$291.12	$1.1M	1,128,914 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−6,000	$292.13	$1.8M	1,122,914 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−2,500	$293.85	$735K	1,120,414 See Footnotes	Filing · EDGAR
Mar 26, 2015	Open-market or private sale	−90	$294.82	$27K	1,120,324 See Footnotes	Filing · EDGAR
Mar 25, 2015	Open-market or private sale	−2,800	$270.23	$757K	1,277,524 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−6,764	$268.13	$1.8M	1,319,160 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−1,539	$269.10	$414K	1,317,621 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−9,574	$270.13	$2.6M	1,308,047 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−6,063	$271.15	$1.6M	1,301,984 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−3,050	$272.13	$830K	1,298,934 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−2,700	$273.19	$738K	1,296,234 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−12,066	$275.00	$3.3M	1,284,168 See Footnotes	Filing · EDGAR
Mar 24, 2015	Open-market or private sale	−3,844	$275.56	$1.1M	1,280,324 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−40,598	$270.70	$11M	1,444,726 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−7,764	$271.70	$2.1M	1,436,962 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−8,638	$272.79	$2.4M	1,428,324 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−11,869	$273.89	$3.3M	1,416,455 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−3,579	$274.86	$984K	1,412,876 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−37,666	$275.95	$10.4M	1,375,210 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−8,195	$276.96	$2.3M	1,367,015 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−14,152	$278.00	$3.9M	1,352,863 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−3,668	$279.00	$1M	1,349,195 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−9,465	$280.00	$2.7M	1,339,730 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−6,306	$281.01	$1.8M	1,333,424 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−3,500	$282.00	$987K	1,329,924 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−1,548	$283.29	$439K	1,328,376 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−52	$283.44	$15K	1,328,324 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−1,400	$286.04	$400K	1,326,924 See Footnotes	Filing · EDGAR
Mar 23, 2015	Open-market or private sale	−1,000	$288.60	$289K	1,325,924 See Footnotes	Filing · EDGAR
Aug 26, 2014	Open-market or private sale	−10,400	$299.13	$3.1M	1,536,182 See Footnotes	Filing · EDGAR
Aug 26, 2014	Open-market or private sale	−45,058	$300.11	$13.5M	1,491,124 See Footnotes	Filing · EDGAR
Aug 26, 2014	Open-market or private sale	−5,400	$301.36	$1.6M	1,485,724 See Footnotes	Filing · EDGAR
Aug 26, 2014	Open-market or private sale	−400	$302.34	$121K	1,485,324 See Footnotes	Filing · EDGAR
Aug 25, 2014	Open-market or private sale	−12,558	$294.67	$3.7M	1,584,024 See Footnotes	Filing · EDGAR
Aug 25, 2014	Open-market or private sale	−25,442	$295.52	$7.5M	1,558,582 See Footnotes	Filing · EDGAR
Aug 25, 2014	Open-market or private sale	−10,010	$296.59	$3M	1,548,572 See Footnotes	Filing · EDGAR
Aug 25, 2014	Open-market or private sale	−1,990	$297.26	$592K	1,546,582 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−3,704	$292.70	$1.1M	1,652,878 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−4,468	$293.85	$1.3M	1,648,410 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−3,254	$294.96	$960K	1,645,156 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−7,062	$296.21	$2.1M	1,638,094 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−6,192	$296.86	$1.8M	1,631,902 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−9,985	$297.76	$3M	1,621,917 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−100	$298.61	$30K	1,621,817 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−3,985	$300.21	$1.2M	1,617,832 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−1,710	$301.42	$515K	1,616,122 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−1,100	$302.55	$333K	1,615,022 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−1,193	$303.77	$362K	1,613,829 See Footnotes	Filing · EDGAR
Aug 14, 2014	Open-market or private sale	−1,732	$305.14	$529K	1,612,097 See Footnotes	Filing · EDGAR

25 earlier transactions are in the filing list below.

Mirati Therapeutics 10% owner · filings 2013 to 2015 · sold $2.3M · bought $4.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 3, 2015	Open-market or private purchase	+100,000	$20.00	$2M	1,267,000 See Footnotes	Filing · EDGAR
Jul 1, 2014	Open-market or private sale	−5,000	$20.04	$100K	1,167,000 See Footnotes	Filing · EDGAR
Jun 30, 2014	Open-market or private sale	−9,283	$20.33	$189K	1,176,717 See Footnotes	Filing · EDGAR
Jun 30, 2014	Open-market or private sale	−4,717	$21.11	$100K	1,172,000 See Footnotes	Filing · EDGAR
Jun 27, 2014	Open-market or private sale	−79,120	$21.79	$1.7M	1,195,212 See Footnotes	Filing · EDGAR
Jun 27, 2014	Open-market or private sale	−9,212	$23.09	$213K	1,186,000 See Footnotes	Filing · EDGAR
Oct 29, 2013	Open-market or private purchase	+125,000	$17.50	$2.2M	1,274,332 See Footnotes	Filing · EDGAR

Acceleron Pharma Other · filings 2013 to 2013

Date	Transaction	Shares	Held after	Source
Sep 24, 2013	Derivative converted	+1,127,346	1,133,171 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+422,101	424,282 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+175,419	1,308,590 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+65,680	489,962 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+23,442	1,332,032 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+8,777	498,739 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+133,930	1,465,962 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+50,145	548,884 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+35,873	1,501,835 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+13,431	562,315 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+38,924	1,540,759 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted	+14,574	576,889 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series B Convertible Preferred Stock	−1,127,346	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series B Convertible Preferred Stock	−422,101	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series C Convertible Preferred	−175,419	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series C Convertible Preferred Stock	−65,680	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series D Convertible Preferred	−23,442	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series D Convertible Preferred Stock	−8,777	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series E Convertible Preferred	−83,097	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series E Convertible Preferred Stock	−31,113	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series E Convertible Preferred	−22,612	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series E Convertible Preferred	−8,466	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series F Convertible Preferred	−38,924	0 See footnote	Filing · EDGAR
Sep 24, 2013	Derivative converted Series F Convertible Preferred	−14,574	0 See footnote	Filing · EDGAR

Ambit Biosciences 10% owner · filings 2013 to 2013 · bought $5.7M

Date	Transaction	Shares	Price	Value	Held after	Source
May 23, 2013	Open-market or private purchase	+12,380	$6.99	$87K	1,476,702 See Footnotes	Filing · EDGAR
May 23, 2013	Open-market or private purchase	+120	$6.99	$839	14,067 See Footnotes	Filing · EDGAR
May 22, 2013	Open-market or private purchase	+21,100	$6.86	$145K	1,464,322 See Footnotes	Filing · EDGAR
May 22, 2013	Open-market or private purchase	+200	$6.86	$1K	13,947 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+367,315			378,122 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+3,498			3,600 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+219,863			597,985 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+2,094			5,694 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+181,689			779,674 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted	+1,730			7,424 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+593,618	$8.00	$4.7M	1,373,292 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+5,653	$8.00	$45K	13,077 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+61,910	$8.00	$495K	1,435,202 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+590	$8.00	$5K	13,667 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+8,020	$6.90	$55K	1,443,222 See Footnotes	Filing · EDGAR
May 21, 2013	Open-market or private purchase	+80	$6.90	$552	13,747 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series E Convertible Preferred Stock	−8,815,565			0 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series E Convertible Preferred Stock	−83,959			0 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series D-2 Convertible Preferred Stock	−5,276,702			0 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series D-2 Convertible Preferred Stock	−50,256			0 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series D Convertible Preferred Stock	−1,973,439			0 See Footnotes	Filing · EDGAR
May 21, 2013	Derivative converted Series D Convertible Preferred Stock	−18,795			0 See Footnotes	Filing · EDGAR
May 20, 2013	Open-market or private purchase	+10,500	$6.78	$71K	10,807 See Footnotes	Filing · EDGAR
May 20, 2013	Open-market or private purchase	+100	$6.78	$678	102 See Footnotes	Filing · EDGAR

Supernus Pharmaceuticals 10% owner · filings 2012 to 2013 · sold $4.3M · bought $5.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 13, 2013	Open-market or private sale	−108,900	$7.58	$825K	2,183,000 See Footnotes	Filing · EDGAR
Feb 13, 2013	Open-market or private sale	−41,100	$7.58	$311K	817,000 See Footnotes	Filing · EDGAR
Feb 12, 2013	Open-market or private sale	−110,700	$7.52	$833K	2,291,900 See Footnotes	Filing · EDGAR
Feb 12, 2013	Open-market or private sale	−41,483	$7.52	$312K	858,100 See Footnotes	Filing · EDGAR
Dec 18, 2012	Open-market or private sale	−100,000	$7.08	$708K	0 See Footnotes	Filing · EDGAR
Dec 17, 2012	Open-market or private sale	−197,815	$6.85	$1.4M	100,000 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted	+1,668,472			1,668,472 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted	+624,710			624,710 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted	+206,816			206,816 See Footnotes	Filing · EDGAR
May 4, 2012	Open-market or private purchase	+734,128	$5.00	$3.7M	2,402,600 See Footnotes	Filing · EDGAR
May 4, 2012	Open-market or private purchase	+274,873	$5.00	$1.4M	899,583 See Footnotes	Filing · EDGAR
May 4, 2012	Open-market or private purchase	+90,999	$5.00	$455K	297,815 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted Series A Convertible Preferred Stock	−6,673,891			0 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted Series A Convertible Preferred Stock	−2,498,842			0 See Footnotes	Filing · EDGAR
May 4, 2012	Derivative converted Series A Convertible Preferred Stock	−827,627			0 See Footnotes	Filing · EDGAR

Anthera Pharmaceuticals Director · filings 2010 to 2013 · sold $9.5M · bought $1.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 30, 2013	Open-market or private purchase	+5,700,000			7,462,000 See Footnotes	Filing · EDGAR
Jan 25, 2013	Open-market or private purchase	+1,762,000	$0.65	$1.1M	1,762,000 See Footnotes	Filing · EDGAR
Jun 29, 2012	Open-market or private sale	−1,283,300	$0.73	$942K	0 See Footnotes	Filing · EDGAR
Mar 22, 2012	Open-market or private sale	−1,306,700	$2.40	$3.1M	1,283,300 See Footnotes	Filing · EDGAR
Mar 21, 2012	Open-market or private sale	−125,000	$2.87	$358K	2,590,000 See Footnotes	Filing · EDGAR
Mar 20, 2012	Open-market or private sale	−116,800	$2.90	$339K	2,715,000 See Footnotes	Filing · EDGAR
Dec 13, 2011	Open-market or private sale	−16,200	$6.50	$105K	2,831,800 See Footnotes	Filing · EDGAR
Dec 9, 2011	Open-market or private sale	−40,000	$6.75	$270K	2,848,000 See Footnotes	Filing · EDGAR
Nov 18, 2011	Open-market or private sale	−3,000	$6.50	$20K	2,888,000 See Footnotes	Filing · EDGAR
Nov 17, 2011	Open-market or private sale	−24,000	$6.67	$160K	2,891,000 See Footnotes	Filing · EDGAR
Nov 16, 2011	Open-market or private sale	−25,000	$6.87	$172K	2,915,000 See Footnotes	Filing · EDGAR
Nov 15, 2011	Open-market or private sale	−50,000	$6.93	$347K	2,940,000 See Footnotes	Filing · EDGAR
Nov 14, 2011	Open-market or private sale	−5,000	$6.95	$35K	2,990,000 See Footnotes	Filing · EDGAR
Nov 11, 2011	Open-market or private sale	−5,000	$7.14	$36K	2,995,000 See Footnotes	Filing · EDGAR
Jun 10, 2011	Open-market or private sale	−30,000	$8.18	$245K	3,000,000 See Footnotes	Filing · EDGAR
Jun 9, 2011	Open-market or private sale	−37,000	$8.11	$300K	3,030,000 See Footnotes	Filing · EDGAR
Jun 8, 2011	Open-market or private sale	−33,000	$8.02	$265K	3,067,000 See Footnotes	Filing · EDGAR
May 26, 2011	Open-market or private sale	−34,200	$8.53	$292K		Filing · EDGAR
May 25, 2011	Open-market or private sale	−4,800	$8.65	$42K		Filing · EDGAR
May 18, 2011	Open-market or private sale	−69,334	$8.03	$557K	3,139,000 See Footnotes	Filing · EDGAR
May 17, 2011	Open-market or private sale	−100,000	$8.32	$832K	3,208,334 See Footnotes	Filing · EDGAR
May 16, 2011	Open-market or private sale	−12,000	$7.20	$86K	3,308,334 See Footnotes	Filing · EDGAR
May 11, 2011	Open-market or private sale	−13,000	$7.22	$94K	3,320,334 See Footnotes	Filing · EDGAR
May 10, 2011	Open-market or private sale	−106,400	$7.23	$769K	3,333,334 See Footnotes	Filing · EDGAR
May 9, 2011	Open-market or private sale	−10,000	$7.26	$73K	3,439,734 See Footnotes	Filing · EDGAR
Sep 30, 2010	Open-market or private purchase	+19,900	$4.08	$81K	3,449,734 See Footnotes	Filing · EDGAR

Amarin Director · filings 2011 to 2012 · sold $95.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 4, 2012	Sale under a 10b5-1 plan	−231,456	$14.43	$3.3M	594,300 See Footnotes	Filing · EDGAR
Sep 4, 2012	Sale under a 10b5-1 plan	−2,244	$14.43	$32K	5,700 See Footnotes	Filing · EDGAR
Jul 27, 2012	Sale under a 10b5-1 plan	−362,844	$14.61	$5.3M	825,756 See Footnotes	Filing · EDGAR
Jul 27, 2012	Sale under a 10b5-1 plan	−3,456	$14.61	$50K	7,944 See Footnote	Filing · EDGAR
Jun 19, 2012	Open-market or private sale	−611,200	$12.91	$7.9M	1,188,600 See Footnotes	Filing · EDGAR
Jun 19, 2012	Open-market or private sale	−5,900	$12.91	$76K	11,400 See Footnote	Filing · EDGAR
May 2, 2011	Open-market or private sale	−32,600	$16.30	$531K	1,799,800 See Footnotes	Filing · EDGAR
May 2, 2011	Open-market or private sale	−300	$16.30	$5K	17,300 See Footnote	Filing · EDGAR
Apr 29, 2011	Open-market or private sale	−99,000	$16.01	$1.6M	1,832,400 See Footnotes	Filing · EDGAR
Apr 29, 2011	Open-market or private sale	−1,000	$16.01	$16K	17,600 See Footnote	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−247,633	$16.18	$4M	2,426,667 See Footnotes	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−2,367	$16.18	$38K	23,333 See Footnote	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−495,267	$16.91	$8.4M	1,931,400 See Footnotes	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−4,733	$16.91	$80K	18,600 See Footnote	Filing · EDGAR
Apr 20, 2011	Open-market or private sale	−792,400	$15.79	$12.5M	2,674,300 See Footnotes	Filing · EDGAR
Apr 20, 2011	Open-market or private sale	−7,600	$15.79	$120K	25,700 See Footnote	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−1,756,471	$14.86	$26.1M	4,682,029 See Footnotes	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−16,668	$14.86	$248K	44,832 See Footnote	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−1,214,227	$15.65	$19M	3,467,802 See Footnotes	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−11,522	$15.65	$180K	33,310 See Footnote	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−1,102	$16.26	$18K	3,466,700 See Footnotes	Filing · EDGAR
Apr 18, 2011	Sale under a 10b5-1 plan	−10	$16.26	$163	33,300 See Footnote	Filing · EDGAR
Mar 28, 2011	Open-market or private sale	−92,200	$7.35	$678K	6,438,500 See Footnotes	Filing · EDGAR
Mar 28, 2011	Open-market or private sale	−900	$7.35	$7K	61,500 See Footnote	Filing · EDGAR
Mar 25, 2011	Open-market or private sale	−56,400	$7.47	$421K	6,530,700 See Footnotes	Filing · EDGAR
Mar 25, 2011	Open-market or private sale	−500	$7.47	$4K	62,400 See Footnote	Filing · EDGAR
Mar 24, 2011	Open-market or private sale	−22,800	$7.50	$171K	6,587,100 See Footnotes	Filing · EDGAR
Mar 24, 2011	Open-market or private sale	−200	$7.50	$2K	62,900 See Footnote	Filing · EDGAR
Mar 21, 2011	Open-market or private sale	−76,300	$7.05	$538K	6,609,900 See Footnotes	Filing · EDGAR
Mar 21, 2011	Open-market or private sale	−700	$7.05	$5K	63,100 See Footnote	Filing · EDGAR
Mar 15, 2011	Open-market or private sale	−49,500	$7.24	$358K	6,686,200 See Footnotes	Filing · EDGAR
Mar 15, 2011	Open-market or private sale	−500	$7.24	$4K	63,800 See Footnote	Filing · EDGAR
Mar 14, 2011	Open-market or private sale	−74,300	$7.33	$545K	6,735,700 See Footnotes	Filing · EDGAR
Mar 14, 2011	Open-market or private sale	−700	$7.33	$5K	64,300 See Footnote	Filing · EDGAR
Mar 11, 2011	Open-market or private sale	−99,100	$7.43	$736K	6,810,000 See Footnotes	Filing · EDGAR
Mar 11, 2011	Open-market or private sale	−900	$7.43	$7K	65,000 See Footnote	Filing · EDGAR
Mar 7, 2011	Open-market or private sale	−24,800	$7.68	$190K	6,909,100 See Footnotes	Filing · EDGAR
Mar 7, 2011	Open-market or private sale	−200	$7.68	$2K	65,900 See Footnote	Filing · EDGAR
Mar 4, 2011	Open-market or private sale	−42,600	$7.62	$325K	6,933,900 See Footnotes	Filing · EDGAR
Mar 4, 2011	Open-market or private sale	−400	$7.62	$3K	66,100 See Footnote	Filing · EDGAR
Mar 3, 2011	Open-market or private sale	−6,900	$7.76	$54K	6,976,500 See Footnotes	Filing · EDGAR
Mar 3, 2011	Open-market or private sale	−100	$7.76	$776	66,500 See Footnote	Filing · EDGAR
Mar 2, 2011	Open-market or private sale	−94,100	$7.72	$726K	6,983,400 See Footnotes	Filing · EDGAR
Mar 2, 2011	Open-market or private sale	−900	$7.72	$7K	66,600 See Footnote	Filing · EDGAR
Mar 1, 2011	Open-market or private sale	−49,500	$7.56	$374K	7,077,500 See Footnotes	Filing · EDGAR
Mar 1, 2011	Open-market or private sale	−500	$7.56	$4K	67,500 See Footnote	Filing · EDGAR
Feb 28, 2011	Open-market or private sale	−99,100	$7.73	$766K	7,127,000 See Footnotes	Filing · EDGAR
Feb 28, 2011	Open-market or private sale	−900	$7.73	$7K	68,000 See Footnote	Filing · EDGAR

Complete Genomics 10% owner · filings 2010 to 2012 · sold $3.3M · bought $5.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 13, 2012	Open-market or private sale	−474,800	$2.51	$1.2M	2,922,141 See Footnotes	Filing · EDGAR
Jul 13, 2012	Open-market or private sale	−4,500	$2.51	$11K	27,859 See Footnotes	Filing · EDGAR
Jul 12, 2012	Open-market or private sale	−218,624	$2.85	$623K	3,396,941 See Footnotes	Filing · EDGAR
Jul 12, 2012	Open-market or private sale	−2,076	$2.85	$6K	32,359 See Footnotes	Filing · EDGAR
Jul 11, 2012	Open-market or private sale	−503,144	$2.90	$1.5M	3,615,565 See Footnotes	Filing · EDGAR
Jul 11, 2012	Open-market or private sale	−4,792	$2.90	$14K	34,435 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted	+2,252,898			2,252,898 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted	+1,267,070			3,519,968 See Footnotes	Filing · EDGAR
Nov 16, 2010	Open-market or private purchase	+597,091	$9.00	$5.4M	4,117,059 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted	+21,456			21,456 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted	+12,068			33,524 See Footnotes	Filing · EDGAR
Nov 16, 2010	Open-market or private purchase	+5,687	$9.00	$51K	39,211 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted Series D Preferred Stock	−2,252,898			0 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted Series D Preferred Stock	−21,456			0 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted Series E Preferred Stock	−1,267,070			0 See Footnotes	Filing · EDGAR
Nov 16, 2010	Derivative converted Series E Preferred Stock	−12,068			0 See Footnotes	Filing · EDGAR

Pacira Pharmaceuticals 10% owner · filings 2011 to 2012 · sold $4.2M · bought $3.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 12, 2012	Open-market or private sale	−62,400	$11.03	$688K	2,446,700 See footnotes	Filing · EDGAR
Mar 12, 2012	Open-market or private sale	−700	$11.03	$8K	2,446,000 See footnotes	Filing · EDGAR
Mar 9, 2012	Open-market or private sale	−36,700	$11.25	$413K	2,509,400 See footnotes	Filing · EDGAR
Mar 9, 2012	Open-market or private sale	−300	$11.25	$3K	2,509,100 See footnotes	Filing · EDGAR
Feb 29, 2012	Open-market or private sale	−3,000	$10.86	$33K	2,546,100 See footnotes	Filing · EDGAR
Feb 28, 2012	Open-market or private sale	−10,000	$11.12	$111K	2,549,200 See footnotes	Filing · EDGAR
Feb 28, 2012	Open-market or private sale	−100	$11.12	$1K	2,549,100 See footnotes	Filing · EDGAR
Feb 27, 2012	Open-market or private sale	−28,700	$11.05	$317K	2,559,500 See footnotes	Filing · EDGAR
Feb 27, 2012	Open-market or private sale	−300	$11.05	$3K	2,559,200 See footnotes	Filing · EDGAR
Feb 3, 2012	Open-market or private sale	−49,500	$10.79	$534K	2,588,700 See footnotes	Filing · EDGAR
Feb 3, 2012	Open-market or private sale	−500	$10.79	$5K	2,588,200 See footnotes	Filing · EDGAR
Feb 2, 2012	Open-market or private sale	−23,100	$10.85	$251K	2,638,400 See footnotes	Filing · EDGAR
Feb 2, 2012	Open-market or private sale	−200	$10.85	$2K	2,638,200 See footnotes	Filing · EDGAR
Feb 1, 2012	Open-market or private sale	−69,300	$11.01	$763K	2,662,200 See footnotes	Filing · EDGAR
Feb 1, 2012	Open-market or private sale	−700	$11.01	$8K	2,661,500 See footnotes	Filing · EDGAR
Oct 31, 2011	Open-market or private sale	−96,554	$10.53	$1M	2,732,387 See footnotes	Filing · EDGAR
Oct 31, 2011	Open-market or private sale	−887	$10.53	$9K	2,731,500 See footnotes	Filing · EDGAR
Feb 8, 2011	Derivative converted	+1,473,645			1,566,625 See footnotes	Filing · EDGAR
Feb 8, 2011	Derivative converted	+14,035			1,580,660 See footnote	Filing · EDGAR
Feb 8, 2011	Derivative converted	+705,845	$13.44	$9.5M	2,286,505 See footnotes	Filing · EDGAR
Feb 8, 2011	Derivative converted	+6,722	$13.44	$90K	2,293,227 See footnote	Filing · EDGAR
Feb 8, 2011	Open-market or private purchase	+265,331	$7.00	$1.9M	2,558,558 See footnotes	Filing · EDGAR
Feb 8, 2011	Open-market or private purchase	+2,526	$7.00	$18K	2,561,084 See footnote	Filing · EDGAR
Feb 8, 2011	Open-market or private purchase	+265,330	$7.00	$1.9M	2,826,414 See footnotes	Filing · EDGAR
Feb 8, 2011	Open-market or private purchase	+2,527	$7.00	$18K	2,828,941 See footnote	Filing · EDGAR
Feb 8, 2011	Derivative converted Series A Convertible Preferred Stock	−1,473,645			0 See footnote	Filing · EDGAR
Feb 8, 2011	Derivative converted Series A Convertible Preferred Stock	−14,035			0 See footnote	Filing · EDGAR
Feb 8, 2011	Derivative converted Convertible Promissory Notes	−705,845			0 See footnote	Filing · EDGAR
Feb 8, 2011	Derivative converted Convertible Promissory Notes	−6,722			0 See footnote	Filing · EDGAR

ChemoCentryx 10% owner · filings 2012 to 2012

Date	Transaction	Shares	Held after	Source
Feb 13, 2012	Derivative converted	+44,817	44,817 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted	+2,201,388	2,201,388 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted	+908,509	908,509 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series B Preferred Stock	−78,928	0 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series C Preferred Stock	−10,706	0 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series B Preferred Stock	−3,888,423	0 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series C Preferred Stock	−514,354	0 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series B Preferred Stock	−1,574,345	0 See Footnotes	Filing · EDGAR
Feb 13, 2012	Derivative converted Series C Preferred Stock	−242,674	0 See Footnotes	Filing · EDGAR

Athersys 10% owner · filings 2007 to 2011 · sold $552K · bought $16.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 26, 2011	Open-market or private sale	−7,625	$2.90	$22K	1,600,450 See Footnotes	Filing · EDGAR
Apr 26, 2011	Open-market or private sale	−75	$2.90	$218	15,250 See Footnote	Filing · EDGAR
Apr 25, 2011	Open-market or private sale	−36,250	$2.90	$105K	1,608,075 See Footnotes	Filing · EDGAR
Apr 25, 2011	Open-market or private sale	−350	$2.90	$1K	15,325 See Footnote	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−1,975	$2.90	$6K	1,644,325 See Footnotes	Filing · EDGAR
Apr 21, 2011	Open-market or private sale	−25	$2.90	$73	15,675 See Footnote	Filing · EDGAR
Apr 20, 2011	Open-market or private sale	−1,300	$2.90	$4K	1,646,300 See Footnotes	Filing · EDGAR
Apr 18, 2011	Open-market or private sale	−15,600	$2.93	$46K	1,647,600 See Footnotes	Filing · EDGAR
Apr 18, 2011	Open-market or private sale	−100	$2.93	$293	15,700 See Footnote	Filing · EDGAR
Apr 15, 2011	Open-market or private sale	−29,900	$2.90	$87K	1,663,200 See Footnotes	Filing · EDGAR
Apr 15, 2011	Open-market or private sale	−300	$2.90	$870	15,800 See Footnote	Filing · EDGAR
Apr 14, 2011	Open-market or private sale	−20,700	$2.91	$60K	1,693,100 See Foonotes	Filing · EDGAR
Apr 14, 2011	Open-market or private sale	−200	$2.91	$582	16,100 See Foonote	Filing · EDGAR
Apr 13, 2011	Open-market or private sale	−47,200	$2.94	$139K	1,713,800 See Footnotes	Filing · EDGAR
Apr 13, 2011	Open-market or private sale	−500	$2.94	$1K	16,300 See Footnotes	Filing · EDGAR
Apr 12, 2011	Open-market or private sale	−14,200	$2.90	$41K	1,761,000 See Footnotes	Filing · EDGAR
Apr 12, 2011	Open-market or private sale	−100	$2.90	$290	16,800 See Footnote	Filing · EDGAR
Apr 11, 2011	Open-market or private sale	−12,900	$2.91	$38K	1,775,200 See Footnotes	Filing · EDGAR
Apr 11, 2011	Open-market or private sale	−100	$2.91	$291	16,900 See Footnote	Filing · EDGAR
Jan 7, 2010	Other acquisition or disposition (see the filing)	−4,947			1,805,100 See Footnotes	Filing · EDGAR
Dec 28, 2009	Other acquisition or disposition (see the filing)	−1,800,153			1,810,047 See Footnotes	Filing · EDGAR
Mar 17, 2009	Open-market or private purchase	+110,000	$0.84	$92K	3,610,200 See Footnotes	Filing · EDGAR
Mar 16, 2009	Open-market or private purchase	+52,200	$0.65	$34K	3,500,200 See Footnotes	Filing · EDGAR
May 22, 2008	Open-market or private purchase	+268,000	$2.40	$643K	3,448,000 See Footnotes	Filing · EDGAR
May 21, 2008	Open-market or private purchase	+130,000	$2.40	$312K	3,180,000 See Footnotes	Filing · EDGAR
May 13, 2008	Open-market or private purchase	+50,000	$2.40	$120K	3,050,000 See Footnotes	Filing · EDGAR
Jun 8, 2007	Grant or award from the company Director's Stock Option (right to buy)	−75,000			75,000 See Footnote	Filing · EDGAR
Jun 8, 2007	Open-market or private purchase Warrant (right to buy)	−750,000			750,000 See Footnotes	Filing · EDGAR
Jun 8, 2007	Grant or award from the company Director's Stock Option (right to buy)	−75,000			75,000 See Footnote	Filing · EDGAR
Jun 8, 2007	Open-market or private purchase Warrant (right to buy)	−750,000			750,000 See Footnotes	Filing · EDGAR
Jun 8, 2007	Grant or award from the company Director's Stock Option (right to buy)	−75,000			75,000 See Footnote	Filing · EDGAR
Jun 8, 2007	Open-market or private purchase Warrant (right to buy)	−750,000			750,000 See Footnotes	Filing · EDGAR
Jun 8, 2007	Open-market or private purchase	+3,000,000	$5.00	$15M	3,000,000 See footnote	Filing · EDGAR
Jun 8, 2007	Grant or award from the company Director stock option (right to purchase)	−75,000			75,000 See footnote	Filing · EDGAR
Jun 8, 2007	Open-market or private purchase Warrant (right to purchase)	−750,000			750,000 See footnote	Filing · EDGAR

NxStage Medical Director · filings 2008 to 2010 · sold $33.9M · bought $25.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 9, 2010	Open-market or private sale	−2,356	$22.60	$53K	0 direct	Filing · EDGAR
Oct 13, 2010	Other acquisition or disposition (see the filing)	−1,009,524			2,690,476 See Footnotes	Filing · EDGAR
Oct 13, 2010	Other acquisition or disposition (see the filing)	+2,356			2,356 direct	Filing · EDGAR
Sep 15, 2010	Open-market or private sale	−54,000	$16.23	$876K	3,700,000 See Footnotes	Filing · EDGAR
Sep 14, 2010	Open-market or private sale	−96,000	$16.49	$1.6M	3,754,000 See Footnotes	Filing · EDGAR
Sep 13, 2010	Open-market or private sale	−100,000	$16.70	$1.7M	3,850,000 See Footnotes	Filing · EDGAR
Sep 10, 2010	Open-market or private sale	−193,900	$16.52	$3.2M	3,950,000 See Footnotes	Filing · EDGAR
Sep 9, 2010	Open-market or private sale	−8,800	$16.36	$144K	4,143,900 See Footnotes	Filing · EDGAR
Sep 8, 2010	Open-market or private sale	−7,000	$16.50	$116K	4,152,700 See Footnotes	Filing · EDGAR
Sep 7, 2010	Open-market or private sale	−40,100	$16.79	$673K	4,159,700 See Footnotes	Filing · EDGAR
Aug 18, 2010	Open-market or private sale	−100,200	$16.94	$1.7M	4,199,800 See Footnotes	Filing · EDGAR
Aug 17, 2010	Open-market or private sale	−288,000	$17.06	$4.9M	4,300,000 See Footnotes	Filing · EDGAR
Aug 16, 2010	Open-market or private sale	−112,000	$17.11	$1.9M	4,588,000 See Footnotes	Filing · EDGAR
Aug 4, 2010	Open-market or private sale	−101,100	$16.31	$1.6M	4,700,000 See Footnotes	Filing · EDGAR
Aug 3, 2010	Open-market or private sale	−199,200	$16.41	$3.3M	4,801,100 See Footnotes	Filing · EDGAR
Aug 2, 2010	Open-market or private sale	−17,400	$16.39	$285K	5,000,300 See Footnotes	Filing · EDGAR
Jul 28, 2010	Open-market or private sale	−128,000	$16.66	$2.1M	5,017,700 See Footnotes	Filing · EDGAR
Jul 27, 2010	Open-market or private sale	−572,556	$16.93	$9.7M	5,145,700 See Footnotes	Filing · EDGAR
Aug 26, 2008	Open-market or private purchase	+27,700	$3.50	$97K	5,718,256 See Footnotes	Filing · EDGAR
Aug 25, 2008	Open-market or private purchase	+108,900	$3.37	$367K	5,690,556 See Footnotes	Filing · EDGAR
Aug 21, 2008	Open-market or private purchase	+26,100	$3.25	$85K	5,581,656 See Footnotes	Filing · EDGAR
Jul 23, 2008	Grant or award from the company Director's Stock Option (right to buy)	+11,667			11,667 See Footnotes	Filing · EDGAR
Jul 23, 2008	Grant or award from the company Director's Stock Option (right to buy)	+11,667			11,667 See Footnotes	Filing · EDGAR
Jul 23, 2008	Grant or award from the company Director's Stock Option (right to buy)	+11,667			11,667 See Footnotes	Filing · EDGAR
May 23, 2008	Open-market or private purchase Warrant (right to buy)	+1,111,111			1,111,111 See Footnotes	Filing · EDGAR
May 23, 2008	Open-market or private purchase Warrant (right to buy)	+1,111,111			1,111,111 See Footnotes	Filing · EDGAR
May 23, 2008	Open-market or private purchase	+5,555,556	$4.50	$25M	5,555,556 See Footnotes	Filing · EDGAR
May 23, 2008	Open-market or private purchase Warrant (right to buy)	+1,111,111			1,111,111 See Footnotes	Filing · EDGAR

Kun Run Biotechnology 10% owner · filings 2010 to 2010

No transactions in the filings read; Form 144 notices are listed above.

Biodel Director · filings 2007 to 2009 · sold $2.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 10, 2009	Open-market or private sale	−26,988	$5.24	$141K	1,485,904 See footnotes	Filing · EDGAR
Jun 9, 2009	Other acquisition or disposition (see the filing)	−300,000			1,512,892 See footnotes	Filing · EDGAR
Feb 12, 2008	Open-market or private sale	−154,000	$14.48	$2.2M	1,812,892 See footnote	Filing · EDGAR
Feb 2, 2008	Grant or award from the company Director's Stock Option (right to buy)	+10,000			10,000 See Footnote	Filing · EDGAR
May 16, 2007	Derivative converted	+1,258,756			1,966,892 See footnote	Filing · EDGAR
May 16, 2007	Derivative converted Series B Convertible Preferred Stock	−1,258,756			0 See footnote	Filing · EDGAR

ARYx Therapeutics 10% owner · filings 2007 to 2009 · sold $8M · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
May 22, 2009	Open-market or private sale	−2,000,000	$4.00	$8M	1,340,139 See Footnotes	Filing · EDGAR
Nov 14, 2008	Open-market or private purchase Common Stock Warrants (right to buy)	+364,395			364,395 See footnote	Filing · EDGAR
Nov 14, 2008	Open-market or private purchase	+1,214,646			3,340,139 See footnote	Filing · EDGAR
Nov 14, 2008	Open-market or private purchase Common Stock Warrants (right to buy)	+364,395			364,395 See footnote	Filing · EDGAR
Nov 13, 2007	Derivative converted	+1,825,493			1,825,493 FN	Filing · EDGAR
Nov 13, 2007	Open-market or private purchase	+300,000	$10.00	$3M	2,125,493 FN	Filing · EDGAR
Nov 13, 2007	Derivative converted Series C Conv. Pfd. Stk.	−897,866			0 FN	Filing · EDGAR
Nov 13, 2007	Derivative converted Series D Conv. Pfd. Stk.	−604,228			0 FN	Filing · EDGAR
Nov 13, 2007	Derivative converted Series E Conv. Pfd. Stk.	−323,399			0 FN	Filing · EDGAR

Cryocor 10% owner · filings 2005 to 2007

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 14, 2007	Other acquisition or disposition (see the filing)	−842,504			389,432 See Footnote	Filing · EDGAR
Jul 13, 2005	Derivative converted	+1,096,936			1,231,936 FN	Filing · EDGAR
Jul 13, 2005	Derivative converted Series D Redeemable Convertible Preferred Stock	−30,241,936			1,096,936 FN	Filing · EDGAR
Jul 13, 2005	Open-market or private sale	+135,000	$11.00	$1.5M	1,231,936 FN, 1, 2, 3	Filing · EDGAR

Insulet Director · filings 2007 to 2007

Date	Transaction	Shares	Price	Value	Held after	Source
May 18, 2007	Derivative converted	+1,568,841			1,568,841 See Footnote	Filing · EDGAR
May 18, 2007	Derivative converted Series E Preferred Stock	−1,568,841			0 See Footnote	Filing · EDGAR

Volcano Director · filings 2006 to 2006

Date	Transaction	Shares	Held after	Source
Jun 20, 2006	Derivative converted	+1,578,832	1,578,832 By Caduceus Private Investments II, LP	Filing · EDGAR
Jun 20, 2006	Derivative converted	+591,146	591,146 By Caduceus Private Investments II (QP), LP	Filing · EDGAR
Jun 20, 2006	Derivative converted	+195,705	195,705 By UBS Juniper Crossover Fund, L.L.C.	Filing · EDGAR
Jun 20, 2006	Derivative converted Series C Convertible Preferred Stock	−1,734,981	0 By Caduceaus Private Investments II, LP	Filing · EDGAR
Jun 20, 2006	Derivative converted Series C Convertible Preferred Stock	−649,612	0 By Caduceaus Private Investments II (QP), LP	Filing · EDGAR
Jun 20, 2006	Derivative converted Series C Convertible Preferred Stock	−215,061	0 By UBS Juniper Crossover Fund, L.L.C.	Filing · EDGAR

Avanir Pharmaceuticals Director · filings 2006 to 2006 · sold $6.2M

Date	Transaction	Shares	Price	Value	Held after	Source
May 31, 2006	Other acquisition or disposition (see the filing)	−629,121	$9.79	$6.2M	1,706,137 FN	Filing · EDGAR
May 31, 2006	Open-market or private sale	−629,121	$9.79	$6.2M	1,706,137 FN	Filing · EDGAR
Feb 13, 2006	Grant or award from the company	+6,435			6,435 See FN	Filing · EDGAR
Feb 13, 2006	Grant or award from the company	+2,335,258	$5.08	$11.9M	2,335,258 See FN	Filing · EDGAR

Given Imaging Director, 10% owner · filings 2004 to 2006 · sold $5.5M

Date	Transaction	Shares	Price	Value	Held after	Source
May 26, 2006	Other acquisition or disposition (see the filing) warrants	+0			2,302 FN 3 and 4	Filing · EDGAR
May 24, 2006	Open-market or private sale	−22,500	$18.14	$408K	3,610,402 FN 3 and 4	Filing · EDGAR
Sep 21, 2004	Other acquisition or disposition (see the filing)	−235,005	$39.32	$9.2M	3,637,255 see footnotes below	Filing · EDGAR
Jun 23, 2004	Open-market or private sale	−170,000	$30.08	$5.1M	3,872,260 see footnotes below	Filing · EDGAR

Dov Pharmaceutical Director · filings 2003 to 2006 · sold $6.8M

Date	Transaction	Shares	Price	Value	Held after	Source
May 16, 2006	Open-market or private sale	−547,491	$3.25	$1.8M	548,000 FN	Filing · EDGAR
May 16, 2006	Open-market or private sale	−11,422	$3.25	$37K	11,400 FN	Filing · EDGAR
May 16, 2006	Open-market or private sale	−258,858	$3.25	$841K	258,000 FN	Filing · EDGAR
Aug 15, 2005	Open-market or private sale	−138,400	$18.24	$2.5M	2,028,028 FN	Filing · EDGAR
Aug 12, 2005	Open-market or private sale	−85,000	$18.47	$1.6M	2,166,428 FN	Filing · EDGAR

Orphan Medical Director · filings 2005 to 2005

No transactions in the filings read; Form 144 notices are listed above.

Aerogen 10% owner · filings 2004 to 2004

No transactions in the filings read; Form 144 notices are listed above.

Memory Pharmaceuticals Director · filings 2004 to 2004

Date	Transaction	Shares	Held after	Source
Apr 8, 2004	Derivative converted	+1,006,280	1,006,280 See	Filing · EDGAR
Apr 8, 2004	Derivative converted Series C Preferred Stock	−2,000,000	0 See	Filing · EDGAR
Apr 8, 2004	Derivative converted Series D Preferred Stock	−883,722	0 See	Filing · EDGAR

Orthovita 10% owner · filings 2003 to 2004 · sold $790K

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 14, 2004	Open-market or private sale	−200,000	$3.95	$790K	5,350,000 See footnote	Filing · EDGAR
Jan 14, 2004	Open-market or private purchase	−200,000	$3.95	$790K	5,350,000 See	Filing · EDGAR
Jan 12, 2004	Open-market or private purchase	−815,145	$3.79	$3.1M	5,550,000 See	Filing · EDGAR
Sep 25, 2003	Open-market or private purchase	−2,030,100	$3.50	$7.1M	6,365,144 See footnote 1 and 2	Filing · EDGAR
Jul 22, 2003	Open-market or private purchase	+8,395,244			8,395,244 see footnote 2 and 6	Filing · EDGAR
Jul 22, 2003	Open-market or private purchase Warrant	−6			0 see footnote 2 and 6	Filing · EDGAR
Jul 22, 2003	Open-market or private purchase Preferred Stock	−1,000			0 see footnote 2 and 6	Filing · EDGAR
Oct 18, 2002	Open-market or private purchase Warrant	+3			6 see footnote 2 and 6	Filing · EDGAR
Oct 18, 2002	Open-market or private purchase Preferred Stock	+500			1,000 see footnote 2 and 6	Filing · EDGAR

Lifecell 10% owner · filings 2003 to 2003 · sold $4M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 23, 2003	Open-market or private sale	−700,750	$5.65	$4M	1,643,000 see footnote 2	Filing · EDGAR
Dec 23, 2003	Open-market or private sale Warrants				1,312,500 see footnote 2	Filing · EDGAR

All 672 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Nov 4, 2026	Form 4	Aspen Neuroscience ASPE	Filing · EDGAR
Oct 29, 2026	Form 3	Aspen Neuroscience ASPE	Filing · EDGAR
Sep 30, 2026	Form 4	ADARx Pharmaceuticals ADRX	Filing · EDGAR
Sep 24, 2026	Form 3	ADARx Pharmaceuticals ADRX	Filing · EDGAR
Sep 23, 2026	Form 4	Electra Therapeutics ETRA	Filing · EDGAR
Sep 18, 2026	Form 3	Electra Therapeutics ETRA	Filing · EDGAR
Aug 12, 2026	Form 4	BlossomHill Therapeutics BLSM	Filing · EDGAR
Aug 11, 2026	Form 4	Braveheart Bio BRVE	Filing · EDGAR
Aug 6, 2026	Form 3	BlossomHill Therapeutics BLSM	Filing · EDGAR
Aug 5, 2026	Form 3	Braveheart Bio BRVE	Filing · EDGAR
Jul 29, 2026	Form 3	Yarrow Bioscience YARW	Filing · EDGAR
Jul 29, 2026	Form 4	Scribe Therapeutics SCTX	Filing · EDGAR
Jul 23, 2026	Form 3	Scribe Therapeutics SCTX	Filing · EDGAR
Jul 9, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Jul 2, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Jun 24, 2026	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 22, 2026	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 22, 2026	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 17, 2026	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 15, 2026	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 15, 2026	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
Jun 15, 2026	Form 4	Shattuck Labs STTK	Filing · EDGAR
Jun 9, 2026	Form 4	Shattuck Labs STTK	Filing · EDGAR
Jun 1, 2026	Form 4	Q32 Bio QTTB	Filing · EDGAR
Jun 1, 2026	Form 144/A	Sionna Therapeutics SION	Filing · EDGAR
May 29, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
May 29, 2026	Form 144	Sionna Therapeutics SION	Filing · EDGAR
May 11, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Apr 28, 2026	Form 4	Traws Pharma TRAW	Filing · EDGAR
Apr 23, 2026	Form 4	Prelude Therapeutics PRLD	Filing · EDGAR
Apr 21, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Apr 16, 2026	Form 4	ImageneBio IKNA	Filing · EDGAR
Apr 16, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Apr 9, 2026	Form 4	Adicet Bio TORC	Filing · EDGAR
Apr 9, 2026	Form 144	Adicet Bio TORC	Filing · EDGAR
Mar 31, 2026	Form 144	Keros Therapeutics KROS	Filing · EDGAR
Feb 4, 2026	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Dec 29, 2025	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Dec 19, 2025	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Dec 18, 2025	Form 4	Keros Therapeutics KROS	Filing · EDGAR
Nov 26, 2025	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Nov 24, 2025	Form 144	Sionna Therapeutics SION	Filing · EDGAR
Oct 27, 2025	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
Oct 23, 2025	Form 144	PMV Pharmaceuticals PMVP	Filing · EDGAR
Oct 20, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 20, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 20, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 10, 2025	Form 4	Adicet Bio TORC	Filing · EDGAR
Sep 12, 2025	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
Sep 10, 2025	Form 144	PMV Pharmaceuticals PMVP	Filing · EDGAR
Sep 2, 2025	Form 4	Shattuck Labs STTK	Filing · EDGAR
Sep 2, 2025	Form 3	Shattuck Labs STTK	Filing · EDGAR
Aug 12, 2025	Form 4	Turnstone Biologics TSBX	Filing · EDGAR
Jul 30, 2025	Form 4	ImageneBio IKNA	Filing · EDGAR
Jul 21, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
Jul 15, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
Jul 7, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
Jul 1, 2025	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jun 26, 2025	Form 4	Passage BIO PASG	Filing · EDGAR
Jun 24, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
May 16, 2025	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 24, 2025	Form 4	Passage BIO PASG	Filing · EDGAR
Apr 17, 2025	Form 4	Passage BIO PASG	Filing · EDGAR
Apr 15, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
Apr 14, 2025	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Apr 11, 2025	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
Apr 9, 2025	Form 144	Compass Therapeutics CMPX	Filing · EDGAR
Apr 4, 2025	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Mar 26, 2025	Form 4	Disc Medicine GMTX	Filing · EDGAR
Mar 21, 2025	Form 4	Disc Medicine GMTX	Filing · EDGAR
Mar 12, 2025	Form 4	Disc Medicine GMTX	Filing · EDGAR
Mar 10, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Mar 10, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Mar 10, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Feb 19, 2025	Form 4	MBX Biosciences MBX	Filing · EDGAR
Feb 10, 2025	Form 4	Sionna Therapeutics SION	Filing · EDGAR
Feb 6, 2025	Form 3	Sionna Therapeutics SION	Filing · EDGAR
Jan 27, 2025	Form 4	Traws Pharma TRAW	Filing · EDGAR
Jan 14, 2025	Form 4	Passage BIO PASG	Filing · EDGAR
Jan 8, 2025	Form 4	Passage BIO PASG	Filing · EDGAR
Jan 6, 2025	Form 144	Passage BIO PASG	Filing · EDGAR
Dec 26, 2024	Form 4	Passage BIO PASG	Filing · EDGAR
Dec 11, 2024	Form 4	Passage BIO PASG	Filing · EDGAR
Dec 6, 2024	Form 4	Passage BIO PASG	Filing · EDGAR
Dec 4, 2024	Form 144	Passage BIO PASG	Filing · EDGAR
Nov 5, 2024	Form 4	Lomond Therapeutics Holdings	Filing · EDGAR
Nov 5, 2024	Form 3	Lomond Therapeutics Holdings	Filing · EDGAR
Oct 17, 2024	Form 4	Upstream Bio	Filing · EDGAR
Oct 10, 2024	Form 3	Upstream Bio	Filing · EDGAR
Sep 23, 2024	Form 4	Passage BIO PASG	Filing · EDGAR
Sep 23, 2024	Form 3	Traws Pharma TRAW	Filing · EDGAR
Sep 18, 2024	Form 4	Passage BIO PASG	Filing · EDGAR
Sep 17, 2024	Form 4	MBX Biosciences MBX	Filing · EDGAR
Sep 16, 2024	Form 144	Passage BIO PASG	Filing · EDGAR
Sep 12, 2024	Form 3	MBX Biosciences MBX	Filing · EDGAR
Aug 28, 2024	Form 4	ARS Pharmaceuticals	Filing · EDGAR
Aug 23, 2024	Form 4	ARS Pharmaceuticals	Filing · EDGAR
Aug 15, 2024	Form 4	Keros Therapeutics KROS	Filing · EDGAR
Aug 15, 2024	Form 4	scPharmaceuticals	Filing · EDGAR
Aug 13, 2024	Form 144	Keros Therapeutics KROS	Filing · EDGAR
Aug 13, 2024	Form 144	Keros Therapeutics KROS	Filing · EDGAR
Jul 17, 2024	Form 4	Terns Pharmaceuticals	Filing · EDGAR
Jul 15, 2024	Form 144	Terns Pharmaceuticals	Filing · EDGAR
Jul 15, 2024	Form 144	Terns Pharmaceuticals	Filing · EDGAR
Jul 15, 2024	Form 144	Terns Pharmaceuticals	Filing · EDGAR
Jul 2, 2024	Form 4	TELA Bio	Filing · EDGAR
Jun 28, 2024	Form 144	TELA Bio	Filing · EDGAR
Jun 20, 2024	Form 4	Disc Medicine GMTX	Filing · EDGAR
May 20, 2024	Form 4	Alpine Immune Sciences	Filing · EDGAR
May 20, 2024	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
May 17, 2024	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
May 17, 2024	Form 144	Enliven Therapeutics IMRA	Filing · EDGAR
May 8, 2024	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
May 3, 2024	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 26, 2024	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 23, 2024	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 18, 2024	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 15, 2024	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 12, 2024	Form 3/A	Traws Pharma TRAW	Filing · EDGAR
Apr 5, 2024	Form 4	Kinnate Biopharma	Filing · EDGAR
Apr 3, 2024	Form 3	Traws Pharma TRAW	Filing · EDGAR
Mar 27, 2024	Form 3	Q32 Bio QTTB	Filing · EDGAR
Mar 4, 2024	Form 144	Verona Pharma	Filing · EDGAR
Feb 14, 2024	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Jan 31, 2024	Form 4	ArriVent Biopharma	Filing · EDGAR
Jan 26, 2024	Form 4	Adicet Bio TORC	Filing · EDGAR
Jan 25, 2024	Form 3	ArriVent Biopharma	Filing · EDGAR
Jan 25, 2024	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jan 16, 2024	Form 4	Alpine Immune Sciences	Filing · EDGAR
Dec 29, 2023	Form 4	Alpine Immune Sciences	Filing · EDGAR
Dec 27, 2023	Form 144	Alpine Immune Sciences	Filing · EDGAR
Dec 27, 2023	Form 144	Alpine Immune Sciences	Filing · EDGAR
Dec 20, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2023	Form 144/A	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2023	Form 144/A	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2023	Form 144/A	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Dec 14, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2023	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2023	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2023	Form 144	Disc Medicine GMTX	Filing · EDGAR
Nov 24, 2023	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
Nov 22, 2023	Form 144	PMV Pharmaceuticals PMVP	Filing · EDGAR
Oct 4, 2023	Form 4	NeuroPace NPCE	Filing · EDGAR
Oct 2, 2023	Form 144	Galecto	Filing · EDGAR
Oct 2, 2023	Form 144	Galecto	Filing · EDGAR
Oct 2, 2023	Form 144	NeuroPace NPCE	Filing · EDGAR
Sep 21, 2023	Form 4/A	ImageneBio IKNA	Filing · EDGAR
Sep 14, 2023	Form 4	ImageneBio IKNA	Filing · EDGAR
Aug 31, 2023	Form 4	ARS Pharmaceuticals	Filing · EDGAR
Aug 30, 2023	Form 144	Galecto	Filing · EDGAR
Aug 30, 2023	Form 144	Galecto	Filing · EDGAR
Aug 21, 2023	Form 144/A	Galecto	Filing · EDGAR
Aug 21, 2023	Form 144	Galecto	Filing · EDGAR
Aug 21, 2023	Form 144	Galecto	Filing · EDGAR
Aug 17, 2023	Form 4	Galecto	Filing · EDGAR
Aug 15, 2023	Form 144	Galecto	Filing · EDGAR
Aug 15, 2023	Form 144	Galecto	Filing · EDGAR
Aug 2, 2023	Form 4	Galecto	Filing · EDGAR
Jul 31, 2023	Form 144	Galecto	Filing · EDGAR
Jul 31, 2023	Form 144	Galecto	Filing · EDGAR
Jul 27, 2023	Form 4	Galecto	Filing · EDGAR
Jul 25, 2023	Form 144	Galecto	Filing · EDGAR
Jul 25, 2023	Form 144	Galecto	Filing · EDGAR
Jul 24, 2023	Form 4	Turnstone Biologics TSBX	Filing · EDGAR
Jul 20, 2023	Form 3	Turnstone Biologics TSBX	Filing · EDGAR
Jul 19, 2023	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Jul 17, 2023	Form 4	Galecto	Filing · EDGAR
Jul 13, 2023	Form 144	Galecto	Filing · EDGAR
Jul 13, 2023	Form 144	Galecto	Filing · EDGAR
Jun 29, 2023	Form 4	Adicet Bio TORC	Filing · EDGAR
Jun 29, 2023	Form 4	Passage BIO PASG	Filing · EDGAR
Jun 15, 2023	Form 144	Gracell Biotechnologies	Filing · EDGAR
May 24, 2023	Form 4	Prelude Therapeutics PRLD	Filing · EDGAR
May 19, 2023	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
May 15, 2023	Form 4	Verona Pharma	Filing · EDGAR
May 11, 2023	Form 144	Verona Pharma	Filing · EDGAR
May 8, 2023	Form 4	Kinnate Biopharma	Filing · EDGAR
May 2, 2023	Form 4	Kinnate Biopharma	Filing · EDGAR
Apr 21, 2023	Form 4	TELA Bio	Filing · EDGAR
Apr 19, 2023	Form 144	TELA Bio	Filing · EDGAR
Apr 17, 2023	Form 4	Galecto	Filing · EDGAR
Apr 12, 2023	Form 4	Galecto	Filing · EDGAR
Apr 10, 2023	Form 144	Galecto	Filing · EDGAR
Apr 10, 2023	Form 144	Galecto	Filing · EDGAR
Apr 7, 2023	Form 4	Galecto	Filing · EDGAR
Apr 5, 2023	Form 144	Galecto	Filing · EDGAR
Apr 5, 2023	Form 144	Galecto	Filing · EDGAR
Feb 27, 2023	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
Feb 23, 2023	Form 4	Kinnate Biopharma	Filing · EDGAR
Feb 17, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Jan 3, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Jan 3, 2023	Form 3	Disc Medicine GMTX	Filing · EDGAR
Dec 28, 2022	Form 4	Terns Pharmaceuticals	Filing · EDGAR
Dec 27, 2022	Form 4	Verona Pharma	Filing · EDGAR
Nov 29, 2022	Form 4	scPharmaceuticals	Filing · EDGAR
Nov 25, 2022	Form 4	Tricida	Filing · EDGAR
Nov 10, 2022	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
Nov 9, 2022	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Sep 21, 2022	Form 4	Third Harmonic Bio	Filing · EDGAR
Sep 16, 2022	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Sep 14, 2022	Form 3	Third Harmonic Bio	Filing · EDGAR
Sep 14, 2022	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Aug 18, 2022	Form 4	Terns Pharmaceuticals	Filing · EDGAR
Aug 17, 2022	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Aug 10, 2022	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Jul 1, 2022	Form 4	Sierra Oncology	Filing · EDGAR
Jun 28, 2022	Form 4	Arcutis Biotherapeutics	Filing · EDGAR
Jun 24, 2022	Form 4	ImageneBio IKNA	Filing · EDGAR
May 31, 2022	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
May 20, 2022	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
May 13, 2022	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
May 10, 2022	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
May 5, 2022	Form 4	Passage BIO PASG	Filing · EDGAR
May 5, 2022	Form 4/A	Passage BIO PASG	Filing · EDGAR
Apr 8, 2022	Form 4	Arcutis Biotherapeutics	Filing · EDGAR
Mar 31, 2022	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
Feb 15, 2022	Form 4	Kinnate Biopharma	Filing · EDGAR
Jan 28, 2022	Form 4	Sierra Oncology	Filing · EDGAR
Jan 27, 2022	Form 4	89bio	Filing · EDGAR
Jan 24, 2022	Form 4	Passage BIO PASG	Filing · EDGAR
Jan 21, 2022	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Jan 20, 2022	Form 4	Passage BIO PASG	Filing · EDGAR
Jan 13, 2022	Form 4	Passage BIO PASG	Filing · EDGAR
Jan 13, 2022	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Dec 30, 2021	Form 4	Janux Therapeutics	Filing · EDGAR
Dec 23, 2021	Form 4	Janux Therapeutics	Filing · EDGAR
Dec 17, 2021	Form 4	Janux Therapeutics	Filing · EDGAR
Dec 14, 2021	Form 4	Adicet Bio TORC	Filing · EDGAR
Nov 17, 2021	Form 4	Tricida	Filing · EDGAR
Nov 8, 2021	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
Oct 14, 2021	Form 4	Theseus Pharmaceuticals	Filing · EDGAR
Oct 6, 2021	Form 3	Theseus Pharmaceuticals	Filing · EDGAR
Sep 22, 2021	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Sep 21, 2021	Form 4	Alpine Immune Sciences	Filing · EDGAR
Sep 8, 2021	Form 4	Repare Therapeutics	Filing · EDGAR
Sep 2, 2021	Form 4	Repare Therapeutics	Filing · EDGAR
Aug 30, 2021	Form 4	Repare Therapeutics	Filing · EDGAR
Aug 25, 2021	Form 4	Repare Therapeutics	Filing · EDGAR
Aug 19, 2021	Form 4	Repare Therapeutics	Filing · EDGAR
Aug 17, 2021	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Jul 23, 2021	Form 4/A	Enliven Therapeutics IMRA	Filing · EDGAR
Jul 21, 2021	Form 4	Acutus Medical	Filing · EDGAR
Jul 16, 2021	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
Jul 6, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Jun 30, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Jun 25, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Jun 16, 2021	Form 4	Janux Therapeutics	Filing · EDGAR
Jun 14, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Jun 10, 2021	Form 3	Janux Therapeutics	Filing · EDGAR
Jun 9, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Apr 26, 2021	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 23, 2021	Form 4	NeuroPace NPCE	Filing · EDGAR
Apr 22, 2021	Form 4	Synlogic	Filing · EDGAR
Apr 20, 2021	Form 3	NeuroPace NPCE	Filing · EDGAR
Apr 13, 2021	Form 4/A	ImageneBio IKNA	Filing · EDGAR
Apr 1, 2021	Form 4	ImageneBio IKNA	Filing · EDGAR
Mar 31, 2021	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Mar 31, 2021	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Mar 26, 2021	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Mar 25, 2021	Form 3	Edgewise Therapeutics EWTX	Filing · EDGAR
Mar 25, 2021	Form 3	ImageneBio IKNA	Filing · EDGAR
Mar 23, 2021	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Mar 18, 2021	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Mar 15, 2021	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Mar 3, 2021	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Feb 19, 2021	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Feb 19, 2021	Form 4	Decibel Therapeutics	Filing · EDGAR
Feb 18, 2021	Form 4	Adicet Bio TORC	Filing · EDGAR
Feb 11, 2021	Form 3	Decibel Therapeutics	Filing · EDGAR
Feb 10, 2021	Form 3	Disc Medicine GMTX	Filing · EDGAR
Feb 9, 2021	Form 4	Terns Pharmaceuticals	Filing · EDGAR
Feb 4, 2021	Form 3	Terns Pharmaceuticals	Filing · EDGAR
Jan 26, 2021	Form 4	Prevail Therapeutics	Filing · EDGAR
Jan 12, 2021	Form 4	Prelude Therapeutics PRLD	Filing · EDGAR
Jan 11, 2021	Form 4	Cti Biopharma	Filing · EDGAR
Jan 5, 2021	Form 3	Verona Pharma	Filing · EDGAR
Dec 30, 2020	Form 4	Alpine Immune Sciences	Filing · EDGAR
Dec 10, 2020	Form 4	Aerpio Pharmaceuticals	Filing · EDGAR
Dec 9, 2020	Form 4	Kinnate Biopharma	Filing · EDGAR
Dec 8, 2020	Form 4	ARS Pharmaceuticals	Filing · EDGAR
Dec 4, 2020	Form 4	Kinnate Biopharma	Filing · EDGAR
Dec 3, 2020	Form 3	ARS Pharmaceuticals	Filing · EDGAR
Dec 2, 2020	Form 3	Kinnate Biopharma	Filing · EDGAR
Nov 19, 2020	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Nov 4, 2020	Form 4	Galecto	Filing · EDGAR
Oct 28, 2020	Form 3	Galecto	Filing · EDGAR
Oct 6, 2020	Form 4	Arcutis Biotherapeutics	Filing · EDGAR
Oct 5, 2020	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Oct 5, 2020	Form 4	LogicBio Therapeutics	Filing · EDGAR
Sep 30, 2020	Form 4/A	Prelude Therapeutics PRLD	Filing · EDGAR
Sep 29, 2020	Form 4	Prelude Therapeutics PRLD	Filing · EDGAR
Sep 29, 2020	Form 4	Graybug Vision	Filing · EDGAR
Sep 29, 2020	Form 4	PMV Pharmaceuticals PMVP	Filing · EDGAR
Sep 24, 2020	Form 3	Graybug Vision	Filing · EDGAR
Sep 24, 2020	Form 3	Prelude Therapeutics PRLD	Filing · EDGAR
Sep 24, 2020	Form 3	PMV Pharmaceuticals PMVP	Filing · EDGAR
Sep 23, 2020	Form 4	89bio	Filing · EDGAR
Sep 17, 2020	Form 4	Adicet Bio TORC	Filing · EDGAR
Aug 19, 2020	Form 4	Inspire Medical Systems	Filing · EDGAR
Aug 14, 2020	Form 4	Inspire Medical Systems	Filing · EDGAR
Aug 12, 2020	Form 4	Acutus Medical	Filing · EDGAR
Aug 11, 2020	Form 4	Inspire Medical Systems	Filing · EDGAR
Aug 5, 2020	Form 3	Acutus Medical	Filing · EDGAR
Jul 16, 2020	Form 3	Pandion Therapeutics	Filing · EDGAR
Jul 2, 2020	Form 4	Fusion Pharmaceuticals	Filing · EDGAR
Jun 25, 2020	Form 4	Repare Therapeutics	Filing · EDGAR
Jun 25, 2020	Form 3	Fusion Pharmaceuticals	Filing · EDGAR
Jun 23, 2020	Form 4	Compass Therapeutics CMPX	Filing · EDGAR
Jun 23, 2020	Form 3	Compass Therapeutics CMPX	Filing · EDGAR
Jun 18, 2020	Form 3	Repare Therapeutics	Filing · EDGAR
May 26, 2020	Form 4	scPharmaceuticals	Filing · EDGAR
May 20, 2020	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Apr 28, 2020	Form 4	Oric Pharmaceuticals	Filing · EDGAR
Apr 23, 2020	Form 3	Oric Pharmaceuticals	Filing · EDGAR
Apr 16, 2020	Form 4	Alector	Filing · EDGAR
Apr 13, 2020	Form 4	Keros Therapeutics KROS	Filing · EDGAR
Apr 9, 2020	Form 4	Alector	Filing · EDGAR
Apr 9, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Apr 9, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Apr 7, 2020	Form 3	Keros Therapeutics KROS	Filing · EDGAR
Apr 2, 2020	Form 4	Alector	Filing · EDGAR
Mar 30, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Mar 30, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Mar 25, 2020	Form 4	Alector	Filing · EDGAR
Mar 24, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Mar 24, 2020	Form 144	Paper or text filing, not machine-readable	EDGAR
Mar 16, 2020	Form 4	Enliven Therapeutics IMRA	Filing · EDGAR
Mar 11, 2020	Form 3	Enliven Therapeutics IMRA	Filing · EDGAR
Mar 10, 2020	Form 4	Inspire Medical Systems	Filing · EDGAR
Mar 10, 2020	Form 3	Cti Biopharma	Filing · EDGAR
Mar 5, 2020	Form 4	Inspire Medical Systems	Filing · EDGAR
Mar 4, 2020	Form 4	Alector	Filing · EDGAR
Mar 3, 2020	Form 4	Passage BIO PASG	Filing · EDGAR
Feb 27, 2020	Form 3	Passage BIO PASG	Filing · EDGAR
Feb 7, 2020	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Feb 4, 2020	Form 4	Arcutis Biotherapeutics	Filing · EDGAR
Jan 31, 2020	Form 4	Sierra Oncology	Filing · EDGAR
Jan 30, 2020	Form 3	Arcutis Biotherapeutics	Filing · EDGAR
Jan 13, 2020	Form 4	Alector	Filing · EDGAR
Dec 26, 2019	Form 4	Alector	Filing · EDGAR
Dec 19, 2019	Form 4	Alector	Filing · EDGAR
Dec 12, 2019	Form 4	Tricida	Filing · EDGAR
Nov 29, 2019	Form 4	Inspire Medical Systems	Filing · EDGAR
Nov 26, 2019	Form 3	Sierra Oncology	Filing · EDGAR
Nov 13, 2019	Form 4	TELA Bio	Filing · EDGAR
Nov 13, 2019	Form 4	89bio	Filing · EDGAR
Nov 8, 2019	Form 3	89bio	Filing · EDGAR
Nov 7, 2019	Form 3	TELA Bio	Filing · EDGAR
Oct 31, 2019	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Sep 19, 2019	Form 4	SpringWorks Therapeutics	Filing · EDGAR
Sep 12, 2019	Form 3	SpringWorks Therapeutics	Filing · EDGAR
Aug 9, 2019	Form 4	Alector	Filing · EDGAR
Aug 8, 2019	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jul 1, 2019	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jun 26, 2019	Form 4	Prevail Therapeutics	Filing · EDGAR
Jun 19, 2019	Form 3	Prevail Therapeutics	Filing · EDGAR
May 22, 2019	Form 4	Principia Biopharma	Filing · EDGAR
May 13, 2019	Form 4	NextCure	Filing · EDGAR
May 8, 2019	Form 3	NextCure	Filing · EDGAR
Apr 24, 2019	Form 4	Turning Point Therapeutics	Filing · EDGAR
Apr 16, 2019	Form 3	Turning Point Therapeutics	Filing · EDGAR
Apr 5, 2019	Form 4	Tricida	Filing · EDGAR
Apr 3, 2019	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Mar 11, 2019	Form 4	Inspire Medical Systems	Filing · EDGAR
Feb 19, 2019	Form 4	Avedro	Filing · EDGAR
Feb 13, 2019	Form 3	Avedro	Filing · EDGAR
Feb 11, 2019	Form 4	Alector	Filing · EDGAR
Feb 6, 2019	Form 3	Alector	Filing · EDGAR
Jan 23, 2019	Form 4	Alpine Immune Sciences	Filing · EDGAR
Dec 13, 2018	Form 4	Synthorx	Filing · EDGAR
Dec 13, 2018	Form 4	Inspire Medical Systems	Filing · EDGAR
Dec 6, 2018	Form 3	Synthorx	Filing · EDGAR
Oct 25, 2018	Form 4	LogicBio Therapeutics	Filing · EDGAR
Oct 19, 2018	Form 4	SI-BONE	Filing · EDGAR
Oct 18, 2018	Form 3	LogicBio Therapeutics	Filing · EDGAR
Oct 16, 2018	Form 3	SI-BONE	Filing · EDGAR
Oct 11, 2018	Form 4	Guardant Health	Filing · EDGAR
Oct 3, 2018	Form 3	Guardant Health	Filing · EDGAR
Sep 26, 2018	Form 3	Arvinas Holding Company	Filing · EDGAR
Sep 20, 2018	Form 4	Principia Biopharma	Filing · EDGAR
Sep 19, 2018	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Sep 13, 2018	Form 3	Principia Biopharma	Filing · EDGAR
Sep 7, 2018	Form 4	SteadyMed	Filing · EDGAR
Aug 21, 2018	Form 4/A	ViewRay	Filing · EDGAR
Aug 21, 2018	Form 4/A	ViewRay	Filing · EDGAR
Aug 20, 2018	Form 4	ViewRay	Filing · EDGAR
Aug 15, 2018	Form 4	ViewRay	Filing · EDGAR
Aug 10, 2018	Form 4	ViewRay	Filing · EDGAR
Aug 7, 2018	Form 4	ViewRay	Filing · EDGAR
Jul 24, 2018	Form 4	Constellation Pharmaceuticals	Filing · EDGAR
Jul 18, 2018	Form 3	Constellation Pharmaceuticals	Filing · EDGAR
Jul 17, 2018	Form 3	Crinetics Pharmaceuticals	Filing · EDGAR
Jul 2, 2018	Form 4	Tricida	Filing · EDGAR
Jul 2, 2018	Form 4	Aerpio Pharmaceuticals	Filing · EDGAR
Jun 27, 2018	Form 3	Tricida	Filing · EDGAR
Jun 22, 2018	Form 4	ARMO BioSciences	Filing · EDGAR
Jun 6, 2018	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
Jun 1, 2018	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
May 24, 2018	Form 4	Rhythm Pharmaceuticals	Filing · EDGAR
May 21, 2018	Form 4	Rhythm Pharmaceuticals	Filing · EDGAR
May 16, 2018	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
May 9, 2018	Form 4	Inspire Medical Systems	Filing · EDGAR
May 2, 2018	Form 3	Inspire Medical Systems	Filing · EDGAR
May 2, 2018	Form 4	Pieris Pharmaceuticals	Filing · EDGAR
Mar 29, 2018	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
Mar 14, 2018	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Mar 12, 2018	Form 4	Audentes Therapeutics	Filing · EDGAR
Mar 6, 2018	Form 4	GLAUKOS	Filing · EDGAR
Mar 6, 2018	Form 4	Audentes Therapeutics	Filing · EDGAR
Feb 23, 2018	Form 4	Xtant Medical Holdings XTNT	Filing · EDGAR
Feb 15, 2018	Form 4	Pieris Pharmaceuticals	Filing · EDGAR
Feb 12, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Feb 6, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Feb 2, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Jan 30, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Jan 30, 2018	Form 4	Adicet Bio TORC	Filing · EDGAR
Jan 30, 2018	Form 4	ARMO BioSciences	Filing · EDGAR
Jan 30, 2018	Form 4	Synlogic	Filing · EDGAR
Jan 25, 2018	Form 3	Adicet Bio TORC	Filing · EDGAR
Jan 25, 2018	Form 3	ARMO BioSciences	Filing · EDGAR
Jan 24, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Jan 19, 2018	Form 3	Xtant Medical Holdings XTNT	Filing · EDGAR
Jan 12, 2018	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Jan 12, 2018	Form 3	Kala Pharmaceuticals	Filing · EDGAR
Jan 4, 2018	Form 4	Pieris Pharmaceuticals	Filing · EDGAR
Dec 20, 2017	Form 4	Pieris Pharmaceuticals	Filing · EDGAR
Dec 12, 2017	Form 4	Loxo Oncology	Filing · EDGAR
Nov 27, 2017	Form 4	Loxo Oncology	Filing · EDGAR
Nov 21, 2017	Form 4	scPharmaceuticals	Filing · EDGAR
Nov 20, 2017	Form 4	Loxo Oncology	Filing · EDGAR
Nov 20, 2017	Form 4	Arsanis	Filing · EDGAR
Nov 16, 2017	Form 3	scPharmaceuticals	Filing · EDGAR
Nov 15, 2017	Form 3	Arsanis	Filing · EDGAR
Oct 10, 2017	Form 4	Rhythm Pharmaceuticals	Filing · EDGAR
Oct 5, 2017	Form 4	Roka BioScience	Filing · EDGAR
Oct 4, 2017	Form 3	Rhythm Pharmaceuticals	Filing · EDGAR
Oct 2, 2017	Form 4	Roka BioScience	Filing · EDGAR
Sep 29, 2017	Form 4	Audentes Therapeutics	Filing · EDGAR
Sep 28, 2017	Form 4	Roka BioScience	Filing · EDGAR
Sep 11, 2017	Form 4	Audentes Therapeutics	Filing · EDGAR
Sep 5, 2017	Form 4	GLAUKOS	Filing · EDGAR
Aug 30, 2017	Form 3	Synlogic	Filing · EDGAR
Aug 25, 2017	Form 4	Roka BioScience	Filing · EDGAR
Aug 22, 2017	Form 4	Roka BioScience	Filing · EDGAR
Aug 17, 2017	Form 4	GLAUKOS	Filing · EDGAR
Jul 27, 2017	Form 4	Kala Pharmaceuticals	Filing · EDGAR
Jul 26, 2017	Form 4	Alpine Immune Sciences	Filing · EDGAR
Jul 26, 2017	Form 3	Alpine Immune Sciences	Filing · EDGAR
Jul 19, 2017	Form 3	Kala Pharmaceuticals	Filing · EDGAR
Jun 15, 2017	Form 4	Cti Biopharma	Filing · EDGAR
Jun 9, 2017	Form 3	Cti Biopharma	Filing · EDGAR
Apr 27, 2017	Form 4	SteadyMed	Filing · EDGAR
Mar 28, 2017	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
Mar 17, 2017	Form 4	Aerpio Pharmaceuticals	Filing · EDGAR
Mar 17, 2017	Form 3	Aerpio Pharmaceuticals	Filing · EDGAR
Mar 14, 2017	Form 4	GLAUKOS	Filing · EDGAR
Mar 7, 2017	Form 4	GLAUKOS	Filing · EDGAR
Feb 21, 2017	Form 4	Aeglea BioTherapeutics	Filing · EDGAR
Jan 20, 2017	Form 4	ViewRay	Filing · EDGAR
Dec 30, 2016	Form 3	Nabriva Therapeutics	Filing · EDGAR
Dec 1, 2016	Form 4	Response Biomedical	Filing · EDGAR
Sep 23, 2016	Form 4	Roka BioScience	Filing · EDGAR
Aug 24, 2016	Form 4	ViewRay	Filing · EDGAR
Aug 12, 2016	Form 4	GLAUKOS	Filing · EDGAR
Aug 12, 2016	Form 3	SteadyMed	Filing · EDGAR
Aug 12, 2016	Form 4	Loxo Oncology	Filing · EDGAR
Aug 5, 2016	Form 4	GLAUKOS	Filing · EDGAR
Jul 26, 2016	Form 4	Relypsa	Filing · EDGAR
Jul 25, 2016	Form 4	Audentes Therapeutics	Filing · EDGAR
Jul 19, 2016	Form 3	Audentes Therapeutics	Filing · EDGAR
Jun 29, 2016	Form 4	Selecta Biosciences	Filing · EDGAR
Jun 29, 2016	Form 4	Selecta Biosciences	Filing · EDGAR
Jun 27, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jun 21, 2016	Form 3	Selecta Biosciences	Filing · EDGAR
Jun 21, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jun 20, 2016	Form 4	Response Biomedical	Filing · EDGAR
Jun 16, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jun 13, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
May 25, 2016	Form 4	Adaptimmune Therapeutics	Filing · EDGAR
May 24, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
May 20, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
May 13, 2016	Form 4	Intellia Therapeutics	Filing · EDGAR
May 5, 2016	Form 3	Intellia Therapeutics	Filing · EDGAR
Apr 19, 2016	Form 3	Aeglea BioTherapeutics	Filing · EDGAR
Mar 30, 2016	Form 3	ViewRay	Filing · EDGAR
Mar 29, 2016	Form 4	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Mar 22, 2016	Form 3	Corvus Pharmaceuticals CRVS	Filing · EDGAR
Jan 4, 2016	Form 3	Adaptimmune Therapeutics	Filing · EDGAR
Dec 23, 2015	Form 4	Relypsa	Filing · EDGAR
Nov 30, 2015	Form 4	Otonomy	Filing · EDGAR
Nov 24, 2015	Form 4	Otonomy	Filing · EDGAR
Nov 19, 2015	Form 4	Otonomy	Filing · EDGAR
Oct 29, 2015	Form 4	Dimension Therapeutics	Filing · EDGAR
Oct 22, 2015	Form 4	Relypsa	Filing · EDGAR
Oct 21, 2015	Form 3	Dimension Therapeutics	Filing · EDGAR
Oct 13, 2015	Form 4	Sientra	Filing · EDGAR
Oct 9, 2015	Form 4	Sientra	Filing · EDGAR
Oct 6, 2015	Form 4	Sientra	Filing · EDGAR
Oct 1, 2015	Form 4	Sientra	Filing · EDGAR
Sep 28, 2015	Form 4	Sientra	Filing · EDGAR
Jul 21, 2015	Form 4	Sierra Oncology	Filing · EDGAR
Jul 21, 2015	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Jul 15, 2015	Form 3	Sierra Oncology	Filing · EDGAR
Jul 8, 2015	Form 4	Pieris Pharmaceuticals	Filing · EDGAR
Jun 30, 2015	Form 4	GLAUKOS	Filing · EDGAR
Jun 29, 2015	Form 3	Pieris Pharmaceuticals	Filing · EDGAR
Jun 24, 2015	Form 3	GLAUKOS	Filing · EDGAR
May 20, 2015	Form 4	Relypsa	Filing · EDGAR
Mar 30, 2015	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Mar 25, 2015	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Feb 5, 2015	Form 4	Mirati Therapeutics	Filing · EDGAR
Oct 28, 2014	Form 3	Sientra	Filing · EDGAR
Sep 18, 2014	Form 4	Relypsa	Filing · EDGAR
Aug 27, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Aug 19, 2014	Form 4	Otonomy	Filing · EDGAR
Aug 19, 2014	Form 4	Relypsa	Filing · EDGAR
Aug 18, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Aug 12, 2014	Form 3	Otonomy	Filing · EDGAR
Aug 11, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Aug 6, 2014	Form 4	Loxo Oncology	Filing · EDGAR
Jul 31, 2014	Form 3	Loxo Oncology	Filing · EDGAR
Jul 24, 2014	Form 4	Roka BioScience	Filing · EDGAR
Jul 16, 2014	Form 3	Roka BioScience	Filing · EDGAR
Jul 1, 2014	Form 4	Mirati Therapeutics	Filing · EDGAR
May 9, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Apr 11, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Feb 11, 2014	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Nov 20, 2013	Form 4	Relypsa	Filing · EDGAR
Nov 14, 2013	Form 3	Relypsa	Filing · EDGAR
Nov 12, 2013	Form 4	Response Biomedical	Filing · EDGAR
Nov 12, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Oct 31, 2013	Form 4	Mirati Therapeutics	Filing · EDGAR
Oct 23, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Oct 17, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Sep 26, 2013	Form 4	Acceleron Pharma	Filing · EDGAR
Sep 18, 2013	Form 3	Acceleron Pharma	Filing · EDGAR
Aug 13, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Jul 16, 2013	Form 3	Mirati Therapeutics	Filing · EDGAR
May 24, 2013	Form 4	Ambit Biosciences	Filing · EDGAR
May 22, 2013	Form 4	Ambit Biosciences	Filing · EDGAR
May 15, 2013	Form 3	Ambit Biosciences	Filing · EDGAR
May 13, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Apr 15, 2013	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Feb 14, 2013	Form 4	Supernus Pharmaceuticals	Filing · EDGAR
Feb 1, 2013	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Jan 29, 2013	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Dec 19, 2012	Form 4	Supernus Pharmaceuticals	Filing · EDGAR
Oct 16, 2012	Form 4	Intercept Pharmaceuticals	Filing · EDGAR
Oct 10, 2012	Form 3	Intercept Pharmaceuticals	Filing · EDGAR
Sep 5, 2012	Form 4	Amarin	Filing · EDGAR
Jul 30, 2012	Form 4	Amarin	Filing · EDGAR
Jul 13, 2012	Form 4	Complete Genomics	Filing · EDGAR
Jul 3, 2012	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Jun 19, 2012	Form 4	Amarin	Filing · EDGAR
May 8, 2012	Form 4	Supernus Pharmaceuticals	Filing · EDGAR
Apr 30, 2012	Form 3	Supernus Pharmaceuticals	Filing · EDGAR
Mar 22, 2012	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Mar 13, 2012	Form 4	Pacira Pharmaceuticals	Filing · EDGAR
Feb 29, 2012	Form 4	Pacira Pharmaceuticals	Filing · EDGAR
Feb 15, 2012	Form 4	ChemoCentryx	Filing · EDGAR
Feb 8, 2012	Form 3	ChemoCentryx	Filing · EDGAR
Feb 3, 2012	Form 4	Pacira Pharmaceuticals	Filing · EDGAR
Jan 11, 2012	Form 3	Response Biomedical	Filing · EDGAR
Dec 13, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Nov 18, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Nov 15, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Nov 2, 2011	Form 4	Pacira Pharmaceuticals	Filing · EDGAR
Jun 10, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
May 27, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
May 18, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
May 11, 2011	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
May 3, 2011	Form 4	Amarin	Filing · EDGAR
Apr 29, 2011	Form 4	Athersys	Filing · EDGAR
Apr 26, 2011	Form 4/A	Amarin	Filing · EDGAR
Apr 25, 2011	Form 4	Amarin	Filing · EDGAR
Apr 20, 2011	Form 4	Amarin	Filing · EDGAR
Mar 28, 2011	Form 4	Amarin	Filing · EDGAR
Mar 23, 2011	Form 4	Amarin	Filing · EDGAR
Mar 15, 2011	Form 4	Amarin	Filing · EDGAR
Mar 7, 2011	Form 4	Amarin	Filing · EDGAR
Mar 2, 2011	Form 4	Amarin	Filing · EDGAR
Feb 10, 2011	Form 4	Pacira Pharmaceuticals	Filing · EDGAR
Feb 2, 2011	Form 3	Pacira Pharmaceuticals	Filing · EDGAR
Jan 3, 2011	Form 3	Amarin	Filing · EDGAR
Dec 13, 2010	Form 4	NxStage Medical	Filing · EDGAR
Nov 16, 2010	Form 4	Complete Genomics	Filing · EDGAR
Nov 10, 2010	Form 3	Complete Genomics	Filing · EDGAR
Oct 15, 2010	Form 4	NxStage Medical	Filing · EDGAR
Oct 4, 2010	Form 4	Anthera Pharmaceuticals	Filing · EDGAR
Oct 4, 2010	Form 3	Anthera Pharmaceuticals	Filing · EDGAR
Sep 17, 2010	Form 4	NxStage Medical	Filing · EDGAR
Sep 14, 2010	Form 4	NxStage Medical	Filing · EDGAR
Sep 9, 2010	Form 4	NxStage Medical	Filing · EDGAR
Aug 18, 2010	Form 4	NxStage Medical	Filing · EDGAR
Aug 4, 2010	Form 4	NxStage Medical	Filing · EDGAR
Jul 29, 2010	Form 4	NxStage Medical	Filing · EDGAR
May 10, 2010	Form 3	Kun Run Biotechnology	Filing · EDGAR
Jan 12, 2010	Form 4	Athersys	Filing · EDGAR
Jun 11, 2009	Form 4	Biodel	Filing · EDGAR
May 26, 2009	Form 4	ARYx Therapeutics	Filing · EDGAR
Mar 18, 2009	Form 4	Athersys	Filing · EDGAR
Nov 18, 2008	Form 4	ARYx Therapeutics	Filing · EDGAR
Aug 28, 2008	Form 4	NxStage Medical	Filing · EDGAR
Aug 25, 2008	Form 4	NxStage Medical	Filing · EDGAR
Aug 12, 2008	Form 4	NxStage Medical	Filing · EDGAR
May 30, 2008	Form 3	NxStage Medical	Filing · EDGAR
May 23, 2008	Form 4	Athersys	Filing · EDGAR
May 21, 2008	Form 4	Athersys	Filing · EDGAR
May 15, 2008	Form 4	Athersys	Filing · EDGAR
Feb 14, 2008	Form 4	Biodel	Filing · EDGAR
Nov 15, 2007	Form 4	ARYx Therapeutics	Filing · EDGAR
Nov 7, 2007	Form 3	ARYx Therapeutics	Filing · EDGAR
Jun 19, 2007	Form 4	Cryocor	Filing · EDGAR
Jun 12, 2007	Form 4	Athersys	Filing · EDGAR
Jun 12, 2007	Form 3	Athersys	Filing · EDGAR
May 18, 2007	Form 4	Insulet	Filing · EDGAR
May 18, 2007	Form 4	Biodel	Filing · EDGAR
May 14, 2007	Form 3	Insulet	Filing · EDGAR
May 10, 2007	Form 3	Biodel	Filing · EDGAR
Jun 20, 2006	Form 4	Volcano	Filing · EDGAR
Jun 15, 2006	Form 3	Volcano	Filing · EDGAR
Jun 5, 2006	Form 4/A	Avanir Pharmaceuticals	Filing · EDGAR
Jun 2, 2006	Form 4	Avanir Pharmaceuticals	Filing · EDGAR
May 26, 2006	Form 4	Given Imaging	Filing · EDGAR
May 18, 2006	Form 4	Dov Pharmaceutical	Filing · EDGAR
Feb 23, 2006	Form 4	Avanir Pharmaceuticals	Filing · EDGAR
Feb 21, 2006	Form 3	Avanir Pharmaceuticals	Filing · EDGAR
Aug 22, 2005	Form 4	Cryocor	Filing · EDGAR
Aug 22, 2005	Form 3/A	Cryocor	Filing · EDGAR
Aug 16, 2005	Form 4	Dov Pharmaceutical	Filing · EDGAR
Jul 18, 2005	Form 4	Cryocor	Filing · EDGAR
Jul 14, 2005	Form 3	Cryocor	Filing · EDGAR
May 6, 2005	Form 3	Orphan Medical	Filing · EDGAR
Sep 28, 2004	Form 4	Given Imaging	Filing · EDGAR
May 17, 2004	Form 3	Aerogen	Filing · EDGAR
Apr 12, 2004	Form 4	Memory Pharmaceuticals	Filing · EDGAR
Apr 7, 2004	Form 3	Memory Pharmaceuticals	Filing · EDGAR
Feb 10, 2004	Form 4/A	Orthovita	Filing · EDGAR
Jan 16, 2004	Form 4/A	Orthovita	Filing · EDGAR
Jan 14, 2004	Form 4/A	Orthovita	Filing · EDGAR
Dec 30, 2003	Form 4	Lifecell	Filing · EDGAR
Sep 29, 2003	Form 4/A	Orthovita	Filing · EDGAR
Sep 4, 2003	Form 4	Orthovita	Filing · EDGAR
Sep 4, 2003	Form 3	Orthovita	Filing · EDGAR
Jul 16, 2003	Form 3	Dov Pharmaceutical	Filing · EDGAR
Jul 16, 2003	Form 3	Dov Pharmaceutical	Filing · EDGAR
Jun 3, 2003	Form 4	Lifecell	Filing · EDGAR
Nov 21, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Sep 25, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Sep 17, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Sep 9, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Jul 31, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Jun 21, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Jun 21, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Jun 4, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
May 23, 2002	Form 3	Paper or text filing, not machine-readable	EDGAR
May 22, 2002	Form 4/A	Paper or text filing, not machine-readable	EDGAR
May 22, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Apr 19, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Apr 12, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Feb 15, 2002	Form 5	Paper or text filing, not machine-readable	EDGAR
Feb 15, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Feb 15, 2002	Form 5	Paper or text filing, not machine-readable	EDGAR
Feb 15, 2002	Form 5	Paper or text filing, not machine-readable	EDGAR
Nov 1, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR
Sep 10, 2001	Form 4	Paper or text filing, not machine-readable	EDGAR
Aug 15, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR
Jul 19, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR
Apr 25, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR
Feb 21, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR
Jan 11, 2001	Form 3	Paper or text filing, not machine-readable	EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.